<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002795.pub2" GROUP_ID="DEPRESSN" ID="890499102416084979" MERGED_FROM="" MODIFIED="2016-04-12 17:10:59 +0100" MODIFIED_BY="Sarah Davies" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-04-12 17:03:40 +0100" NOTES_MODIFIED_BY="Sarah  R Davies" REVIEW_NO="C01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2016-04-12 17:10:59 +0100" MODIFIED_BY="Sarah Davies">
<TITLE>Pharmacotherapy for post traumatic stress disorder (PTSD)</TITLE>
<CONTACT MODIFIED="2016-04-12 17:10:59 +0100" MODIFIED_BY="Sarah Davies"><PERSON ID="6972" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dan</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Stein</LAST_NAME><POSITION>Professor &amp; Chair</POSITION><EMAIL_1>dan.stein@uct.ac.za</EMAIL_1><URL>http://uct.academia.edu/DanStein</URL><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>Education Centre, Valkenberg Hospital</ADDRESS_1><ADDRESS_2>Private Bage X1, Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9389161</PHONE_1><FAX_1>+27 21 9335790</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-04-12 17:10:59 +0100" MODIFIED_BY="Sarah Davies"><PERSON ID="6972" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dan</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Stein</LAST_NAME><POSITION>Professor &amp; Chair</POSITION><EMAIL_1>dan.stein@uct.ac.za</EMAIL_1><URL>http://uct.academia.edu/DanStein</URL><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>Education Centre, Valkenberg Hospital</ADDRESS_1><ADDRESS_2>Private Bage X1, Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9389161</PHONE_1><FAX_1>+27 21 9335790</FAX_1></ADDRESS></PERSON><PERSON ID="18674" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Ipser</LAST_NAME><EMAIL_1>jonathanipser@gmail.com</EMAIL_1><EMAIL_2>jonathanipser@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>J-Block, Groote Schuur Hospital</ADDRESS_1><ADDRESS_2>Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY></ADDRESS></PERSON><PERSON ID="18673" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Soraya</FIRST_NAME><LAST_NAME>Seedat</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>s.seedat@sun.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>MRC Research Unit for Anxiety and Stress Disorders</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>PO Box 19063</ADDRESS_1><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 9389374</PHONE_1><FAX_1>+27 21 9335790</FAX_1></ADDRESS></PERSON><PERSON ID="46699927915435270329090925132831" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carli</FIRST_NAME><LAST_NAME>Sager</LAST_NAME><EMAIL_1>carlisager@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><CITY>Cape Town</CITY><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>27791717905</PHONE_1></ADDRESS></PERSON><PERSON ID="14177418716966590049110526110219" ROLE="AUTHOR"><FIRST_NAME>Taryn</FIRST_NAME><LAST_NAME>Amos</LAST_NAME><EMAIL_1>tarynamos@gmail.com</EMAIL_1><MOBILE_PHONE>0833200071</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry and Mental Health</DEPARTMENT><ORGANISATION>University of Cape Town</ORGANISATION><ADDRESS_1>Education Centre, Valkenberg Hospital</ADDRESS_1><ADDRESS_2>Private Bage X1, Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 404 5483</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-04-12 17:02:09 +0100" MODIFIED_BY="Sarah  R Davies">
<UP_TO_DATE>
<DATE DAY="14" MONTH="10" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="10" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="4" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-12 17:02:27 +0100" MODIFIED_BY="Sarah  R Davies" NOTES="&lt;p&gt;The review has been updated to include studies up to 2004.&lt;/p&gt;" NOTES_MODIFIED="2016-04-12 17:02:27 +0100" NOTES_MODIFIED_BY="Sarah  R Davies">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2016-04-12 17:02:27 +0100" MODIFIED_BY="Sarah  R Davies">
<DATE DAY="12" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>Feedback incorporated and small amendments made to the description of studies and effects of intervention sections.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="4" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="10" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>MRC Research Unit on Anxiety and Stress Disorders, Cape Town</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Cochrane Collaboration</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-04-12 16:40:14 +0100" MODIFIED_BY="Sarah  R Davies">
<SUMMARY MODIFIED="2008-11-04 12:14:24 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-04 12:14:24 +0000" MODIFIED_BY="[Empty name]">Medication for post traumatic stress disorder</TITLE>
<SUMMARY_BODY>
<P>Post traumatic stress disorder (PTSD) occurs after exposure to significant trauma and results in enormous personal and societal costs. Although traditionally treated with psychotherapy, there is increasing recognition of a theoretical basis for medication treatments. This was a systematic review of 35 short-term randomised controlled trials of pharmacotherapy for PTSD (4597 participants). A significantly larger proportion of patients responded to medication (59.1%) than to placebo (38.5%) (13 trials, 1272 participants). Symptom severity was significantly reduced in 17 trials (2507 participants). The largest trials showing efficacy were of the selective serotonin reuptake inhibitors, with long-term efficacy also observed for these medications. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Post traumatic stress disorder (PTSD) is a prevalent and disabling disorder. Evidence that PTSD is characterised by specific psychobiological dysfunctions has contributed to a growing interest in the use of medication in its treatment.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of medication for post traumatic stress disorder.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Depression, Anxiety and Neurosis Group specialised register (CCDANCTR-Studies) on 18 August 2005, the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library issue 4, 2004), MEDLINE (January 1966 to December 2004), PsycINFO (1966 to 2004), and the National PTSD Center Pilots database. Reference lists of retrieved articles were searched for additional studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials (RCTs) of pharmacotherapy for PTSD.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two raters independently assessed RCTs for inclusion in the review, collated trial data, and assessed trial quality. Investigators were contacted to obtain missing data. Summary statistics were stratified by medication class, and by medication agent for the selective serotonin reuptake inhibitors (SSRIs). Dichotomous and continuous measures were calculated using a random effects model, heterogeneity was assessed, and subgroup/sensitivity analyses were undertaken. <BR/> </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>35 short-term (14 weeks or less) RCTs were included in the analysis (4597 participants). Symptom severity for 17 trials was significantly reduced in the medication groups, relative to placebo (weighted mean difference -5.76, 95% confidence intervals (CI) -8.16 to -3.36, number of participants (N) = 2507). Similarly, summary statistics for responder status from 13 trials demonstrated overall superiority of a variety of medication agents to placebo (relative risk 1.49, 95% CI 1.28 to 1.73, number needed to treat = 4.85, 95% CI 3.85 to 6.25, N = 1272). Medication and placebo response occurred in 59.1% (N = 644) and 38.5% (628) of patients, respectively. Of the medication classes, evidence of treatment efficacy was most convincing for the SSRIs.</P>
<P>Medication was superior to placebo in reducing the severity of PTSD symptom clusters, comorbid depression and disability. Medication was also less well tolerated than placebo. A narrative review of 3 maintenance trials suggested that long term medication may be required in treating PTSD. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Medication treatments can be effective in treating PTSD, acting to reduce its core symptoms, as well as associated depression and disability. The findings of this review support the status of SSRIs as first line agents in the pharmacotherapy of PTSD, as well as their value in long-term treatment. However, there remain important gaps in the evidence base, and a continued need for more effective agents in the management of PTSD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-04-12 16:39:43 +0100" MODIFIED_BY="Sarah  R Davies">
<BACKGROUND MODIFIED="2016-02-12 15:27:24 +0000" MODIFIED_BY="[Empty name]">
<P>Although the phenomenon of post traumatic stress disorder (PTSD) has long been recognised (for example as "shell shock" or "combat neurosis"), it is only relatively recently that this disorder has been officially recognised in the psychiatric nomenclature (<LINK REF="REF-APA-1980" TYPE="REFERENCE">APA 1980</LINK>). Diagnostic criteria for PTSD provided by the 3rd edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) encouraged research on the epidemiology, psychobiology, and treatment of PTSD. Subsequent epidemiological research determined that the disorder is highly prevalent in a wide range of settings, particularly in those subjects who have been exposed to significant traumas (<LINK REF="REF-Breslau-1991" TYPE="REFERENCE">Breslau 1991</LINK>; <LINK REF="REF-Davidson-1991" TYPE="REFERENCE">Davidson 1991</LINK>; <LINK REF="REF-Kessler-1995" TYPE="REFERENCE">Kessler 1995</LINK>). In addition, there is growing evidence that PTSD results in enormous personal and societal costs; this is based on chronicity of symptoms, high comorbidity of psychiatric and medical disorders, marked functional impairment, and estimations of economic costs (<LINK REF="REF-Solomon-1997" TYPE="REFERENCE">Solomon 1997</LINK>; <LINK REF="REF-Brunello-2001" TYPE="REFERENCE">Brunello 2001</LINK>). </P>
<P>By definition prior psychological trauma plays a causal role in PTSD, and psychotherapy has been widely employed in its management. Although psychodynamic psychotherapy has long been the mainstay of treatment, there have been few controlled studies of this modality (<LINK REF="REF-Brom-1989" TYPE="REFERENCE">Brom 1989</LINK>; <LINK REF="REF-Gersons-2000" TYPE="REFERENCE">Gersons 2000</LINK>). Furthermore, the value of so-called psychological debriefing in the immediate aftermath of trauma remains to be proven (<LINK REF="REF-Rose-1998" TYPE="REFERENCE">Rose 1998</LINK>; <LINK REF="REF-Rose-2002" TYPE="REFERENCE">Rose 2002</LINK>). Nevertheless, there is a growing body of evidence demonstrating that cognitive-behavioural and similar psychotherapies are indeed effective in the treatment of PTSD (<LINK REF="REF-Keane-1989" TYPE="REFERENCE">Keane 1989</LINK>; <LINK REF="REF-Solomon-1992" TYPE="REFERENCE">Solomon 1992</LINK>; <LINK REF="REF-Glynn-1995" TYPE="REFERENCE">Glynn 1995</LINK>; <LINK REF="REF-Sherman-1998" TYPE="REFERENCE">Sherman 1998</LINK>; <LINK REF="REF-van-Etten-1998" TYPE="REFERENCE">van Etten 1998</LINK>; <LINK REF="REF-Harvey-2003" TYPE="REFERENCE">Harvey 2003</LINK>; <LINK REF="REF-Bisson-2005" TYPE="REFERENCE">Bisson 2005</LINK>; <LINK REF="REF-Bradley-2005" TYPE="REFERENCE">Bradley 2005</LINK>; <LINK REF="REF-NICE-2005" TYPE="REFERENCE">NICE 2005</LINK>). </P>
<P>There has also been increasing recognition, however, that PTSD is characterised by specific psychobiological dysfunctions (<LINK REF="REF-Yehuda-1995" TYPE="REFERENCE">Yehuda 1995</LINK>; <LINK REF="REF-Bonne-2004" TYPE="REFERENCE">Bonne 2004</LINK>; <LINK REF="REF-Charney-2004" TYPE="REFERENCE">Charney 2004</LINK>), so providing a rationale for the use of medication treatments. PTSD is characterised by different symptom clusters, including intrusive/re-experiencing, avoidant/numbing, and hyperarousal symptoms, and it is possible that each is mediated by different neurobiological mechanisms (<LINK REF="REF-Charney-1993" TYPE="REFERENCE">Charney 1993</LINK>), which may be normalised by specific pharmacological interventions. Certainly, there is growing evidence for rather specific dysregulations of neurotransmitter systems (including the serotonin, noradrenaline, and dopamine systems) and neuroendocrine systems (including the hypothalamus-pituitary-adrenal axis), as well as for structural and functional neuranatomical abnormalities in PTSD (<LINK REF="REF-Charney-1993" TYPE="REFERENCE">Charney 1993</LINK>; <LINK REF="REF-Yehuda-1995" TYPE="REFERENCE">Yehuda 1995</LINK>; <LINK REF="REF-Canive-1997" TYPE="REFERENCE">Canive 1997</LINK>; <LINK REF="REF-Connor-1998" TYPE="REFERENCE">Connor 1998</LINK>; <LINK REF="REF-Hull-2002" TYPE="REFERENCE">Hull 2002</LINK>; <LINK REF="REF-Bremner-2004" TYPE="REFERENCE">Bremner 2004</LINK>). </P>
<P>Thus, whereas an older model was that medications might be valuable primarily as an adjunct to psychotherapy techniques in post-traumatic reactions (<LINK REF="REF-Sargent-1940" TYPE="REFERENCE">Sargent 1940</LINK>), contemporary psychobiological theory speculates that comorbid substance use in PTSD may represent an attempt at "self-medication" and that prescribed medication may be able to play a primary role in preventing or reversing the dysfunctions of PTSD (<LINK REF="REF-Charney-1993" TYPE="REFERENCE">Charney 1993</LINK>; <LINK REF="REF-Charney-2004" TYPE="REFERENCE">Charney 2004</LINK>). Furthermore, several psychiatric disorders are often found comorbid with PTSD disorders (<LINK REF="REF-Kessler-1995" TYPE="REFERENCE">Kessler 1995</LINK>), and certain of these are known to respond to medication. Indeed, the position that medication treatment may be useful in PTSD seems to have gained gradually increasing acceptance (<LINK REF="REF-van-der-Kolk-1983" TYPE="REFERENCE">van der Kolk 1983</LINK>; <LINK REF="REF-Wise-1983" TYPE="REFERENCE">Wise 1983</LINK>; <LINK REF="REF-Friedman-1988" TYPE="REFERENCE">Friedman 1988</LINK>; <LINK REF="REF-Friedman-1991" TYPE="REFERENCE">Friedman 1991</LINK>; <LINK REF="REF-Faustman-1989" TYPE="REFERENCE">Faustman 1989</LINK>; <LINK REF="REF-Walker-1989" TYPE="REFERENCE">Walker 1989</LINK>; <LINK REF="REF-Silver-1990" TYPE="REFERENCE">Silver 1990</LINK>; <LINK REF="REF-Allodi-1991" TYPE="REFERENCE">Allodi 1991</LINK>; <LINK REF="REF-Davidson-1992" TYPE="REFERENCE">Davidson 1992</LINK>; <LINK REF="REF-Davidson-1997a" TYPE="REFERENCE">Davidson 1997a</LINK>; <LINK REF="REF-Davidson-2000" TYPE="REFERENCE">Davidson 2000</LINK>; <LINK REF="REF-Marshall-1996" TYPE="REFERENCE">Marshall 1996</LINK>; <LINK REF="REF-Marshall-1998a" TYPE="REFERENCE">Marshall 1998a</LINK>; <LINK REF="REF-Shalev-1996" TYPE="REFERENCE">Shalev 1996</LINK>; <LINK REF="REF-Connor-1998" TYPE="REFERENCE">Connor 1998</LINK>; <LINK REF="REF-Foa-1999" TYPE="REFERENCE">Foa 1999</LINK>; <LINK REF="REF-Cyr-2000" TYPE="REFERENCE">Cyr 2000</LINK>; <LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>; <LINK REF="REF-Asnis-2004" TYPE="REFERENCE">Asnis 2004</LINK>; <LINK REF="REF-Ursano-2004" TYPE="REFERENCE">Ursano 2004</LINK>).</P>
<P>Early reports of the pharmacotherapy of PTSD focused on the tricyclic antidepressants (TCAs) and the irreversible monoamine oxidase inhibitors (MAOIs) (<LINK REF="REF-Hogben-1981" TYPE="REFERENCE">Hogben 1981</LINK>; <LINK REF="REF-White-1983" TYPE="REFERENCE">White 1983</LINK>; <LINK REF="REF-Burstein-1984" TYPE="REFERENCE">Burstein 1984</LINK>; <LINK REF="REF-Milanes-1984" TYPE="REFERENCE">Milanes 1984</LINK>; <LINK REF="REF-Falcon-1985" TYPE="REFERENCE">Falcon 1985</LINK>; <LINK REF="REF-Bleich-1986" TYPE="REFERENCE">Bleich 1986</LINK>; <LINK REF="REF-Davidson-1987" TYPE="REFERENCE">Davidson 1987</LINK>; <LINK REF="REF-Lerer-1987" TYPE="REFERENCE">Lerer 1987</LINK>; <LINK REF="STD-Frank-1988" TYPE="STUDY">Frank 1988</LINK>; <LINK REF="STD-Shestatzky-1988" TYPE="STUDY">Shestatzky 1988</LINK>; <LINK REF="REF-Davidson-1989" TYPE="REFERENCE">Davidson 1989</LINK>; <LINK REF="REF-Irwin-1989" TYPE="REFERENCE">Irwin 1989</LINK>; <LINK REF="STD-Reist-1989" TYPE="STUDY">Reist 1989</LINK>; <LINK REF="REF-Olivera-1990" TYPE="REFERENCE">Olivera 1990</LINK>; <LINK REF="REF-Chen-1991" TYPE="REFERENCE">Chen 1991</LINK>; <LINK REF="STD-Kosten-1991" TYPE="STUDY">Kosten 1991</LINK>; <LINK REF="REF-Basoglu-1992" TYPE="REFERENCE">Basoglu 1992</LINK>; <LINK REF="REF-Rubin-1993" TYPE="REFERENCE">Rubin 1993</LINK>; <LINK REF="REF-Demartino-1995" TYPE="REFERENCE">Demartino 1995</LINK>). More recent work has focused on the selective serotonin reuptake inhibitors (SSRIs) (<LINK REF="STD-Davidson-1990" TYPE="STUDY">Davidson 1990</LINK>;<LINK REF="REF-Burdon-1991" TYPE="REFERENCE">Burdon 1991</LINK>; <LINK REF="REF-McDougle-1991" TYPE="REFERENCE">McDougle 1991</LINK>; <LINK REF="REF-De-Boer-1992" TYPE="REFERENCE">De Boer 1992</LINK>; <LINK REF="REF-Dominiak-1992" TYPE="REFERENCE">Dominiak 1992</LINK>; <LINK REF="REF-Shay-1992" TYPE="REFERENCE">Shay 1992</LINK>; <LINK REF="REF-Nagy-1993" TYPE="REFERENCE">Nagy 1993</LINK>; <LINK REF="REF-Fichtner-1994" TYPE="REFERENCE">Fichtner 1994</LINK>; <LINK REF="STD-Kline-1994" TYPE="STUDY">Kline 1994</LINK>; <LINK REF="STD-van-der-Kolk-1994" TYPE="STUDY">van der Kolk 1994</LINK>; <LINK REF="REF-Brady-1995" TYPE="REFERENCE">Brady 1995</LINK>; <LINK REF="REF-Marmar-1996" TYPE="REFERENCE">Marmar 1996</LINK>; <LINK REF="STD-Nagy-1996" TYPE="STUDY">Nagy 1996</LINK>; <LINK REF="REF-Rothbaum-1996" TYPE="REFERENCE">Rothbaum 1996</LINK>; <LINK REF="REF-Connor-1998" TYPE="REFERENCE">Connor 1998</LINK>; <LINK REF="REF-Davidson-1998a" TYPE="REFERENCE">Davidson 1998a</LINK>; <LINK REF="REF-Marshall-1998b" TYPE="REFERENCE">Marshall 1998b</LINK>; <LINK REF="STD-Marshall-2001" TYPE="STUDY">Marshall 2001</LINK>; <LINK REF="STD-Brady-2000" TYPE="STUDY">Brady 2000</LINK>; <LINK REF="STD-Hertzberg-2000" TYPE="STUDY">Hertzberg 2000</LINK>; <LINK REF="STD-Smajkic-2001" TYPE="STUDY">Smajkic 2001</LINK>; <LINK REF="STD-Tucker-2001" TYPE="STUDY">Tucker 2001</LINK>; <LINK REF="STD-Martenyi-2002a" TYPE="STUDY">Martenyi 2002a</LINK>; <LINK REF="STD-Zohar-2002" TYPE="STUDY">Zohar 2002</LINK>; <LINK REF="STD-Tucker-2003" TYPE="STUDY">Tucker 2003</LINK>; <LINK REF="STD-Brady-2004" TYPE="STUDY">Brady 2004</LINK>), and the serotonin antagonists and reuptake inhibitors (SARIs) (<LINK REF="REF-Liebowitz-1989" TYPE="REFERENCE">Liebowitz 1989</LINK>; <LINK REF="REF-Hertzberg-1996" TYPE="REFERENCE">Hertzberg 1996</LINK>; <LINK REF="REF-Hertzberg-1998" TYPE="REFERENCE">Hertzberg 1998</LINK>; <LINK REF="REF-Hidalgo-1999" TYPE="REFERENCE">Hidalgo 1999</LINK>).</P>
<P>Several other newly introduced antidepressants have also been studied (<LINK REF="STD-Katz-1994" TYPE="STUDY">Katz 1994</LINK>; <LINK REF="STD-Baker-1995-a" TYPE="STUDY">Baker 1995 a</LINK>; <LINK REF="REF-Neal-1997" TYPE="REFERENCE">Neal 1997</LINK>; <LINK REF="REF-Canive-1998" TYPE="REFERENCE">Canive 1998</LINK>; <LINK REF="REF-Davidson-1998a" TYPE="REFERENCE">Davidson 1998a</LINK>; <LINK REF="REF-Hamner-1998" TYPE="REFERENCE">Hamner 1998</LINK>; <LINK REF="REF-Connor-1999" TYPE="REFERENCE">Connor 1999</LINK>; <LINK REF="REF-Davis-2000" TYPE="REFERENCE">Davis 2000</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Davidson-2003" TYPE="STUDY">Davidson 2003</LINK>). In addition, benzodiazepines (<LINK REF="REF-Dunner-1985" TYPE="REFERENCE">Dunner 1985</LINK>; <LINK REF="REF-Lowenstein-1988" TYPE="REFERENCE">Lowenstein 1988</LINK>; <LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>), beta-blockers (<LINK REF="REF-Kolb-1984" TYPE="REFERENCE">Kolb 1984</LINK>; <LINK REF="REF-Famularo-1988" TYPE="REFERENCE">Famularo 1988</LINK>), buspirone (<LINK REF="REF-Simpson-1991" TYPE="REFERENCE">Simpson 1991</LINK>; <LINK REF="REF-Wells-1991" TYPE="REFERENCE">Wells 1991</LINK>; <LINK REF="REF-Duffy-1992" TYPE="REFERENCE">Duffy 1992</LINK>; <LINK REF="REF-Duffy-1994" TYPE="REFERENCE">Duffy 1994</LINK>; <LINK REF="REF-LaPorta-1992" TYPE="REFERENCE">LaPorta 1992</LINK>; <LINK REF="REF-Fichtner-1994" TYPE="REFERENCE">Fichtner 1994</LINK>), clonidine (<LINK REF="REF-Kolb-1984" TYPE="REFERENCE">Kolb 1984</LINK>; <LINK REF="REF-Kinzie-1989" TYPE="REFERENCE">Kinzie 1989</LINK>; <LINK REF="REF-Harmon-1996" TYPE="REFERENCE">Harmon 1996</LINK>) and guanfacine (<LINK REF="REF-Horrigan-1996" TYPE="REFERENCE">Horrigan 1996</LINK>), cyproheptadine (<LINK REF="REF-Brophy-1991" TYPE="REFERENCE">Brophy 1991</LINK>; <LINK REF="REF-Gupta-1998" TYPE="REFERENCE">Gupta 1998</LINK>), d-cycloserine (<LINK REF="STD-Heresco_x002d_Levy-2002" TYPE="STUDY">Heresco-Levy 2002</LINK>), inositol (<LINK REF="STD-Kaplan-1996" TYPE="STUDY">Kaplan 1996</LINK>), mood-stabilizers (<LINK REF="REF-Kitchner-1985" TYPE="REFERENCE">Kitchner 1985</LINK>; <LINK REF="REF-Lipper-1986" TYPE="REFERENCE">Lipper 1986</LINK>; <LINK REF="REF-Stewart-1986" TYPE="REFERENCE">Stewart 1986</LINK>; <LINK REF="REF-van-der-Kolk-1987" TYPE="REFERENCE">van der Kolk 1987</LINK>; <LINK REF="REF-Wolf-1988" TYPE="REFERENCE">Wolf 1988</LINK>; <LINK REF="REF-Irwin-1989" TYPE="REFERENCE">Irwin 1989</LINK>; <LINK REF="REF-Fichtner-1990" TYPE="REFERENCE">Fichtner 1990</LINK>; <LINK REF="REF-Fesler-1991" TYPE="REFERENCE">Fesler 1991</LINK>; <LINK REF="REF-Szymanski-1991" TYPE="REFERENCE">Szymanski 1991</LINK>; <LINK REF="REF-Keck-1992" TYPE="REFERENCE">Keck 1992</LINK>; <LINK REF="REF-Forster-1994" TYPE="REFERENCE">Forster 1994</LINK>; <LINK REF="REF-Looff-1995" TYPE="REFERENCE">Looff 1995</LINK>; <LINK REF="REF-Ford-1996" TYPE="REFERENCE">Ford 1996</LINK>; <LINK REF="STD-Hertzberg-1999" TYPE="STUDY">Hertzberg 1999</LINK>); typical (<LINK REF="REF-Bleich-1986" TYPE="REFERENCE">Bleich 1986</LINK>; <LINK REF="REF-Dillard-1993" TYPE="REFERENCE">Dillard 1993</LINK>) and atypical neuroleptics (<LINK REF="REF-Hamner-1996" TYPE="REFERENCE">Hamner 1996</LINK>; <LINK REF="REF-Leyba-1998" TYPE="REFERENCE">Leyba 1998</LINK>; <LINK REF="REF-Izrayelit-1998" TYPE="REFERENCE">Izrayelit 1998</LINK>; <LINK REF="REF-Burton-1999" TYPE="REFERENCE">Burton 1999</LINK>; <LINK REF="STD-Butterfield-2001" TYPE="STUDY">Butterfield 2001</LINK>; <LINK REF="STD-Hamner-2003" TYPE="STUDY">Hamner 2003</LINK>); and opioids (<LINK REF="REF-Glover-1993" TYPE="REFERENCE">Glover 1993</LINK>) have also received attention.</P>
<P>A systematic review of studies of pharmacotherapy for PTSD may be useful in tackling several questions for the field. Firstly, is pharmacotherapy in fact an effective form of treatment in PTSD? Given the preponderance of psychological models and evidence for the efficacy of certain forms of psychotherapy in PTSD (<LINK REF="REF-Bisson-2005" TYPE="REFERENCE">Bisson 2005</LINK>), the role of pharmacotherapy remains debatable for many. In a recently published guideline for the treatment of PTSD, the National Institute of Clinical Evidence (NICE) recommended that preference be given to trauma-focused psychological therapy over pharmacotherapy as a routine first line treatment for this disorder (<LINK REF="REF-NICE-2005" TYPE="REFERENCE">NICE 2005</LINK>). For those who accept a more dominant role for pharmacotherapy, questions about appropriate dose and duration arise, with current clinical recommendations suggesting that the SSRIs, for example, are prescribed at doses that increase to maximally effective/tolerated levels over a period of at least eight weeks (<LINK REF="REF-Foa-1999" TYPE="REFERENCE">Foa 1999</LINK>; <LINK REF="REF-Ballenger-2000" TYPE="REFERENCE">Ballenger 2000</LINK>; <LINK REF="REF-Ballenger-2004" TYPE="REFERENCE">Ballenger 2004</LINK>). </P>
<P>Secondly, are particular medication classes more effective in the treatment of symptoms and/or more acceptable to the patient in terms of adverse events than others? The use of novel agents (such as the serotonergic antidepressants) for PTSD in recent years raises the question of how these compare with older agents. Some recommendations, such as the expert consensus guideline series for the treatment of post traumatic stress disorder (<LINK REF="REF-Foa-1999" TYPE="REFERENCE">Foa 1999</LINK>), have suggested that the SSRIs, nefazodone, and venlafaxine are first-line medications for the treatment of PTSD , with benzodiazepines and mood-stabilisers having a role in patients with certain kinds of symptoms. Other recommendations have highlighted paroxetine and mirtazapine (<LINK REF="REF-NICE-2005" TYPE="REFERENCE">NICE 2005</LINK>). Support for such recommendations requires ongoing assessment of the literature on RCTs.</P>
<P>Thirdly, can a systematic review of RCTs provide information about the most important factors affecting pharmacotherapy response? Clinical factors, such as the kind of pre-existing trauma (e.g. combat-related or not), the duration of symptoms, and the presence of comorbid depression, early childhood trauma, and "secondary gain" for symptoms (for example, patients in ongoing litigation or receiving financial compensation) have all been suggested to play a role (<LINK REF="REF-Davidson-1993" TYPE="REFERENCE">Davidson 1993</LINK>; <LINK REF="STD-van-der-Kolk-1994" TYPE="STUDY">van der Kolk 1994</LINK>; <LINK REF="REF-Marshall-1998b" TYPE="REFERENCE">Marshall 1998b</LINK>; <LINK REF="REF-Davidson-2000" TYPE="REFERENCE">Davidson 2000</LINK>). Methodological factors such as the duration of the trial or inclusion of patients with a minimal degree of symptom severity, may also affect treatment response. It is possible that the database of RCTs in PTSD may include information about some of these variables.</P>
<P>A number of reviews of the pharmacotherapy of PTSD have indeed been published in recent years (<LINK REF="REF-van-der-Kolk-1983" TYPE="REFERENCE">van der Kolk 1983</LINK>; <LINK REF="REF-Friedman-1988" TYPE="REFERENCE">Friedman 1988</LINK>; <LINK REF="REF-Friedman-1991" TYPE="REFERENCE">Friedman 1991</LINK>; <LINK REF="REF-Davidson-1992" TYPE="REFERENCE">Davidson 1992</LINK>; <LINK REF="REF-Davidson-1997a" TYPE="REFERENCE">Davidson 1997a</LINK>; <LINK REF="REF-Marshall-1996" TYPE="REFERENCE">Marshall 1996</LINK>; <LINK REF="REF-Marshall-1998a" TYPE="REFERENCE">Marshall 1998a</LINK>; <LINK REF="REF-Solomon-1992" TYPE="REFERENCE">Solomon 1992</LINK>; <LINK REF="REF-Shalev-1996" TYPE="REFERENCE">Shalev 1996</LINK>; <LINK REF="REF-Otto-1996" TYPE="REFERENCE">Otto 1996</LINK>; <LINK REF="REF-Connor-1998" TYPE="REFERENCE">Connor 1998</LINK>; <LINK REF="REF-Albucher-2002" TYPE="REFERENCE">Albucher 2002</LINK>; <LINK REF="REF-Asnis-2004" TYPE="REFERENCE">Asnis 2004</LINK>). These reviews have been useful in summarising the existing research, pointing to methodological flaws, and outlining areas for future research. Nevertheless, few of these reviews have employed a systematic search strategy. It has recently been determined that even MEDLINE searches may miss over half of all RCTs in specialised health care journals (<LINK REF="REF-Hopewell-2002" TYPE="REFERENCE">Hopewell 2002</LINK>). Furthermore, few studies have estimated the effects of medication (<LINK REF="REF-Penava-1996" TYPE="REFERENCE">Penava 1996</LINK>; <LINK REF="REF-Davidson-1997a" TYPE="REFERENCE">Davidson 1997a</LINK>; <LINK REF="REF-van-Etten-1998" TYPE="REFERENCE">van Etten 1998</LINK>). Interestingly, in their meta-analysis, Penava (<LINK REF="REF-Penava-1996" TYPE="REFERENCE">Penava 1996</LINK>) noted that effect size correlated with increased serotonergic specificity of the antidepressant. Further reviews in this area need to adhere to Cochrane Collaboration (<LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>) or similar (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>) guidelines for systematic identification of trials, investigation of sources of heterogeneity, measurement of methodological quality, and estimation of the effects of intervention.</P>
<P>The authors aimed to undertake a systematic review of randomised controlled (RCTs) of the pharmacotherapy of post traumatic stress disorder, following the guidelines and using the software of the Cochrane Collaboration.</P>
</BACKGROUND>
<OBJECTIVES>
<P>1. To identify and review all RCTs, including placebo controlled and comparative trials, of the pharmacotherapy of post traumatic stress disorder (PTSD), whether published or unpublished.</P>
<P>2. To provide an estimate of the effects of medication in reducing PTSD symptoms. </P>
<P>3. To determine whether particular classes of medication are more effective and/or acceptable than others in the treatment of PTSD. </P>
<P>4. To identify which factors (clinical, methodological) predict response to pharmacotherapy.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials (placebo controlled and comparative trials) completed prior to the end of 2004 were considered for inclusion. Publication is not necessarily related to study quality and indeed publication may imply certain biases (<LINK REF="REF-Easterbrook-1991" TYPE="REFERENCE">Easterbrook 1991</LINK>; <LINK REF="REF-Dickersin-1992" TYPE="REFERENCE">Dickersin 1992</LINK>; <LINK REF="REF-Scherer-1994" TYPE="REFERENCE">Scherer 1994</LINK>), so unpublished abstracts and reports were also considered. Studies were not limited to any particular language. Differences between trials (for example, sample size, trial duration) were not used to exclude studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All studies of subjects with PTSD (as determined by the study authors) were included. There was no restriction on the basis of different diagnostic criteria for PTSD, duration and severity of PTSD symptoms, presence of comorbid disorders, or age and gender of subjects. However, these descriptors were tabulated in order to address the question of their possible impact on the effects of medication.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The review focused only on medication treatments, in which the comparator was a placebo (active or non-active) or other medication. A parallel review of the psychotherapy of PTSD has recently been completed by members of the Cochrane Collaboration (<LINK REF="REF-Bisson-2005" TYPE="REFERENCE">Bisson 2005</LINK>). Trials in which ongoing pharmacotherapy is supplemented with augmentation medication (<LINK REF="STD-Hamner-1997" TYPE="STUDY">Hamner 1997</LINK>
<B>; </B>
<LINK REF="STD-Heresco_x002d_Levy-2002" TYPE="STUDY">Heresco-Levy 2002</LINK>
<B>; </B>
<LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK>; <LINK REF="STD-Hamner-2003" TYPE="STUDY">Hamner 2003</LINK>
<B>; </B>
<LINK REF="STD-Monnelly-2003" TYPE="STUDY">Monnelly 2003</LINK>
<B>; </B>
<LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>) will be included in a separate review of pharmacotherapy for treatment-resistant anxiety disorders (<LINK REF="REF-Dhansay-2005" TYPE="REFERENCE">Dhansay 2005</LINK>). RCTs of medication prophylaxis for PTSD (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>
<B>; </B>
<LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="STD-Schelling-2004" TYPE="STUDY">Schelling 2004</LINK>) have also been reserved for a future Cochrane protocol.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcomes<BR/>
</B>
<BR/>PTSD symptom and symptom cluster response was determined from the total score on the Clinician Administered PTSD Scale (CAPS) (<LINK REF="REF-Blake-1990" TYPE="REFERENCE">Blake 1990</LINK>), a symptom severity measure that is increasingly used in RCTs of PTSD. </P>
<P>Treatment response (responders versus non-responders) was determined from the Clinical Global Impressions scale <B>- </B>improvement item (CGI-I), or closely related measure such as the Duke Global Rating for PTSD scale (<LINK REF="REF-Davidson-1998b" TYPE="REFERENCE">Davidson 1998b</LINK>), or a closely related definition (<LINK REF="STD-Brady-2000" TYPE="STUDY">Brady 2000</LINK>). Responders are defined on the CGI-I as those with a score of 1 = "very much" or 2 = "much" improved (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>); this is a widely used global outcome measure in RCTs of PTSD, where it appears robust (<LINK REF="REF-Davidson-1997b" TYPE="REFERENCE">Davidson 1997b</LINK>). </P>
<P>
<B>Secondary outcomes</B>
</P>
<P>PTSD symptom response was assessed for those trials which used other continuous measures of symptom severity besides the CAPS, as well as from summary statistics from self-rated scales such as the Impact of Events Scale (IES) (<LINK REF="REF-Horowitz-1979" TYPE="REFERENCE">Horowitz 1979</LINK>), and the Davidson Trauma Scale (DTS) (<LINK REF="REF-Davidson-1997c" TYPE="REFERENCE">Davidson 1997c</LINK>). Self-rated scales were frequently the only outcome measures used in older trials, and may continue to have a role in clinical practice. The efficacy of medication in alleviating symptoms within the three symptom clusters characteristic of PTSD (re-experiencing/intrusion, avoidance/numbing, and hyperarousal) was determined using the CAPS-B, CAPS-C, and CAPS-D subscales of the CAPS, as well as the relevant subscales of the self-rated outcome measures.</P>
<P>The response of comorbid symptoms was measured by (a) depression scales, such as the Beck Depression Inventory (BDI) (<LINK REF="REF-Beck-1961" TYPE="REFERENCE">Beck 1961</LINK>), the Hamilton Depression scale (HAM-D) (<LINK REF="REF-Hamilton-1959" TYPE="REFERENCE">Hamilton 1959</LINK>), and the Montgomery-Asberg Depression Rating Scale (MADRS) (<LINK REF="REF-Montgomery-1979" TYPE="REFERENCE">Montgomery 1979</LINK>), and (b) anxiety scales, such as the Covi Anxiety Scale (CAS) (<LINK REF="REF-Covi-1984" TYPE="REFERENCE">Covi 1984</LINK>) and the Hamilton Anxiety scale (HAM-A) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>). </P>
<P>Quality of life measures, as well as measures of functional disability, such as the Sheehan Disability Scale (SDS), which includes subscales to assess work, social and family related impairment (<LINK REF="REF-Sheehan-1996" TYPE="REFERENCE">Sheehan 1996</LINK>), were also included when provided, to address the question of medication effectiveness. </P>
<P>The total proportion of participants who withdrew  from the RCTs due to treatment emergent adverse events was included in the analysis as a surrogate measure of medication acceptability, in the absence of other more direct indicators of acceptability.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>
<B>Electronic Searches<BR/>
</B>
<BR/>1. The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies) was searched using the following search strategy on 18 August 2005:</P>
<P>Diagnosis = Post-Traumatic Stress Disorders </P>
<P>and </P>
<P>"Antidepressive Agents" OR "Monoamine Oxidase InhibitORs" OR "Selective Serotonin Reuptake InhibitORs" OR "Tricyclic Drugs" OR Acetylcarnitine OR Alaproclate OR Amersergide OR Amiflamine OR Amineptine OR Amitriptyline OR Amoxapine OR Befloxatone OR Benactyzine OR Brofaromine OR Bupropion OR Butriptyline OR Caroxazone OR ChlORpoxiten OR Cilosamine OR Cimoxatone OR Citalopram OR Clomipramine OR ClORgyline OR ClORimipramine OR Clovoxamine OR Deanol OR Demexiptiline OR Deprenyl OR Desipramine OR Dibenzipin OR Diclofensine OR Dothiepin OR Doxepin OR Duloxetine OR Escitalopram OR Etoperidone OR Femoxetine OR Fluotracen OR Fluoxetine OR Fluparoxan OR Fluvoxamine OR Idazoxan OR Imipramine OR Iprindole OR Iproniazid OR isocarboxazid OR Litoxetine OR Lofepramine OR Maprotiline OR Medifoxamine OR Melitracen OR Metapramine OR Mianserin OR Milnacipran OR Minaprine OR Mirtazapine OR Moclobemide OR Nefazodone OR Nialamide OR Nomifensine OR NORtriptyline OR Noxiptiline OR Opipramol OR Oxaflozane OR Oxaprotiline OR Pargyline OR Paroxetine OR Phenelzine OR Piribedil OR Pirlindole OR Pivagabine OR Prosulpride OR Protriptyline OR Quinupramine OR Reboxetine OR Rolipram OR Sertraline OR Setiptiline OR Teniloxine OR Tetrindole OR Thiazesim OR Thozalinone OR Tianeptine OR Toloxatone OR Tomoxetine OR Tranylcypromine OR Trazodone OR Trimipramine OR Venlafaxine OR Viloxazine OR Viqualine OR Zimeldine. </P>
<P>2. Additional searches were carried out on MEDLINE (via PubMed), PsycINFO, and The National PTSD Center Pilots database.</P>
<P>The MEDLINE search query, as derived from a highly sensitive search strategy developed by Robinson and Dickersin (<LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK>), was the following:</P>
<P>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ("latin square" [tw]) OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]) AND (Stress Disorders, Post-Traumatic [mh:noexp] OR "posttraumatic stress disorder" [tw] OR "post traumatic stress disorder" [tw] OR PTSD [tw]) AND (pharmacother* [tw] OR medicat* [tw] OR drug* [tw] OR Drug Therapy [mh]).<B>
<BR/>
</B>
<BR/>The PsycINFO search used the following search query: ("randomisation" OR "randomization") OR "controlled" AND ("post-traumatic" OR posttraumatic) AND (medication OR pharmacotherapy OR treatment). PsycINFO includes the Dissertation Abstracts International database - a database of unpublished dissertations.</P>
<P>The National PTSD Center Pilots database contains published and unpublished articles on PTSD. It was searched using the following search query: (randomisation or randomization) or controlled AND (post-traumatic OR posttraumatic) AND (medication OR pharmacotherapy).</P>
<P>3. Unpublished trials were retrieved via the metaRegister module [mRCT] of the Controlled Trials database (http://www.controlled-trials.com). The search terms used were "PTSD", "posttraumatic stress disorder", and "post traumatic stress disorder".</P>
<P>An initial broad strategy was undertaken to find not only RCTs, but also open-label trials, as well as journal and chapter reviews of the pharmacotherapy of PTSD.</P>
<P>
<B>Reference Lists<BR/>
</B>
<BR/>Additional RCTs were sought in reference lists of the retrieved articles and included studies in any language.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Trial selection<BR/>
</B>
<BR/>RCTs identified from the search were independently assessed for inclusion by two raters, based on information included in the abstract and/or main body of the trial report. RCTs which both raters regarded as satisfying the inclusion criteria specified in the "criteria for considering studies" section were collated. Studies for which additional information is required in order to determine their suitability for inclusion in the review have been listed in the "studies awaiting assessment" table in the Review Manager (RevMan) software, pending the availability of this information. Any disagreements in assessment and collation were resolved by discussion. </P>
<P>
<B>Data extraction<BR/>
</B>
<BR/>Spreadsheet forms were designed for the purpose of recording descriptive information, summary statistics of the outcome measures, the quality scale ratings, and associated commentary. The data was subsequently exported to the RevMan software, which was used to conduct the meta-analysis. Where information was missing, the reviewers contacted investigators by email in an attempt to obtain this information. In the case of one trial for which it was not possible to obtain exact treatment response figures (<LINK REF="STD-Marshall-2001" TYPE="STUDY">Marshall 2001</LINK>), one of the reviewers used a ruler to estimate the mean number of responders within the comparison groups from a graph contained within the original trial report. </P>
<P>
<B>Data synthesis<BR/>
</B>
<BR/>The following information was collated from each trial (additional information can be found in the "Characteristics of Included Studies" table):</P>
<P>(a) Description of the trials, including the primary researcher, the year of publication, and the source of funding.</P>
<P>(b) Characteristics of the interventions, including the number of participants randomised to the treatment and control groups, the number of total drop-outs per group as well as the number that dropped out due to adverse effects, the dose of medication and the period over which it was administered, and the name and class of the medication (SSRIs, TCAs, MAOIs and "other medication"). </P>
<P>(c) Characteristics of trial methodology, including the diagnostic (eg. DSM-IV (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>)) and exclusionary criteria employed, the screening instrument used (eg. the Structured Clinical Interview for DSM-IV (SCID) (<LINK REF="REF-Spitzer-1996" TYPE="REFERENCE">Spitzer 1996</LINK>)) for both the primary and comorbid diagnoses, the presence of comorbid major depressive disorder (MDD), the use of a placebo run-in or of a minimal severity criterion, the number of centres involved, and the trial's methodological quality (see below).</P>
<P>(d) Characteristics of participants, including gender distribution and mean and range of ages, mean length of time with PTSD symptoms, whether they have been treated with the medication in the past (treatment naivety), the number of participants in the sample with MDD, the number who experienced combat trauma, and the baseline severity of PTSD, as assessed by the trial's primary outcome measure or another commonly employed scale. </P>
<P>(e) Outcome measures employed (primary and secondary), and summary continuous (means and standard deviations (SD)) and dichotomous (number of responders) data. Additional information included whether data reflected the intent-to-treat (ITT) with last observation carried forward (LOCF) or mixed methods (MM) sample, or whether a completer/observed cases (OC) sample was reported. </P>
<P>
<B>Data analysis</B>
</P>
<P>Summary statistics for categorical and continuous measures were obtained from a random effects model (the random effects model includes both within-study sampling error and between-studies variation in determining the precision of the confidence interval (CI) around the overall effect size, whereas the fixed effects model takes only within-study variation into account). The summary statistics were expressed in terms of an average effect size for each subgroup, as well as by means of 95% CIs.</P>
<P>Cross-over trials were only included in the calculation of summary statistics when it was (a) possible to extract medication and placebo/comparator data from the first treatment period, or (b) when the inclusion of data from both treatment periods was justified through a wash-out period of sufficient duration as to minimise the risk of carry-over effects (a minimum of two weeks or longer in the case of trials assessing the efficacy of agents with extended half-lives, such as the SSRI, fluoxetine (<LINK REF="REF-Gury-1999" TYPE="REFERENCE">Gury 1999</LINK>)). In the latter case, data from both periods were only included when it was possible to determine the correlation between participants' responses to the interventions in the different phases (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). </P>
<P>In recognition of the possibility of differential effects for different types of medication, all of the comparisons were stratified by medication class. Medications which could not be classified as either SSRIs, TCAs or MAOIs were placed in a separate category, labelled "other medication". In addition, in the case of the SSRIs, in view of the large number of SSRI trials, comparisons between medication and placebo on the primary outcome measures and on the number of drop-outs due to drug-related adverse events were stratified by individual agents.<B>
<I> <BR/>
</I>
</B>
<BR/>
<B>Categorical data<BR/>
</B>
<BR/>Relative risk (RR) of failure to respond to treatment was used as the summary statistic for the dichotomous outcome of interest (CGI-I or related measure). RR was used instead of odds ratios, as odd ratios tend to underestimate the size of the treatment effect when the occurrence of the adverse outcome of interest is common (as was the case in this review, with an anticipated non-response greater than 20%) (<LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>), and because of the greater ease with which this statistic can be interpreted. Number needed to treat (NNT) was also included. The NNT is calculated as the inverse of the absolute risk reduction between the medication and control groups (<LINK REF="REF-McQuay-1997" TYPE="REFERENCE">McQuay 1997</LINK>). It provides an indication of the number of patients who require treatment with medication before a single additional patient in the medication group responds to treatment, relative to the control group. The confidence intervals for the NNT were only calculated for significant treatment effects, given the difficulty of interpreting CIs which contain infinity (<LINK REF="REF-Altman-1998" TYPE="REFERENCE">Altman 1998</LINK>).</P>
<P>
<B>Continuous data<BR/>
</B>
<BR/>Weighted mean differences (WMD) were calculated for continuous summary data obtained from studies that employed the CAPS. Alternatively, in cases in which a range of scales were employed, such as in the assessment of symptom severity on the self-rated IES and DTS scales, or in the assessment of comorbid depression on the MADRS and HAM-D, the standardised mean difference (SMD) was determined. This method of analysis standardises the differences between the means of the treatment and control groups in terms of the variability observed in the trial. </P>
<P>In the case of data from trials employing multiple fixed doses of medication, the bias introduced through comparing the summary statistics for multiple groups against the same placebo control was avoided by pooling the means and standard deviations across all of the treatment arms as a function of the number of participants in each arm. For the same reason, outcome comparisons were limited to those between only one medication and placebo in trials which compared several different medications with placebo. Selection of medication for analysis was done (prior to analysis, to avoid introducing bias) on the basis of which of the three major medication classes (TCAs, MAOIs, SSRIs) was least well represented. In addition, when including summary statistics from the self-rated scales, preference was given to data from the DTS over the IES in trials which used both scales, given the late inclusion in the former of a subscale assessing the hyperarousal symptom cluster (<LINK REF="REF-Weiss-1997" TYPE="REFERENCE">Weiss 1997</LINK>), and concerns regarding the psychometric properties of the IES subscales (<LINK REF="REF-Creamer-2003" TYPE="REFERENCE">Creamer 2003</LINK>). </P>
<P>
<B>Quality assessment<BR/>
</B>
<BR/>There has been some debate about how best to measure the quality of trials, and further work in this area remains necessary (<LINK REF="REF-Berlin-1999" TYPE="REFERENCE">Berlin 1999</LINK>). In this review, one of the reviewers assessed the quality of the trials by means of the CCDAN Quality of Research Scale (CCDAN-QRS) (<LINK REF="REF-Moncrieff-1999" TYPE="REFERENCE">Moncrieff 1999</LINK>) (http://www.iop.kcl.ac.uk/IoP/ccdan/qrs.htm). This 23 item scale assesses a range of features such as sample size, the duration of the intervention, inclusion and exclusion criteria, and whether or not the power of the trial to detect a treatment effect was calculated. In addition, data for other trial characteristics which have been recognised as a potential sources of bias, such as the method used in generating the allocation sequence, the concealment of allocation, whether outcome assessment was blinded, and the number of participants lost to follow up, were also collated. This was regarded as necessary given doubts concerning the usefulness of an overall quality score from a scale composed of multiple items (<LINK REF="REF-Alderson-2003" TYPE="REFERENCE">Alderson 2003</LINK>). </P>
<P>
<B>Heterogeneity<BR/>
</B>
<BR/>Heterogeneity of treatment response, that is whether the differences between the results of trials were greater than would be expected by chance alone, was assessed visually from the forest plot of RR. It was also determined by means of the chi-square test of heterogeneity, with a significance level of less than 0.10 interpreted as evidence of heterogeneity, given the low power of the chi squared statistic when the number of trials is small (<LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>). <BR/> <BR/>In addition, the I-square heterogeneity statistic reported by RevMan was used to test the robustness of the chi squared statistic to differences in the number of trials included in the groups being compared within each subgroup analysis (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Differences on continuous measures in medication efficacy between these groups were assessed by means of Deeks' stratified test of heterogeneity (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). This method subtracts the sum of the chi squared statistics for each of the groups from the total chi squared for the subgroup analysis, to provide a measure (Q<SUB>b</SUB>) of heterogeneity between groups. Differences in treatment response on the CGI-I was determined by whether the confidence intervals for the effect sizes of the subgroups overlap. This method was chosen in preference to the stratified test, due to inaccuracies in the calculation in RevMan of the chi squared statistic for dichotomous measures (<LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>). </P>
<P>
<B>Subgroup analyses<BR/>
</B>
<BR/>Subgroup analyses (<LINK REF="REF-Thomson-1994" TYPE="REFERENCE">Thomson 1994</LINK>) were undertaken in order to assess the degree to which methodological differences between trials might have systematically influenced differences observed in the primary treatment outcomes. </P>
<P>The trials were grouped according to the following methodological sources of heterogeneity:</P>
<UL>
<LI>The involvement of participants from a single centre or multiple centres. Single-centre trials are more likely to be associated with lower sample size but less variability in clinician ratings.</LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>Whether or not trials were industry funded. In general, published trials which are sponsored by pharmaceutical companies appear more likely to report positive findings than trials which are not supported by for-profit companies (<LINK REF="REF-Als_x002d_Nielsen-2003" TYPE="REFERENCE">Als-Nielsen 2003</LINK>; <LINK REF="REF-Baker-2003" TYPE="REFERENCE">Baker 2003</LINK>).</LI>
</UL>
<P> <BR/>In addition, the following criteria were used to assess the extent of clinical sources of heterogeneity:</P>
<UL>
<LI>Whether or not the sample included combat veterans (this subgroup has been regarded as more resistant to treatment, and is arguably more likely to have more chronic and severe symptoms, to have comorbid depression, and to be male). For the purpose of this review, those trials for which 10 percent or fewer of the sample consisted of war veterans were classified as non-combat veteran RCTs.</LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>Whether or not the sample included patients diagnosed with major depression. Such an analysis might assist in determining the extent to which the efficacy of a medication agent in treating PTSD is independent of its ability to reduce symptoms of depression, an important consideration given the classification of many of these medications as antidepressants.</LI>
</UL>
<P>
<BR/>
<B>Sensitivity analysis<BR/>
</B>
<BR/>Sensitivity analyses, which determine the robustness of the reviewers' conclusion to methodological assumptions made in conducting the meta-analysis, were also performed. Sensitivity analyses were conducted to determine whether treatment response on the CGI-I differed as a result of:</P>
<UL>
<LI>Treatment response versus non-response as the unit of comparison in determining medication efficacy. This comparison is regarded as necessary given concerns that the former may result in less consistent summary statistics than the latter (<LINK REF="REF-Deeks-2002" TYPE="REFERENCE">Deeks 2002</LINK>). </LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>The exclusion of participants who were lost to follow up (LTF). This was determined through a "worst case/best case" scenario (<LINK REF="REF-Deeks-2003" TYPE="REFERENCE">Deeks 2003</LINK>). In the worst case, all the missing data for the treatment group were recorded as non-responders, whereas in the best case, all missing data in the control group were treated as non-responders. (In the case of the one SSRI (Marshall 2004) and MAOI trial (<LINK REF="STD-Baker-1995-a" TYPE="STUDY">Baker 1995 a</LINK>) which only reported total LTF, the ratio of participants who dropped out in the medication and placebo group was determined from the average ratio between these groups for those RCTs in the respective classes which did provide this information). Should the conclusions regarding treatment efficacy not differ between these two comparisons, it can be assumed that missing data in trial reports do not have a significant influence on outcome. </LI>
</UL>
<P>
<BR/>
<B>Publication bias<BR/>
</B>
<BR/>Publication bias was determined by visual inspection of a funnel plot of treatment response. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-04-12 16:39:43 +0100" MODIFIED_BY="Sarah  R Davies">
<STUDY_DESCRIPTION MODIFIED="2016-04-12 16:36:30 +0100" MODIFIED_BY="Sarah  R Davies">
<P>The review included 35 short term RCTs of PTSD (4597 participants), three of which contained a maintenance component (<LINK REF="STD-Davidson-2001a" TYPE="STUDY">Davidson 2001a</LINK>, <LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>, <LINK REF="STD-Martenyi-2002a" TYPE="STUDY">Martenyi 2002a</LINK>)(see Comparison 06). Of the 35 trials, 30 were published, and all of these publications were in English. A placebo comparison group was employed in all but four of the trials (<LINK REF="STD-McRae-2004" TYPE="STUDY">McRae 2004</LINK> and <LINK REF="STD-Saygin-2002" TYPE="STUDY">Saygin 2002</LINK> compared nefazodone with the SSRI sertraline, while <LINK REF="STD-Smajkic-2001" TYPE="STUDY">Smajkic 2001</LINK> compared the efficacy of the SSRIs sertraline, paroxetine and the serotonin - noradrenaline reuptake inhibitor (SNRI) venlafaxine. <LINK REF="STD-Chung-2004" TYPE="STUDY">Chung 2004</LINK> assessed the efficacy and tolerability of mirtrazapine against that of sertraline). Of the remaining 31 short term RCTs, 17 of the trials included a SSRI treatment arm (one citalopramine, six fluoxetine, four paroxetine, seven sertraline), two trials a TCA intervention (one amitriptyline, one desipramine), four a MAOI intervention (two brofaromine, two phenelzine), and seven studies employed an intervention classified as "other medication". This last category included one benzodiazepine (alprazolam), two antipsychotics (olanzapine and risperidone), one anticonvulsant (lamotrigine), one second messenger system precursor (inositol), one SNRI (venlafaxine) and two novel antidepressants (mirtazapine and nefazodone). <B>
<BR/>
</B>
<BR/>The SSRI trials can be distinguished from the non-SSRI trials on a number of different study characteristics. The SSRI trials were significantly larger (mean = 184 participants) on average than the non-SSRI trials (mean = 41 participants) (one-sided Wilcoxon Mann-Whitney test: W = 208, P = &lt; 0.01), even when adjusting for the smaller number of participants in the non-SSRI crossover trials (through doubling the sample size). The majority of the 17 placebo controlled short term trials published since 2000 have included SSRIs (N = 13), with only two SSRI trials being published prior to 2000 (<LINK REF="STD-Conner-1999" TYPE="STUDY">Conner 1999</LINK>; <LINK REF="STD-van-der-Kolk-1994" TYPE="STUDY">van der Kolk 1994</LINK>).</P>
<P>None of the four acute RCTs which employed a cross-over design (<LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>; <LINK REF="STD-Kaplan-1996" TYPE="STUDY">Kaplan 1996</LINK>; <LINK REF="STD-Reist-1989" TYPE="STUDY">Reist 1989</LINK>; <LINK REF="STD-Shestatzky-1988" TYPE="STUDY">Shestatzky 1988</LINK>) provided sufficient information for inclusion in the calculation of summary statistics. These trials were all small and of poor quality (mean CCDAN-QRS score of 12), however, so their exclusion is unlikely to have had a significant effect on the primary outcomes of the meta-analysis. (In brief: <LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK> compared an intervention of alprazolam with placebo using a sample of 16 outpatients over a period of 12 weeks. <LINK REF="STD-Kaplan-1996" TYPE="STUDY">Kaplan 1996</LINK> investigated the efficacy of inositol for a sample of 13 patients from two different outpatient clinics. <LINK REF="STD-Reist-1989" TYPE="STUDY">Reist 1989</LINK> conducted a crossover trial of the TCA, desipramine, in treating 27 combat veterans over a period of 10 weeks. <LINK REF="STD-Shestatzky-1988" TYPE="STUDY">Shestatzky 1988</LINK> assessed the efficacy of the MAOI phenelzine in a 12 week trial of 13 PTSD outpatients).</P>
<P>In determining the long-term effects of medication, Marshall (2004) assessed whether 17 responders in the medication arm of a 10 week trial of paroxetine continued to respond after an additional maintenance period of 12 weeks. In a relapse-prevention trial of sertraline, Davidson (2001) set out to determine whether 50 patients who were randomised to a placebo control for 28 weeks were more likely to experience clinical deterioration or relapse than those 46 patients randomised to a sertraline intervention for the same period. Participants in the relapse prevention phase of this trial had completed a 12 week acute RCT of sertraline, and had also met responder criteria following the subsequent open-label administration of this medication for a period of six months. In another relapse-prevention trial, Martenyi (2002) re-randomised 131 responders to a 12 week short-term RCT of fluoxetine to an additional 24 weeks of placebo or medication.</P>
<P>A great deal of clinical heterogeneity was observed across patients in the RCTs included this review. Of the 34 acute trials that provided information on the nature of the index trauma for PTSD, six were composed exclusively of war veterans (<LINK REF="STD-Chung-2004" TYPE="STUDY">Chung 2004</LINK>; <LINK REF="STD-Davidson-1990" TYPE="STUDY">Davidson 1990</LINK>; <LINK REF="STD-Hertzberg-2000" TYPE="STUDY">Hertzberg 2000</LINK>; <LINK REF="STD-Kosten-1991" TYPE="STUDY">Kosten 1991</LINK>; <LINK REF="STD-Pfizer589" TYPE="STUDY">Pfizer589</LINK>; <LINK REF="STD-Reist-1989" TYPE="STUDY">Reist 1989</LINK>), 9 contained individuals exposed to "civilian" traumas, such as earthquakes and child molestation (<LINK REF="STD-Brady-2000" TYPE="STUDY">Brady 2000</LINK>; <LINK REF="STD-Brady-2004" TYPE="STUDY">Brady 2004</LINK>; <LINK REF="STD-Conner-1999" TYPE="STUDY">Conner 1999</LINK>; <LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>; <LINK REF="STD-McRae-2004" TYPE="STUDY">McRae 2004</LINK>; <LINK REF="STD-Pfizer588" TYPE="STUDY">Pfizer588</LINK>; <LINK REF="STD-Reich-2004" TYPE="STUDY">Reich 2004</LINK>; <LINK REF="STD-Saygin-2002" TYPE="STUDY">Saygin 2002</LINK>; <LINK REF="STD-Smajkic-2001" TYPE="STUDY">Smajkic 2001</LINK>) and 19 contained patients exposed to both combat-related and civilian traumas (<LINK REF="STD-Baker-1995-a" TYPE="STUDY">Baker 1995 a</LINK>; <LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>; <LINK REF="STD-Butterfield-2001" TYPE="STUDY">Butterfield 2001</LINK>; <LINK REF="STD-Davidson-2001a" TYPE="STUDY">Davidson 2001a</LINK>; <LINK REF="STD-Davidson-2003" TYPE="STUDY">Davidson 2003</LINK>; <LINK REF="STD-Davidson-2004" TYPE="STUDY">Davidson 2004</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Eli-Lilly-2006" TYPE="STUDY">Eli Lilly 2006</LINK>; <LINK REF="STD-Hertzberg-1999" TYPE="STUDY">Hertzberg 1999</LINK>; <LINK REF="STD-Kaplan-1996" TYPE="STUDY">Kaplan 1996</LINK>; <LINK REF="STD-Katz-1994" TYPE="STUDY">Katz 1994</LINK>; <LINK REF="STD-Marshall-2001" TYPE="STUDY">Marshall 2001</LINK>; <LINK REF="STD-Martenyi-2002a" TYPE="STUDY">Martenyi 2002a</LINK>; <LINK REF="STD-Shestatzky-1988" TYPE="STUDY">Shestatzky 1988</LINK>; <LINK REF="STD-Tucker-2001" TYPE="STUDY">Tucker 2001</LINK>; <LINK REF="STD-Tucker-2003" TYPE="STUDY">Tucker 2003</LINK>; <LINK REF="STD-van-der-Kolk-1994" TYPE="STUDY">van der Kolk 1994</LINK>; <LINK REF="STD-van-der-Kolk-2004" TYPE="STUDY">van der Kolk 2004</LINK>; <LINK REF="STD-Zohar-2002" TYPE="STUDY">Zohar 2002</LINK>).Of the 24 short-term RCTs that providing information on comorbid psychopathology, 18 reported that the patients in the trials were diagnosed with other anxiety disorders besides PTSD, as classified according to DSM III, DSM-IV or DSM-IV-TR criteria (<LINK REF="STD-Brady-2000" TYPE="STUDY">Brady 2000</LINK>; <LINK REF="STD-Brady-2004" TYPE="STUDY">Brady 2004</LINK>; <LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>; <LINK REF="STD-Butterfield-2001" TYPE="STUDY">Butterfield 2001</LINK>; <LINK REF="STD-Davidson-1990" TYPE="STUDY">Davidson 1990</LINK>; <LINK REF="STD-Davidson-2001a" TYPE="STUDY">Davidson 2001a</LINK>; <LINK REF="STD-Davidson-2003" TYPE="STUDY">Davidson 2003</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Hertzberg-2000" TYPE="STUDY">Hertzberg 2000</LINK>; <LINK REF="STD-Kaplan-1996" TYPE="STUDY">Kaplan 1996</LINK>; <LINK REF="STD-Marshall-2001" TYPE="STUDY">Marshall 2001</LINK>; <LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>; <LINK REF="STD-Pfizer589" TYPE="STUDY">Pfizer589</LINK>; <LINK REF="STD-Reich-2004" TYPE="STUDY">Reich 2004</LINK>; <LINK REF="STD-Saygin-2002" TYPE="STUDY">Saygin 2002</LINK>; <LINK REF="STD-Shestatzky-1988" TYPE="STUDY">Shestatzky 1988</LINK>; <LINK REF="STD-Tucker-2001" TYPE="STUDY">Tucker 2001</LINK>; <LINK REF="STD-Tucker-2003" TYPE="STUDY">Tucker 2003</LINK>).The most commonly reported comorbid anxiety was panic disorder with or without agoraphobia, which was reported for 8 of the 12 studies that distinguished between individual anxiety disorder diagnostic categories (<LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>; <LINK REF="STD-Butterfield-2001" TYPE="STUDY">Butterfield 2001</LINK>; <LINK REF="STD-Davidson-1990" TYPE="STUDY">Davidson 1990</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Marshall-2001" TYPE="STUDY">Marshall 2001</LINK>; <LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>; <LINK REF="STD-Saygin-2002" TYPE="STUDY">Saygin 2002</LINK>; <LINK REF="STD-Tucker-2003" TYPE="STUDY">Tucker 2003</LINK>),</P>
<P>Summary statistics for the sertraline arm of the Tucker 2003 trial were excluded from the analysis, in favour of including the data from the less well represented citalopram arm. Data from the venlafaxine group in the unpublished Davidson trial (<LINK REF="STD-Davidson-2004" TYPE="STUDY">Davidson 2004</LINK>) was given preference to that from the sertraline arm, for the same reason. Summary statistics from the phenelzine arm of the Kosten 1991 trial were chosen above those from the imipramine arm in order to equalise the number of MAOI and TCA trials.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-02-12 15:28:29 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Generation of Allocation Sequence<BR/>
</B>
<BR/>The randomisation procedure employed was described in four trials. Computer generated random codes were employed in three of these trials (<LINK REF="STD-Conner-1999" TYPE="STUDY">Conner 1999</LINK>; <LINK REF="STD-Davidson-2001a" TYPE="STUDY">Davidson 2001a</LINK>; <LINK REF="STD-Martenyi-2002a" TYPE="STUDY">Martenyi 2002a</LINK>), while an urn randomisation procedure was followed in <LINK REF="STD-Brady-2004" TYPE="STUDY">Brady 2004</LINK>. </P>
<P>
<B>Allocation Concealment<BR/>
</B>
<BR/>Of the 35 short term RCTs, only five described the allocation sequence which was used in assigning participants to the treatment and comparison groups. Adequate allocation concealment (randomisation log kept by each trial's pharmacy division) was practised in three of these trials (<LINK REF="STD-Conner-1999" TYPE="STUDY">Conner 1999</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-McRae-2004" TYPE="STUDY">McRae 2004</LINK>). The remaining two trials did not provide sufficient information to determine the adequacy of the concealment used (<LINK REF="STD-Kaplan-1996" TYPE="STUDY">Kaplan 1996</LINK>; <LINK REF="STD-Martenyi-2002a" TYPE="STUDY">Martenyi 2002a</LINK>). </P>
<P>
<B>Blinding of Outcome Assessment<BR/>
</B>
<BR/>Although the majority of the trials were described as "double-blinded", only six of the short term trials explicitly described the assessment of outcome as blinded (<LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>; <LINK REF="STD-Davidson-1990" TYPE="STUDY">Davidson 1990</LINK>; <LINK REF="STD-Davis-2001" TYPE="STUDY">Davis 2001</LINK>; <LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>; <LINK REF="STD-Shestatzky-1988" TYPE="STUDY">Shestatzky 1988</LINK>; <LINK REF="STD-van-der-Kolk-2004" TYPE="STUDY">van der Kolk 2004</LINK>). The extent to which blinding was preserved in those flexible dose trials which adjusted dosage on the basis of tolerability is unclear, however. Indeed, outcome was assessed independently of medication administration and side-effect evaluation in only one RCT (<LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>). Two comparative RCTs did not employ any form of blinding (<LINK REF="STD-Smajkic-2001" TYPE="STUDY">Smajkic 2001</LINK>; <LINK REF="STD-Chung-2004" TYPE="STUDY">Chung 2004</LINK>), whereas it is not clear whether blinding was undertaken in another (<LINK REF="STD-Saygin-2002" TYPE="STUDY">Saygin 2002</LINK>). </P>
<P>
<B>Loss to follow up<BR/>
</B>
<BR/>On average, about 31.3 percent (718 out of 2291) of the participants in the 24 short term RCTs that provided drop-out data did not reach study endpoint, with the majority (N = 13) of these trials excluding over a quarter of the sample. Of the 13 trials, six did not attempt to include the withdrawals in the summary statistics through estimating outcomes by means of either LOCF or MM analyses (<LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>
<I>; </I>
<LINK REF="STD-Chung-2004" TYPE="STUDY">Chung 2004</LINK>
<I>; </I>
<LINK REF="STD-Davidson-1990" TYPE="STUDY">Davidson 1990</LINK>
<I>; </I>
<LINK REF="STD-Eli-Lilly-2006" TYPE="STUDY">Eli Lilly 2006</LINK>
<I>; </I>
<LINK REF="STD-Saygin-2002" TYPE="STUDY">Saygin 2002</LINK>
<I>; </I>
<LINK REF="STD-Smajkic-2001" TYPE="STUDY">Smajkic 2001</LINK>).</P>
<P>
<B>Quality Score<BR/>
</B>
<BR/>The average quality score on the CCDAN-QRS for the published short term trials was 22.8 points (range: 11 to 31) out of a maximum of 46 points. On this scale, 19 trials failed either to provide a record of the exclusion criteria used, or to report the number of people excluded by these criteria, 16 provided inadequate details of the side effects experienced by group, six RCTs did not provide information about funding, and three RCTs (excluding crossover trials) did not provide information about the comparability of the medication and control groups. Quality ratings were not calculated for the unpublished trials, due to the lack of sufficient descriptive data for these studies. <B>
<BR/>
</B>
</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-04-12 16:39:43 +0100" MODIFIED_BY="Sarah  R Davies">
<P>
<B>Primary outcome measures</B>
</P>
<P>Significant reductions in symptom severity were observed for patients who received medication in 17 short term trials from which it was possible to retrieve data for this outcome. The mean total CAPS score for the medication group was 5.76 points lower (95% CI -8.16 to -3.36, N = 2507) than that for the placebo group. Evidence for the efficacy of the SSRIs (N = 12) was once again observed (WMD = -5.95, 95% CI -8.9 to -3, N = 1907), with this class of medication making the largest contribution to the overall effect size observed (weight = 82.4%).</P>
<P>The comparison of the efficacy of particular SSRIs in reducing PTSD symptom severity provided evidence for the efficacy of both paroxetine (N = 4, WMD -10.49, 95% CI -13.87 to -7.11, N = 940) and to a lesser extent, sertraline (N = 6, WMD -3.78, 95% CI -6.9 to -0.65, N = 875), but not citalopram (N = 1, WMD -13.41, 95% CI -35 to 8.18, N = 33) or fluoxetine (N = 1, WMD -0.9, 95% CI -12.31 to 10.51, N = 59). The failure to detect a treatment effect for citalopram or fluoxetine presumably reflects the small samples, and hence low power, of these comparisons. There was no indication that brofaromine was more effective than placebo (N = 2, WMD -5.06, 95% CI -15.93 to 5.81, N = 178). Neither the single trials of the novel antidepressant nefazodone or the antipsychotic risperidone provided evidence of efficacy in reducing symptom severity (WMD -5.6, 95% CI -21.26 to 10.06, N = 41 and WMD -11, 95% CI -30.55 to 8.55, N = 21, respectively). This was also true of the single SNRI trial of venlafaxine (N = 1, WMD -4.8, 95% CI -11.73 to 2.13, N = 358).</P>
<P>With regards to direct comparisons, no difference in the reduction of symptom severity was observed in the two head-to-head comparisons of nefazodone and sertraline (SMD -0.19, 95% CI -0.63 to 0.25, N = 80), or in the single unpublished comparison of venlafaxine and sertraline (SMD -0.01, 95% CI -0.22 to 0.20, N = 352). Although the only trial to directly compare mirtazapine and sertraline (<LINK REF="STD-Chung-2004" TYPE="STUDY">Chung 2004</LINK>) reported that treatment with mirtazapine resulted in a larger number of responders on the CAPS than sertraline after six weeks of treatment (treatment response was defined as a reduction of over 30% on the total score of this scale), the authors were unable to detect a difference in efficacy when comparing these groups on the total CAPS score.<B>
<BR/>
</B>
<BR/>Patients who received medication were significantly more likely to be responders than those who received placebo in the 13 trials that provided data on this outcome (RR 1.49, 95% CI 1.28 to 1.73; random effects model, N = 1272), as determined by response rates on the Clinical Global Impressions scale change item (or close equivalent). Response to medication occurred in 59.1% of subjects (N = 644), while response to placebo was seen in 38.5% of subjects (N = 628). The short term efficacy of medication treatment was observed for the SSRIs as a group (N = 7, RR 1.59, 95% CI 1.39 to 1.82, N = 999), to which the significant overall effect of medication on treatment response can once again primarily be attributed (weight = 69.1%).</P>
<P>The pattern of treatment response on the CGI-I for the separate SSRI medications was similar to that observed for symptom severity, with both paroxetine (N = 3, RR 1.62, 95% CI 1.38 to 1.9, N = 719) and sertraline (N = 2, RR 1.71, 95% CI 1.22 to 2.4, N = 215) demonstrating efficacy. There was once again insufficient evidence to determine whether fluoxetine was effective in increasing the number of responders, relative to placebo (N = 2, RR 1.35, 95% CI 0.96 to 1.89, N =65). None of the individual trials of the TCA amitryptyline (RR 3.00, 95% CI 0.98 to 9.14, N = 40), the novel antidepressant mirtazapine (RR 2.91, 95% CI 0.82 to 10.39, N = 26), the antipsychotic olanzapine (N = 1, RR 1.00, 95% CI 0.42 to 2.4, N = 15), the anticonvulsant lamotrigine (N = 1, RR 2.00, 95% CI 0.33 to 12.18, N = 14), or the two trials of MAOI brofaromine (RR 1.16, 95% CI 0.79 to 1.72, N = 178) was significantly more effective than placebo in increasing treatment response.</P>
<P>The NNT analysis revealed that each patient who was treated with medication was approximately 21% more likely to become a responder as a result of being treated with medication over an average of 11 weeks than if they had been given placebo (NNT = 4.85, 95% CI 3.85 to 6.25). The equivalent percentages for the individual SSRIs was 23% for paroxetine (NNT = 4.31, 95% CI 3.33 to 6.25), 22% for sertraline (NNT = 4.49, 95% CI 2.86 to 10), and 16.5% for fluoxetine (NNT = 6.07). By way of comparison, a person diagnosed with PTSD was only 7% more likely to respond to treatment with brofaromine than with placebo (NNT = 13.94, 95% CI 4.76 to 14.29).</P>
<P>Continued reduction of symptom severity on the CAPS was observed in the 10 week extension phase of the 12 week placebo-controlled RCT of paroxetine (<LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>). An increased rate of relapse (defined as a &gt;= 40% increase on the eight item Treatment Outcome PTSD scale (TOP-8) and an increase in CGI-S score of &gt;= 2) was observed in those patients who were randomised to placebo after responding to a 12 week trial of fluoxetine (<LINK REF="STD-Martenyi-2002a" TYPE="STUDY">Martenyi 2002a</LINK>). Davidson (2001) additionally found that over half of the 96 outpatients who had initially responded to six months of treatment with sertraline experienced worsening of symptoms once switched over to placebo, with patients in this group being 6.35 times more likely to relapse than those participants who remained on medication. A patient was considered to have relapsed in this trial if they met all of the following criteria: an increase in CGI-I score of at least three points, an increase in CAPS score of at least 30% and 15 points, and if the patient experienced significant clinical deterioration (as determined by the clinician).</P>
<P>
<B>Secondary outcome measures</B>
</P>
<P>The overall symptom severity effect size for trials which did not employ the CAPS confirmed the presence of a treatment effect of medication relative to placebo (N =6, SMD -0.44, 95% CI -0.87 to -0.01, N = 147). Consistent results were also observed for the total scores of the self-rated scales (IES and DTS), in which medication reduced symptom severity by -0.31 standard deviation units compared to placebo (N = 9, 95% CI -0.51 to -0.11, N = 882). A significant effect of medication treatment was observed for the SSRIs (SMD -0.20, 95% CI -0.34 to -0.06, N = 769), the RCT of the MAOI phenelzine (SMD -1.06, 95% CI -1.75 to -0.36, N = 37), as well as for the TCA amitryptiline (SMD -0.9, 95% CI -1.62 to -0.18, N = 33), while no such effect was found for either of the single olanzapine and nefazodone trials.</P>
<P>The significantly reduced scores on the re-experiencing/intrusion (N = 9, WMD -2.06, 95% CI -3.02 to -1.1, N = 1304), avoidance/numbing (N = 9, WMD -4.06, 95% CI -5.41 to -2.7, N = 1304), and hyperarousal (N = 9, WMD -3.1, 95% CI -4.1 to -2.1, N = 1304) subscales of the CAPS indicates that the efficacy of medication is not limited to particular symptom clusters. The positive findings for the nine trials which provided summary statistics on these subscales was primarily attributable to the seven SSRI trials, which together contributed an average of 95% to the magnitude of the overall effect sizes on these subscales. The remaining trials of nefazodone and risperidone provided no evidence of efficacy on any of the symptom clusters measured by the CAPS. Symptoms of avoidance/numbing (N = 4, SMD -0.49, 95% CI -0.9 to -0.08, N = 268) but not re-experiencing/intrusion (N = 4, SMD -0.43, 95% CI -0.98 to 0.13, N = 268) were reduced after treatment according to the subscales of the self-rated scales.</P>
<P>With regards to comorbidity, medication demonstrated greater efficacy in alleviating the symptoms of depression than placebo, as assessed by a range of depression scales. This was true for both trials which reported mean endpoint scale ratings (N = 7, SMD -0.34, 95% CI -0.57 to -0.10, N = 459), as well as for the RCTs which only reported change scores (N= 3, SMD -0.33, 95% CI -0.6 tp -0.07, N = 887). The finding that SSRIs were more effective than placebo in the trials reporting change scores, but not in those which provided endpoint summary scores (N = 4, SMD -0.19, 95% CI -0.39 to 0.02, N = 364) could be attributed to less variability in the former comparison, as it only included a single medication agent (paroxetine). The increased precision of effect size estimates when change scores are used, and the greater sample size and associated power of this comparison are also likely causes of this discrepancy.</P>
<P>The observation that anxiety symptoms were not noticeably reduced by medication interventions, as assessed by the HAM-A (N =3, WMD -2.17, 95% CI -7.22 to 2.88, N = 287), is largely a reflection of the lack of evidence for the efficacy of the SSRIs (N = 2, WMD 0.58, 95% CI -1.97 to 3.14, N = 254), with single trials of other medications demonstrating efficacy on the HAM-A (amitryptiline) and on other anxiety scales (phenelzine). The only head-to-head comparison of nefazodone with sertraline for which comorbidity summary statistics were available demonstrated that these medications were equally effective in reducing symptoms of depression (WMD -0.84, 95% CI -7.88 to 6.20, N = 26) and of anxiety (WMD -3.23, 95% CI -10.9 to 4.44, N =26). No difference in the efficacy of mirtazapine and sertraline in reducing symptoms of depression on the HAM-D was reported for the one trial which compared these medications.</P>
<P>Quality of life was significantly improved by pharmacotherapy (N = 5, WMD -2.54, 95% CI -3.68 to -1.41, N = 752), according to summary statistics on the Sheehan Disability Scale (SDS). This was primarily due to the SSRI interventions (WMD -2.56, 95% CI -3.7 to -1.41, N = 737), with only one of the four trials in this class not demonstrably superior to placebo in improving functioning according to this measure of social, work and family-related functioning. Patients receiving medication were more likely to withdraw from treatment due to side-effects experienced than those who received placebo (N = 21, RR 1.44, 95% CI 1.04 to 2, N = 2116). Nevertheless, the overall effect sizes for each of the medication classes reveals that the administration of medication in the 10 SSRI (N = 1649), three MAOI (N = 196) and two TCA (N = 100) trials did not result in a significantly greater number of withdrawals due to side effects than administering placebo (although the SSRIs come close (RR = 1.42, 95%CI = 0.99, 2.05 )). The same observation was made with respect to the individual SSRI agents. In addition, the overlap between confidence intervals reveals no differences in tolerability for either the medication classes or the SSRIs. Although Saygin (2002) found that nefazodone resulted in significantly higher side-effect scores than sertraline on the CGI, no differences in tolerability between these medications was observed by McRae (2004). A significantly larger proportion of patients (8 out of 13) who were randomised to the venlafaxine arm of a small unblinded multi-arm RCT dropped out due to adverse events (<LINK REF="STD-Smajkic-2001" TYPE="STUDY">Smajkic 2001</LINK>) than those patients randomised to either the sertraline or paroxetine arms of this trial.</P>
<P>
<B>Heterogeneity<BR/>
</B>
<BR/>With regards to the overall heterogeneity of trial results, the chi squared test revealed a similar degree of variation between the outcomes of trials for both treatment response and symptom severity (Chi = 16.3, P = 0.18, df = 12 and Chi = 22.04, P = 0.14, df = 16, respectively). The same finding was made across all of the secondary outcome measures employed, with the exception of the scores on the HAM-A (Chi = 10, P = 0.007), where amitryptiline demonstrated superiority over the two SSRI trials in reducing anxiety on this scale, relative to placebo. No differences were observed in the reduction of symptom severity between the SSRI and MAOIs trials (Q<SUB>b</SUB> = 0.06, P =0.81, df = 14), while extensive overlap between the confidence intervals for all of the medication classes on the CGI-I indicated little difference in terms of the proportion of non-responders in these groups. The separation of the effects of the SSRIs by agent revealed that paroxetine was more effective in reducing symptom severity than sertraline (Q<SUB>b</SUB> = 8.86, P &lt; 0.01). Indeed, the reduction of symptom severity was nearly twice as large for paroxetine as for all the medications combined (WMD -10.49 versus -5.76). Nevertheless, no such differences in the efficacy of any of the SSRI medications was observed for treatment response. There were too few trials on the secondary outcomes to determine relative efficacy of different medication classes.</P>
<P>
<B>Subgroup analyses<BR/>
</B>
<BR/>Symptom severity in the six trials which took place across multiple centres for which the CAPS total score was available was reduced to a greater extent than the eight trials conducted within single centres (Q<SUB>b</SUB> = 2.8, P = 0.09, df = 13). However, this effect was not observed in the analysis of treatment response (N = 13; 95% CI for single centre trials 1.2 to 2.6, N =188; 95% CI for multi-centre trials 1.2 to 1.72, N = 1084). No difference in treatment response was evident in the comparison of industry funded trials versus non-industry funded trials either, as the confidence interval of the effect size for the former (N = 9, 95% CI 1.41 to 1.84, N = 1053) was contained within the confidence interval of the latter (N = 3, 95% CI 0.81 to 2.87, N = 105).</P>
<P>Symptom severity decreased to an equivalent extent (Q<SUB>b</SUB> = 0.5, P = 0.48) in trials which included depressed participants (N = 9, SMD -0.35, 95% CI -0.46 to -0.23, N = 1304) as in those which did not (N = 2, SMD -0.48, 95% CI -1.52 to 0.56, N = 151). RCTs which contained few combat veterans (N = 8, average proportion of war veterans = 3%) demonstrated a significantly greater reduction in symptom severity following medication treatment (Q<SUB>b</SUB> = 4.12, P = 0.04) than trials with a large percentage of participants with combat-related trauma (N = 4, average proportion = 61.1%). The difference between these groups was not detected with respect to treatment response, however, as evidenced by the inclusion of the confidence interval for the latter group (N = 5, average proportion = 3.8%) within the confidence interval of the former (N = 8, average proportion = 56%).</P>
<P>The finding of a difference in the reduction of symptom severity between trials with few war veterans versus those with many was not surprising, given the general characterisation of the war trauma subgroup of PTSD sufferers as more treatment resistant than other subgroups. War veteran samples are typically predominantly male (86.7% versus 32.8% in the groups compared in this review), and have more severe (84.9 versus 74.6 points on the CAPS) and chronic (21.1 years versus 10.9 years) PTSD than those trials composed of patients with other types of trauma. In addition, although it was not possible to observe differences in treatment response for these two group, four of the five trials with fewer war veterans demonstrated superior treatment response amongst participants given medication, as compared to none of the eight trials with a substantial proportion of veterans.</P>
<P>
<B>Sensitivity analyses</B>
</P>
<P>The comparison of the analysis of treatment efficacy in terms of treatment non-response as opposed to response on the CGI-I (or equivalent) revealed similar outcomes for both the overall short-term efficacy of medication (N = 13, RR 0.66, 95% CI 0.6 to 0.74, N = 1272), as well as the efficacy of the SSRIs in treating PTSD (N = 7, RR 0.65, 95% CI 0.58 to 0.74, N = 999). However, whereas the use of treatment response as a summary statistic indicated that both the TCA amitryptyline and the novel antidepressant mirtazapine were no more effective than placebo, relative risk of non-response to treatment provides evidence that both of these medications are more effective over the short-term than placebo (mirtazapine: RR 0.45, 95% CI 0.22 to 0.94, N = 26; amitryptyline: RR 0.6, 95% CI 0.38 to 0.96, N = 40). It seems probable that the failure to find a significant effect for these two agents on treatment response reflects the lack of sensitivity of the relative risk of benefit for therapeutic trials to the effects of interventions when the placebo response rate is low (<LINK REF="REF-Deeks-2002" TYPE="REFERENCE">Deeks 2002</LINK>), as was the case for these two trials.<BR/>
<BR/>The number of participants responding to medication was significantly higher relative to the placebo control in both the worst case scenario (N = 12, RR 1.37, 95% CI 1.12 to 1.69, N = 1275), where those participants from the medication group who were not included in the analysis were regarded as non-responders, and in the best case scenario (N = 12, RR 1.53, 95% CI 1.22 to 1.9, N = 1262), in which those participants excluded from the placebo control were regarded as non-responders. The overlap in the confidence intervals for these two outcomes indicates that loss to follow up is unlikely to have influenced assumptions made about the overall efficacy of medication.</P>
<P>
<B>Publication bias</B>
</P>
<P>The distribution of trials on a funnel plot for treatment response (see Additional Figures: <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) provides no evidence of substantial publication bias. A slight skewness in the distribution of trials on the funnel plot for the CAPS (see Additional Figures: <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) could be interpreted as evidence of a tendency for trials with larger standard errors and smaller effect sizes to go unreported.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-02-12 15:45:18 +0000" MODIFIED_BY="[Empty name]">
<P>This review provides evidence of the efficacy of medication in the short-term treatment of PTSD, as assessed on the primary outcome measures of responder status and symptom severity. Medication was significantly more effective than placebo across the three symptom clusters which characterize PTSD (re-experiencing/intrusion, avoidance/numbing, and hyperarousal) as assessed by the CAPS subscales. Scores on the self-rated symptom severity scales confirmed medications' effectiveness in reducing overall symptom severity, as well as PTSD avoidance symptoms. In addition, the administration of medication resulted in a reduction in comorbid symptoms, and the improvement in quality of life measures. These findings hold despite the clinical heterogeneity of PTSD subjects included in the reviewed trials (see Table 1 - Characteristics of Included Studies). Although a recent guideline noted that, with few exceptions, the overall effect size for medication trials of PTSD failed to exceed the limit of 0.5 defined as indicative of clinical effectiveness (<LINK REF="REF-NICE-2005" TYPE="REFERENCE">NICE 2005</LINK>), we would caution that there is no direct translation between the effect size statistic and assessments of clinical effectiveness. The findings here that the CGI-I response rate was 59.1% on medication and 38.5% on placebo, and of a relatively low NNT of 4.85, support the growing clinical consensus that medication does have an important role in the treatment of PTSD.</P>
<P>The current evidence base of RCTs is unable to demonstrate superior efficacy or acceptability for any particular medication class. Although some have suggested that the SSRIs are more effective than older antidepressants (<LINK REF="REF-Dow-1997" TYPE="REFERENCE">Dow 1997</LINK>; <LINK REF="REF-Penava-1996" TYPE="REFERENCE">Penava 1996</LINK>), class membership did not contribute significantly to the variation observed in symptom severity outcomes between trials, while the confidence intervals for the summary statistic of responder status on the seven SSRI trials overlapped with that of the MAOI and TCA trials. Similarly, direct comparisons of sertraline and nefazodone demonstrated that these medications were equally effective in reducing PTSD symptom severity. Although the SSRIs have often been said to have superior tolerability in comparison to older medication classes, this was not readily apparent on analysis of drop-out rates due to treatment emergent side-effects in medication versus placebo groups. However, it should be emphasized that drop-out rates due to adverse events may not always provide an accurate measure of medication tolerability (<LINK REF="REF-Loke-2005" TYPE="REFERENCE">Loke 2005</LINK>). In addition, it is important to be aware of the need for careful monitoring after initiation of SSRIs (<LINK REF="REF-CSM-2004" TYPE="REFERENCE">CSM 2004</LINK>). Nevertheless, the SSRI trials constitute the bulk of the evidence for the efficacy of medication in treating PTSD, both in terms of the number of studies and their size. The finding of the effectiveness of the SSRIs were also more robust to differences in the particular summary statistic employed than was the case for either the amitryptiline or mirtazapine trials. It is therefore reasonable to support the expert consensus (<LINK REF="REF-Foa-1999" TYPE="REFERENCE">Foa 1999</LINK>; <LINK REF="REF-Ballenger-2000" TYPE="REFERENCE">Ballenger 2000</LINK>; <LINK REF="REF-Ballenger-2004" TYPE="REFERENCE">Ballenger 2004</LINK>) that SSRIs constitute the first line medication choice in PTSD.</P>
<P>Nevertheless, the efficacy of medication in PTSD is unlikely to extend to all medications. While there is preliminary evidence that paroxetine is more effective than sertraline in reducing the severity of PTSD symptoms, and although the two mirtazapine trials provide some support for the efficacy of this agent, neither of the brofaromine, olanzapine and lamotrigine trials demonstrated efficacy with regards to treatment response or symptom reduction. Given the lack of a placebo control in two of the RCTs of nefazadone, and the negative finding with regards to symptom reduction in the third, evidence of the efficacy of this medication must be regarded as inconclusive. The failure to detect an effect of medication in the olanzapine and lamotrigine trials, despite other open-label evidence that olanzapine is effective in combating PTSD (<LINK REF="REF-Petty-2001" TYPE="REFERENCE">Petty 2001</LINK>
<B>; </B>
<LINK REF="STD-Pivac-2004" TYPE="STUDY">Pivac 2004</LINK>), may, however, be attributable to the small samples employed (average number = 15). Similarly, the failure of amitriptyline to alleviate the symptoms of PTSD in the only trial of this medication can perhaps be explained by the short duration of the trial (four weeks). Methodological limitations in the form of small sample size and short duration might also account for the negative findings of the crossover trials of alprazolam, inositol, desipramine, and phenelzine. This possibility is supported by the finding of reduced symptom severity in the only other controlled trial of phenelzine (<LINK REF="STD-Kosten-1991" TYPE="STUDY">Kosten 1991</LINK>). Nevertheless, the lack of efficacy of desipramine could arguably support the (at this stage speculative) hypothesis that more noradrenergic agents (such as desipramine) are less useful than more serotonergic agents in PTSD (<LINK REF="REF-Dow-1997" TYPE="REFERENCE">Dow 1997</LINK>; <LINK REF="REF-Penava-1996" TYPE="REFERENCE">Penava 1996</LINK>). The question of whether benzodiazepines are useful immediately after trauma (<LINK REF="STD-Gelpin-1996" TYPE="STUDY">Gelpin 1996</LINK>; <LINK REF="REF-Mellman-1998" TYPE="REFERENCE">Mellman 1998</LINK>) or in PTSD remains debated, although recent expert consensus panels have suggested caution (<LINK REF="REF-Foa-1999" TYPE="REFERENCE">Foa 1999</LINK>; <LINK REF="REF-Ballenger-2000" TYPE="REFERENCE">Ballenger 2000</LINK>; <LINK REF="REF-Ballenger-2004" TYPE="REFERENCE">Ballenger 2004</LINK>) in the use of these agents.<BR/>
<BR/>Neither the potential clinical (presence of combat trauma, comorbid depression) or methodological (single versus multi-centre trials, industry versus non-industry funding) predictors of medication response tested in this review can account for the substantial proportion (41%) of patients who do not appear to respond to medication. The finding that symptom severity is reduced to a greater extent in the multi-centre than the single centre trials should be interpreted with caution, not only due to the marginal significance of this finding, but also because it was not possible to replicate this finding with regards to treatment response. The failure to detect an association between the presence of participants with comorbid major depression and treatment efficacy indicates that medications are unlikely to exert their effects in PTSD indirectly via a reduction in depressive symptoms.</P>
<P>This review found some evidence that war veterans are more resistant to pharmacotherapy than other patient groups, at least with regards to the reduction of symptom severity. This was despite the fact that a number of RCTs with war veteran samples were excluded from this review (<LINK REF="STD-Hamner-1997" TYPE="STUDY">Hamner 1997</LINK>; <LINK REF="STD-Hamner-2003" TYPE="STUDY">Hamner 2003</LINK>; <LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK>; <LINK REF="STD-Monnelly-2003" TYPE="STUDY">Monnelly 2003</LINK>; <LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>; <LINK REF="STD-Bartzokis-2005" TYPE="STUDY">Bartzokis 2005</LINK>) (see Table 2 - Characteristics of Excluded Studies), and that it was not possible to classify certain large-scale unpublished trials according to trauma type (<LINK REF="STD-Davidson-2004" TYPE="STUDY">Davidson 2004</LINK>; <LINK REF="STD-Eli-Lilly-2006" TYPE="STUDY">Eli Lilly 2006</LINK>; <LINK REF="STD-SKB627" TYPE="STUDY">SKB627</LINK>). Further research is therefore required to determine conclusively whether being a war veteran is a significant predictor of treatment response, and to distinguish the effects of this trauma subtype from other potential predictors of treatment response with which it is associated (such as being male, and having more chronic and severe PTSD). It is possible that the crucial factor is not so much being a war veteran, but rather being a veteran of particular wars (<LINK REF="STD-Zohar-2002" TYPE="STUDY">Zohar 2002</LINK>). Given the heterogeneous phenomenology of PTSD, it remains crucial to determine the factors which do predict response to medication, and also to delineate whether certain medications are more effective for particular symptom sets (including symptoms such as psychosis (<LINK REF="REF-Hamner-1996" TYPE="REFERENCE">Hamner 1996</LINK>), dissociation (<LINK REF="REF-Fichtner-1990" TYPE="REFERENCE">Fichtner 1990</LINK>; <LINK REF="REF-Marshall-1998b" TYPE="REFERENCE">Marshall 1998b</LINK>) and vulnerability to stress (<LINK REF="REF-Connor-1999" TYPE="REFERENCE">Connor 1999</LINK>)). Future RCTs and meta-analyses should attempt to address such questions in greater detail.</P>
<P>The importance of long-term treatment of PTSD is indicated by the observation of a continued improvement of PTSD symptoms following acute treatment with paroxetine but not placebo (<LINK REF="STD-Marshall-2004" TYPE="STUDY">Marshall 2004</LINK>). The conclusion that a short-term course of treatment with SSRIs may be inadequate is supported by increased relapse rates in trials of both fluoxetine (<LINK REF="STD-Martenyi-2002b" TYPE="STUDY">Martenyi 2002b</LINK>) and sertraline (<LINK REF="STD-Davidson-2001b" TYPE="STUDY">Davidson 2001b</LINK>). The findings of these trials are consistent with consensus recommendations of six to twelve months medication treatment for acute PTSD (<LINK REF="REF-Foa-1999" TYPE="REFERENCE">Foa 1999</LINK>), and interventions of at least 12 months to prevent relapse in the treatment of chronic PTSD (<LINK REF="REF-Foa-1999" TYPE="REFERENCE">Foa 1999</LINK>; <LINK REF="REF-Ballenger-2000" TYPE="REFERENCE">Ballenger 2000</LINK>; <LINK REF="REF-Ballenger-2004" TYPE="REFERENCE">Ballenger 2004</LINK>).<B>
<BR/>
</B>
<BR/>Although the current review does not directly address the question of whether medication or psychotherapy exerts a larger effect in PTSD (<LINK REF="REF-van-Etten-1998" TYPE="REFERENCE">van Etten 1998</LINK>), combined treatment is often used in clinical settings, and this may contribute to the effects of psychotherapy in published studies. Conversely, it has been speculated that the high placebo response rate observed in some of the trials included in this review (<LINK REF="STD-Brady-2000" TYPE="STUDY">Brady 2000</LINK>; <LINK REF="STD-van-der-Kolk-2004" TYPE="STUDY">van der Kolk 2004</LINK>) might be the consequence of psychological support provided to the patients as an inadvertent consequence of participating in the rigorous assessment procedures implemented within the trials (<LINK REF="REF-Krakow-2000" TYPE="REFERENCE">Krakow 2000</LINK>; <LINK REF="STD-van-der-Kolk-2004" TYPE="STUDY">van der Kolk 2004</LINK>). Nevertheless, in one of the trials for which this suggestion was made (<LINK REF="STD-van-der-Kolk-2004" TYPE="STUDY">van der Kolk 2004</LINK>), the authors still discovered psychotherapy (Eye Movement Desensitization and Reprocessing (EMDR)) to be more effective than fluoxetine in maintaining the complete remission of PTSD symptoms six months after the end of a eight week placebo-controlled RCT. There are, however, few direct comparisons of the efficacy of pharmacotherapy and psychotherapy for PTSD, and given that few psychotherapy RCTs have masked treatment assignment (NICE 2005) indirect comparisons of effect sizes may also have limited utility. Theoretically, modern understanding of PTSD as involving psychobiological dysfunctions would indicate that it is unnecessary to institute false dichotomies between brain and mind, and that both kinds of intervention might be useful (<LINK REF="REF-Southwick-1993" TYPE="REFERENCE">Southwick 1993</LINK>; <LINK REF="REF-Khouzam-1997" TYPE="REFERENCE">Khouzam 1997</LINK>). Certain medications (e.g. benzodiazepines) have, however, been argued to diminish the effects of psychotherapy, so rigorous comparative studies are needed.</P>
<P>Additional questions for future pharmacological research in the area of PTSD include the effectiveness of medication in clinical settings, and the precise effects of medication on quality of life measures (<LINK REF="REF-Fossey-1994" TYPE="REFERENCE">Fossey 1994</LINK>; <LINK REF="REF-Rapaport-2002" TYPE="REFERENCE">Rapaport 2002</LINK>). Further research on medication in PTSD in different age samples (<LINK REF="REF-Famularo-1988" TYPE="REFERENCE">Famularo 1988</LINK>; <LINK REF="REF-Looff-1995" TYPE="REFERENCE">Looff 1995</LINK>; <LINK REF="REF-Harmon-1996" TYPE="REFERENCE">Harmon 1996</LINK>; <LINK REF="REF-Horrigan-1996" TYPE="REFERENCE">Horrigan 1996</LINK>; <LINK REF="REF-Seedat-2001" TYPE="REFERENCE">Seedat 2001</LINK>), on patients with comorbid substance use disorders (<LINK REF="REF-Liebowitz-1989" TYPE="REFERENCE">Liebowitz 1989</LINK>; <LINK REF="REF-Brady-1995" TYPE="REFERENCE">Brady 1995</LINK>; <LINK REF="STD-Brady-2004" TYPE="STUDY">Brady 2004</LINK>), and on more treatment-refractory (<LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>; <LINK REF="REF-Demartino-1995" TYPE="REFERENCE">Demartino 1995</LINK>; <LINK REF="STD-Hamner-1997" TYPE="STUDY">Hamner 1997</LINK>; <LINK REF="REF-Hamner-1998" TYPE="REFERENCE">Hamner 1998</LINK>; <LINK REF="REF-Hidalgo-1999" TYPE="REFERENCE">Hidalgo 1999</LINK>; <LINK REF="STD-Stein-2002" TYPE="STUDY">Stein 2002</LINK>; <LINK REF="STD-Raskind-2003" TYPE="STUDY">Raskind 2003</LINK>; <LINK REF="STD-Bartzokis-2005" TYPE="STUDY">Bartzokis 2005</LINK>) or non-compliant (<LINK REF="REF-Kroll-1990" TYPE="REFERENCE">Kroll 1990</LINK>) patients is also needed. In addition, randomised controlled trials are needed to determine the efficacy of promising medications, such as tiagabine (<LINK REF="REF-Taylor-2003" TYPE="REFERENCE">Taylor 2003</LINK>), tianeptine (<LINK REF="REF-Onder-2005" TYPE="REFERENCE">Onder 2005</LINK>) and topirimate (<LINK REF="REF-Berlant-2002" TYPE="REFERENCE">Berlant 2002</LINK>; <LINK REF="REF-Berlant-2004" TYPE="REFERENCE">Berlant 2004</LINK>), for which only open-label trials have been conducted thus far.</P>
<P>Given the high prevalence and enormous personal and societal costs of PTSD, there are still relatively few RCTs of pharmacotherapy for PTSD. No controlled trials were found in paediatric or geriatric subjects. With few exceptions (<LINK REF="STD-Baker-1995-a" TYPE="STUDY">Baker 1995 a</LINK>; <LINK REF="STD-Reist-1989" TYPE="STUDY">Reist 1989</LINK>; <LINK REF="STD-Braun-1990" TYPE="STUDY">Braun 1990</LINK>; <LINK REF="STD-Davidson-1990" TYPE="STUDY">Davidson 1990</LINK>; <LINK REF="STD-Hertzberg-1999" TYPE="STUDY">Hertzberg 1999</LINK>; <LINK REF="STD-Hertzberg-2000" TYPE="STUDY">Hertzberg 2000</LINK>; <LINK REF="STD-Brady-2004" TYPE="STUDY">Brady 2004</LINK>), trials have excluded patients with comorbid substance use. One such exception to be included in this review was a RCT of sertraline in treating concurrent PTSD and alcoholism (<LINK REF="STD-Brady-2004" TYPE="STUDY">Brady 2004</LINK>), in which little difference was found in the efficacy of medication versus placebo in reducing symptom severity. Also, although outside the scope of the current review, there seem to be few RCTS of the treatment of traumatised patients prior to their meeting criteria for PTSD (<LINK REF="REF-Robert-1999" TYPE="REFERENCE">Robert 1999</LINK>; <LINK REF="STD-Pitman-2002" TYPE="STUDY">Pitman 2002</LINK>; <LINK REF="REF-Mellman-2002" TYPE="REFERENCE">Mellman 2002</LINK>; <LINK REF="STD-Schelling-2004" TYPE="STUDY">Schelling 2004</LINK>), a potentially important clinical area.</P>
<P>Finally, the inherent problems of meta-analysis should also be borne in mind (<LINK REF="REF-Bailar-1997" TYPE="REFERENCE">Bailar 1997</LINK>); certainly these are by no means a substitute for clinical research. This is especially the case when there is evidence of the possibility that smaller trials with negative outcomes are not being published. Furthermore, the context of clinical practice differs from controlled trials in many respects, not the least being the inclusion of more complex patients (including patients with possible "secondary gain" from symptoms, a group that has been specifically excluded from more recent RCTs (<LINK REF="STD-Brady-2000" TYPE="STUDY">Brady 2000</LINK>)) and the possible need for polypharmacy in a subgroup of PTSD patients (<LINK REF="REF-Kolb-1984" TYPE="REFERENCE">Kolb 1984</LINK>; <LINK REF="REF-Kinzie-1989" TYPE="REFERENCE">Kinzie 1989</LINK>; <LINK REF="REF-Burdon-1991" TYPE="REFERENCE">Burdon 1991</LINK>; <LINK REF="REF-Hargrave-1993" TYPE="REFERENCE">Hargrave 1993</LINK>; <LINK REF="REF-Leyba-1998" TYPE="REFERENCE">Leyba 1998</LINK>). Moreover, methodological shortcomings, such as failure to employ independent outcome assessors in trials which adjust medication dosage on the basis of side-effect severity, and inadequate statistical methods of compensating for patient withdrawals, risk undermining the best efforts to minimise bias in the findings of systematic reviews of health care interventions.<I>
<BR/>
</I>
<BR/>However, an advantage of the Cochrane Collaboration is that it encourages regular updating of reviews in the light of new data, and hopefully additional data from new randomised controlled trials of medication in PTSD will become available for inclusion in a revised systematic review in the future. Given the high prevalence of PTSD, its chronicity and morbidity, and its enormous personal and societal costs, additional prospective research on the pharmacological prevention and treatment of this disorder is clearly required, and systematic reviews and retrospective analyses may be useful in integrating the findings of such work as well as in suggesting areas for further investigation.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Medication treatments can be effective in PTSD, acting to reduce its core symptoms, and should be considered as part of the treatment of this disorder. The existing evidence base of RCTs includes a heterogenous sample of participants with a range of different traumas, trauma duration and severity, and comorbidity. Although there is also no clear evidence to show that any particular class of medication is more effective or better tolerated than any other, the greatest number of trials showing efficacy to date, as well as the largest, have been with the SSRIs. In contrast, there have been negative studies of benzodiazepines, MAOIs, anti-psychotics, lamotrigine and inositol. In addition, although there was only one RCT in which psychotherapy was compared with pharmacotherapy, from a clinical perspective it is as well to remember the possible value of this modality alone or in combination with pharmacotherapy. The findings of maintenance trials support the value of long-term interventions in increasing the efficacy of medication and preventing relapse. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Given the prevalence and costs of PTSD, there is a need for further controlled clinical trials in the treatment of this disorder. The differential efficacy and acceptability of different classes of medication, including newer agents potentially useful in this disorder (e.g. escitalopram, tiagabine, tianeptine, tropirimate), requires study. Questions for future research also include the precise effects of medication on quality of life measures, appropriate dose and duration of medication, and determining factors which predict response to medication. Further research on the value of medication in PTSD in different trauma groups, in paediatric and geriatric subjects, in patients with comorbid substance use, and in treatment-refractory patients is needed. Clinical trials to determine the possible benefits of early (prophylactic), combined (with psychotherapy), and long-term (maintenance) intervention in PTSD may also be valuable.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors are supported by the MRC Research Unit on Anxiety and Stress Disorders (Cape Town, South Africa). The authors wish to thank Cochrane Collaboration internal and external reviewers for comments on an earlier draft, and for providing advice on the process of a Cochrane Collaboration review. In particular, Dianne O'Connell provided statistical advice for the first version of this review. We would also like to thank George Bartzokis, Susan Brady and Phebe Tucker for responding to requests for additional data for the update to the review, and Bessel van der Kolk and Randall Marshall for letting us have access to unpublished trials. At CCDAN, Hugh McGuire provided help with literature searches. Joy Oliver of the South African Cochrane Centre help retrieve a number of trial reports in updating the review. Finally, we are especially indebted to the UK Cochrane collaboration for providing funding to update this review, and Elizabeth Waters and Nandi Siegfried in particular for their part in organising the funding. Nandi Siegfried also arranged for one of the reviewers (JI) to attend a 5 day Cochrane workshop in preparation for updating this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The MRC Anxiety and Stress Disorders Research Unit has received funding from almost all pharmaceutical companies involved with psychiatry in South Africa. </P>
<P>
<B>Potential conflicts of interest for individual reviewers<BR/>
</B>
<BR/>Dan Stein has received research grants and/or consultancy honoraria from Astrazeneca, Eli-Lilly, GlaxoSmithKline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, and Wyeth. He has participated in a number of ongoing trials, and has presented data from some of these trials on behalf of the sponsoring companies.</P>
<P>Jonathan Ipser has no known conflicts of interest outside of his employment by the MRC Unit on Anxiety Disorders.</P>
<P>Soraya Seedat has received support from several companies (including GlaxoSmithKline, Eli-Lilly, Pfizer, Cephalon) and has participated in several clinical trials.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-04-12 16:40:14 +0100" MODIFIED_BY="Sarah  R Davies">
<P>Dan Stein co-ordinated the intitial work of this review, including literature search, trial assessment, and data analysis. Jonathan Ipser assisted with all aspects of updating the review, including literature search, trial assessment, and data analysis. Soraya Seedat provided help with critical interpretation of studies.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-04-12 16:56:11 +0100" MODIFIED_BY="Sarah  R Davies">
<STUDIES MODIFIED="2016-04-12 16:56:11 +0100" MODIFIED_BY="Sarah  R Davies">
<INCLUDED_STUDIES MODIFIED="2016-04-12 16:56:11 +0100" MODIFIED_BY="Sarah  R Davies">
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-1995-a" NAME="Baker 1995 a" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick D, Keller T et al</AU>
<TI>A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>122</VL>
<NO>4</NO>
<PG>386-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connor KM, Hidalgo RB, Crockett B, Malik M, Katz RJ, Davidson JR</AU>
<TI>Predictors of treatment response in patients with posttraumatic stress disorder</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>2</NO>
<PG>337-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brady-2000" NAME="Brady 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR et al</AU>
<TI>Efficacy and safety of sertraline treatment of posttraumatic stress disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>14</NO>
<PG>1837-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J et al</AU>
<TI>Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>12</NO>
<PG>1974-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Landerman LR, Farfel GM, Clary CM</AU>
<TI>Characterizing the effects of sertraline in post-traumatic stress disorder</TI>
<SO>Psychological Medicine</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>4</NO>
<PG>661-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaffney M</AU>
<TI>Factor analysis of treatment response in posttraumatic stress disorder</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>1</NO>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapaport MH, Endicott J, Clary CM</AU>
<TI>Posttraumatic stress disorder and quality of life: Results across 64 weeks of sertraline treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapaport MH, Farfel G, Clary CM</AU>
<TI>Quality of life improvement in PTSD with sertraline treatment: Results of a multicenter, placebo-controlled trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>294</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Brady-2004" NAME="Brady 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K</AU>
<TI>Sertraline in the treatment of co-occuring alcohol dependence and PTSD</TI>
<SO>Draft manuscript</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sonne SC, Back SE, Diaz Zuniga C, Randall CL, Brady KT</AU>
<TI>Gender differences in individuals with comorbid alcohol dependence and post-traumatic stress disorder</TI>
<SO>American Journal on Addictions</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>5</NO>
<PG>412-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braun-1990" NAME="Braun 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun P, Greenberg D, Dasberg H, Lerer B</AU>
<TI>Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<NO>6</NO>
<PG>236-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Butterfield-2001" NAME="Butterfield 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR</AU>
<TI>Olanzapine in the treatment of post-traumatic stress disorder: A pilot study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>4</NO>
<PG>197-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-2004" NAME="Chung 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM</AU>
<TI>Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial</TI>
<SO>Human Psychopharmacology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>7</NO>
<PG>489-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conner-1999" NAME="Conner 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnett SD, Tharwani HM, Hertzberg MA, Sutherland SM, Connor KM, Davidson JR</AU>
<TI>Tolerability of fluoxetine in posttraumatic stress disorder</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>2</NO>
<PG>363-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR</AU>
<TI>Fluoxetine in post-traumatic stress disorder: Randomized, double-blind study</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>175</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malik ML, Connor KM, Sutherland SM, Smith RD, Davison RM, Davidson JR</AU>
<TI>Quality-of-life and posttraumatic stress disorder: A pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>2</NO>
<PG>387-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1990" NAME="Davidson 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Kudler H, Smith R, Mahorney SL, Lipper S, Hammett E et al</AU>
<TI>Treatment of posttraumatic stress disorder with amitriptyline and placebo</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>3</NO>
<PG>259-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Kudler HS, Saunders WB, Erickson L, Smith RD, Stein RM et al</AU>
<TI>Predicting response to amitriptyline in posttraumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>7</NO>
<PG>1024-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2001a" MODIFIED="2016-02-12 15:29:53 +0000" MODIFIED_BY="[Empty name]" NAME="Davidson 2001a" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Landerman LR, Farfel GM, Clary CM</AU>
<TI>Characterizing the effects of sertraline in post-traumatic stress disorder</TI>
<SO>Psychological Medicine</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>4</NO>
<PG>661-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM</AU>
<TI>Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2001</YR>
<VL>58</VL>
<NO>5</NO>
<PG>485-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2001b" MODIFIED="2016-02-12 15:30:14 +0000" MODIFIED_BY="[Empty name]" NAME="Davidson 2001b" YEAR="">
<REFERENCE MODIFIED="2016-02-12 15:29:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson J, Londborg P, Pearlstein T, Rothbaum B, Brady K, Farfel G</AU>
<TI>Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>292</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-12 15:30:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J et al</AU>
<TI>Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>12</NO>
<PG>1974-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-12 15:29:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapaport MH, Endicott J, Clary CM</AU>
<TI>Posttraumatic stress disorder and quality of life: Results across 64 weeks of sertraline treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2003" NAME="Davidson 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S et al</AU>
<TI>Mirtzapine vs. placebo in posttraumatic stress disorder: A pilot trial</TI>
<SO>Biological Psychiatry</SO>
<YR>2003</YR>
<VL>53</VL>
<NO>2</NO>
<PG>188-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Davidson-2004" MODIFIED="2016-04-12 16:56:11 +0100" MODIFIED_BY="Sarah  R Davies" NAME="Davidson 2004" YEAR="">
<REFERENCE MODIFIED="2016-04-12 16:56:11 +0100" MODIFIED_BY="Sarah  R Davies" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>
Davidson JR,
 
Lipschitz A,
 
Musgnung J
</AU>
<TI>
Treatment of PTSD: A comparison of venlafaxine extended release, sertraline, and placebo
 [abstract NR521]
</TI>
<SO>
157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY
</SO>
<YR>
2004
</YR>
<PG>
195
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-17 14:22:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>
Davidson J, Rothbaum BO, Tucker P, Asnis Gr, Benattia I
,
 Musgnung JJ
</AU>
<TI>
Venlafaxine extended release in posttraumatic stress disorder: A sertraline- and placebo-controlled study
</TI>
<SO>
Journal of clinical psychopharmacology
</SO>
<YR>
2006
</YR>
<VL>
26
</VL>
<NO>
3
</NO>
<PG>
259-267
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Davidson J, Lipschitz A, Musgnung JJ</AU>
<TI>Venlafaxine XR and sertraline in posttraumatic stress disorder: A placebo-controlled trial</TI>
<SO>Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-2001" NAME="Davis 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Davis LL, Ambrose S, English B, Dafore ME, Farley J, Bartolucci Al et al</AU>
<TI>A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder</TI>
<SO>20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davis LL, Jewell ME, Ambrose S, Farley J, English B, Bartolucci A et al</AU>
<TI>A placebo-controlled study of nefazadone for the treatment of chronic posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>3</NO>
<PG>291-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Eli-Lilly-2006" MODIFIED="2013-12-06 16:06:23 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2006" YEAR="">
<REFERENCE MODIFIED="2013-12-06 15:58:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>
Martenyi F,
 
Brown EB,
 
Caldwell CD
</AU>
<TI>
Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study
</TI>
<SO>
Journal of clinical psychopharmacology
</SO>
<YR>
2007
</YR>
<VL>
27
</VL>
<NO>
2
</NO>
<PG>
166-170
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Eli Lilly</AU>
<TI>Unpublished data</TI>
<SO>Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-06 16:04:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-06 16:04:19 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="B1Y-MC-HCJL"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hertzberg-1999" NAME="Hertzberg 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM et al</AU>
<TI>A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>9</NO>
<PG>1226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hertzberg-2000" NAME="Hertzberg 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR</AU>
<TI>Lack of efficacy for fluoxetine in PTSD: A placebo controlled trial in combat veterans</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>2</NO>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1996" NAME="Kaplan 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan Z, Amir M, Swartz M, Levine J</AU>
<TI>Inositol treatment of post-traumatic stress disorder</TI>
<SO>Anxiety</SO>
<YR>1996</YR>
<VL>2</VL>
<NO>1</NO>
<PG>51-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1994" NAME="Katz 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connor KM, Hidalgo RB, Crockett B, Malik M, Katz RJ, Davidson JR</AU>
<TI>Predictors of treatment response in patients with posttraumatic stress disorder</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>2</NO>
<PG>337-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katz RJ, Lott MH, Arbus P, Crocq L, Herlobsen P, Lingjaerde O et al</AU>
<TI>Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic</TI>
<SO>Anxiety</SO>
<YR>1994</YR>
<VL>1</VL>
<NO>4</NO>
<PG>169-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosten-1991" NAME="Kosten 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL Jr</AU>
<TI>Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1991</YR>
<VL>179</VL>
<NO>6</NO>
<PG>366-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marshall-2001" MODIFIED="2013-12-18 14:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Marshall 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-18 14:32:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
GlaxoSmithKline
</AU>
<TI>
A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD)
</TI>
<SO>
GSK - clinical study register [www.gsk-clinicalstudyregister.com]
</SO>
<PG>
 Study ID: PAR 29060 651 (BRL-02960)
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 14:36:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
Food and Drugs Administration (FDA)
</AU>
<TO>
NDA 20-031/S-029 Paxil (Paroxetine Hydrochloride) Tablets; GlaxoSmithKline; Post-traumatic Stress Disorder
</TO>
<SO>
Drugs@FDA [http://www.accessdata.fda.gov]
</SO>
<VL>
 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 17 December 2013)
</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marshall RD, Beebe KL, Oldham M, Zaninelli R</AU>
<TI>Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>12</NO>
<PG>1982-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-18 14:34:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 14:34:26 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="29060/651"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Marshall-2004" NAME="Marshall 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marshall R, Blanco C, Lewis-Fernandez R, Simpson B, Lin SH, Garcia W et al</AU>
<TI>Randomized controlled trial of paroxetine in adults with chronic PTSD</TI>
<SO>18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin S, Garcia W et al</AU>
<TI>A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults</TI>
<SO>draft manuscript</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martenyi-2002a" MODIFIED="2016-02-12 15:27:47 +0000" MODIFIED_BY="[Empty name]" NAME="Martenyi 2002a" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC</AU>
<TI>Fluoxetine versus placebo in posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>3</NO>
<PG>199-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martenyi-2002b" MODIFIED="2016-02-12 15:27:47 +0000" MODIFIED_BY="[Empty name]" NAME="Martenyi 2002b" YEAR="">
<REFERENCE MODIFIED="2016-02-12 15:27:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A</AU>
<TI>Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder.</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>181</VL>
<PG>315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McRae-2004" NAME="McRae 2004" YEAR="McRae">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McRae AL, Brady KT, Mellman TA, Sonn SC, Killeen TK, Timmerman MA et al</AU>
<TI>Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder</TI>
<SO>Depression and Anxiety</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>3</NO>
<PG>190-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pfizer588" MODIFIED="2013-12-17 17:00:22 +0000" MODIFIED_BY="[Empty name]" NAME="Pfizer588" YEAR="">
<REFERENCE MODIFIED="2013-12-17 17:00:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
Food and Drugs Administration (FDA)
</AU>
<TI>
Review and evaluation of clinical data [
Pfizer NDA application: 
Sertraline
 (Zoloft)
 for PTSD]
</TI>
<SO>
Drugs@FDA
 [www.accessdata.fda.gov]
</SO>
<YR>
199
9
</YR>
<VL>
http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf
 (
accessed 31 January 2012
)
</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Pfizer</AU>
<TI>Unpublished data</TI>
<SO>Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-17 15:03:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-17 15:03:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="96CE21-0682"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pfizer589" MODIFIED="2013-12-17 17:00:43 +0000" MODIFIED_BY="[Empty name]" NAME="Pfizer589" YEAR="">
<REFERENCE MODIFIED="2013-12-17 16:01:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>
Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM
</AU>
<TI>
Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting
</TI>
<SO>
Journal of clinical psychiatry
</SO>
<YR>
2007
</YR>
<VL>
68
</VL>
<NO>
5
</NO>
<PG>
711-20
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-17 17:00:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
Food and Drugs Adminstration (FDA)
</AU>
<TI>
Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]
</TI>
<SO>
Drugs@FDA [www.accessdata.fda.gov]
</SO>
<YR>
1999
</YR>
<VL>
http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf (accessed 31 January 2012)
</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Pfizer</AU>
<TI>Unpublished data</TI>
<SO>Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-17 15:04:49 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-17 15:04:49 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="93CE21-0641"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reich-2004" NAME="Reich 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C</AU>
<TI>A preliminary study of risperidone in the treatment of postraumatic stress disorder related to childhood abuse in women</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>12</NO>
<PG>1601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reist-1989" NAME="Reist 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reist C, Kauffmann CD, Chicz Demet A, Chen CC, Demet EM</AU>
<TI>REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>3</NO>
<PG>433-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A et al</AU>
<TI>A controlled trial of desipramine in 18 men with posttraumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>4</NO>
<PG>513-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saygin-2002" NAME="Saygin 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saygin MZ, Sungur MZ, Sabol EU, Cetinkaya P</AU>
<TI>Nefazodone versus sertraline in treatment of posttraumatic stress disorder</TI>
<SO>Bulletin of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shestatzky-1988" NAME="Shestatzky 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shestatzky M, Greenberg D, Lerer B</AU>
<TI>A controlled trial of phenelzine in posttraumatic stress disorder</TI>
<SO>Psychiatric Research</SO>
<YR>1988</YR>
<VL>24</VL>
<NO>2</NO>
<PG>149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SKB627" MODIFIED="2013-12-18 12:01:38 +0000" MODIFIED_BY="[Empty name]" NAME="SKB627" YEAR="">
<REFERENCE MODIFIED="2013-12-17 17:01:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
Food and Drugs Administration (FDA)
</AU>
<TI>
NDA 20-031/S-029 Paxil (Paroxetine Hydrochloride) Tablets; GlaxoSmithKline; Post-traumatic Stress Disorder
</TI>
<SO>
Drugs@FDA [http://www.accessdata.fda.gov]
 
</SO>
<VL>
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 17 December 2013)
</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 11:48:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
GlaxoSmithKline
</AU>
<TI>
A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Posttraumatic Stress Disorder (PTSD)
</TI>
<SO>
GSK - clinical study register [www.gsk-clinicalstudyregister.com]
</SO>
<PG>
 
Study ID:
 29060/627
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 12:01:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>
Stein DJ, Davidson J, Seedat S, Beebe K
</AU>
<TI>
Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies
</TI>
<SO>
Expert Opin
i
on
 
on 
Pharmacother
apy
</SO>
<YR>
2003
</YR>
<VL>
4
</VL>
<NO>
10
</NO>
<PG>
1829-38
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>SmithKline Beecham</AU>
<TI>Unpublished data</TI>
<SO>Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-17 17:08:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-17 17:08:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Study 29060/627"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smajkic-2001" NAME="Smajkic 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smajkic A, Weine S, Djuric-Bijedic Z, Boskailo E, Lewis J, Pavkovic I</AU>
<TI>Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>3</NO>
<PG>445-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tucker-2001" MODIFIED="2013-12-18 11:54:24 +0000" MODIFIED_BY="[Empty name]" NAME="Tucker 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-18 11:54:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
GlaxoSmithKline
</AU>
<TI>
A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Posttraumatic Stress Disorder (PTSD)
</TI>
<SO>
GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]
</SO>
<YR>
2000
</YR>
<PG>
Study ID:
GSK 29060/648
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD</AU>
<TI>Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>11</NO>
<PG>860-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-18 11:53:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 11:53:09 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PAR 648"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tucker-2003" NAME="Tucker 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tucker P, Potter-Kimball R, Wyatt DB, Parker DE, Burgin C, Jones DE et al</AU>
<TI>Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo</TI>
<SO>General Psychopharmacology</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>3</NO>
<PG>135-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Kolk-1994" NAME="van der Kolk 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R et al</AU>
<TI>Fluoxetine treatment in posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>12</NO>
<PG>517-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-van-der-Kolk-2004" NAME="van der Kolk 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>van der Kolk, Spinazzola J, Blaustein M, Hopper J, Hopper E, Korn D et al</AU>
<TI>A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: Treatment effects and long-term maintenance</TI>
<SO>draft manuscript</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zohar-2002" NAME="Zohar 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amital D, Zohar J, Kotler M, Bleich A, Miodovnik H, Nevo A ET AL</AU>
<TI>A placebo-controlled study of sertraline in post traumatic stress disorder</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>269</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Amital D, Zohar J, Kotler M, Bleich A, nrodovnik H, Nevo A et al</AU>
<TI>A placebo-controlled trial pilot study of sertraline in PTSD</TI>
<SO>Annual Meeting of the American Psychiatric Association</SO>
<YR>1999</YR>
<PG>157</PG>
<PB>American Psychiatric Association</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM</AU>
<TI>Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>2</NO>
<PG>190-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Aerni-2004" NAME="Aerni 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A et al</AU>
<TI>Low-dose cortisol for symptoms of posttraumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>8</NO>
<PG>1488-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartzokis-2005" NAME="Bartzokis 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS</AU>
<TI>Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>5</NO>
<PG>474-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bremner-1997" NAME="Bremner 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA et al</AU>
<TI>Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>3</NO>
<PG>246-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coupland-1997" NAME="Coupland 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coupland NJ, Lillywhite A, Bell CE, Potokar JP, Nutt DJ</AU>
<TI>A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>9</NO>
<PG>988-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Eftekhari-2004" NAME="Eftekhari 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Eftekhari A, Miller H, Zoellner L, Feeny N</AU>
<TI>Prolonged exposure vs. sertraline: Secondary outcomes in PTSD treatment</TI>
<SO>20th Annual Meeting, International Society for Traumatic Stress Studies, November 14 - November 18, New Orleans, LA</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frank-1988" NAME="Frank 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frank JB, Kosten TR, Giller EL Jr, Dan E</AU>
<TI>A randomized clinical trial of phenelzine and imipramine for post-traumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<NO>10</NO>
<PG>1289-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frommberger-1998" NAME="Frommberger 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Frommberger U, Nyberg E, Richter H, Stieglitz RD, Berger M</AU>
<TI>Paroxetine vs. cognitive-behavioral therapy in the treatment of depression in PTSD patients</TI>
<SO>XXIst Collegium Internationale Neuro psychopharmacologicum, Glasgow, Scotland. 12th 16th July</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelpin-1996" NAME="Gelpin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY</AU>
<TI>Treatment of recent trauma survivors with benzodiazepines: A prospective study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>9</NO>
<PG>390-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamner-1997" NAME="Hamner 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamner M, Ulmer H, Horne D</AU>
<TI>Buspirone potentiation of antidepressants in the treatment of PTSD</TI>
<SO>Depression and Anxiety</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>3</NO>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamner-1999" NAME="Hamner 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamner MB, Ulmer HG, Horne DF, George MS, Arana GW</AU>
<TI>Procaine administration and behavioral responsivity in post-traumatic stress disorder: a pilot study of tolerability</TI>
<SO>Human Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamner-2003" NAME="Hamner 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW</AU>
<TI>Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heresco_x002d_Levy-2002" NAME="Heresco-Levy 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M et al</AU>
<TI>Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>4</NO>
<PG>301-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs_x002d_Rebhun-2000" NAME="Jacobs-Rebhun 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs-Rebhun S, Schnurr PP, Friedman MJ, Peck R, Brophy M, Fuller D</AU>
<TI>Posttraumatic stress disorder and sleep difficulty</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>9</NO>
<PG>1525-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanter-2001" NAME="Kanter 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanter ED, Wilkinson CW, Radant AD, Petrie EC, Dobie DJ, McFall ME et al</AU>
<TI>Glucocorticoid feedback sensitivity and adrenocortical responsiveness in posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>4</NO>
<PG>238-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kellner-2000" NAME="Kellner 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kellner M, Wiedemann K, Yassouridis A, Levengood R, Guo LS, Holsboer F et al</AU>
<TI>Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>2</NO>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kline-1994" NAME="Kline 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kline NA, Dow BM, Brown SA, Matloff JL</AU>
<TI>Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<NO>4</NO>
<PG>621</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monnelly-2003" NAME="Monnelly 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monnelly EP, Ciraulo DA, Knapp C, Keane T</AU>
<TI>Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>2</NO>
<PG>193-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-1995" NAME="Morgan 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan CA 3rd, Grillon C, Southwick SM, Nagy LM, Davis M, Krystal JH et al</AU>
<TI>Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>117</VL>
<NO>4</NO>
<PG>466-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Nagy-1996" NAME="Nagy 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nagy LM, Southwick SM, Charney DS</AU>
<TI>Placebo-controlled trial of fluoxetine in PTSD</TI>
<SO>International Society for Traumatic Stress Studies 12th Annual Meeting, San Francisco, CA, November 11</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otto-2003" NAME="Otto 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otto MW, Hinton D, Korbly NB, Chea A, Ba P, Gershuny BS et al</AU>
<TI>Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>1271-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitman-1990" NAME="Pitman 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitman RK, van der Kolk BA, Orr SP, Greenberg MS</AU>
<TI>Naloxone-reversible analgesic response to combat-related stimuli in posttraumatic stress disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>6</NO>
<PG>541-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitman-2002" NAME="Pitman 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB et al</AU>
<TI>Pilot study of secondary prevention of posttraumatic stress disorder with propranolol</TI>
<SO>Biological Psychiatry</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>2</NO>
<PG>189-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pivac-2004" NAME="Pivac 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pivac N, Kozaric-Kovacic D, Muck-Seler D</AU>
<TI>Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder</TI>
<SO>Psychopharmacology</SO>
<YR>2004</YR>
<VL>175</VL>
<NO>4</NO>
<PG>451-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Randall-1995" NAME="Randall 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Randall PK, Bremner JD, Krystal JH, Nagy LM, Heninger GR, Nicolaou AL et al</AU>
<TI>Effects of the benzodiazepine antagonist flumazenil in PTSD</TI>
<SO>Biological Psychiatry</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>5</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskind-2003" NAME="Raskind 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE et al</AU>
<TI>Reducation of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>2</NO>
<PG>371-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reist-1995" NAME="Reist 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reist C, Kauffmann CD, Chicz Demet A, Chen CC, Demet EM</AU>
<TI>REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder</TI>
<SO>Progress in Neuropsychopharmacology and Biological Psychiatry</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>3</NO>
<PG>433-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reist-2001" NAME="Reist 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reist C, Duffy JG, Fujimoto K, Cahill L</AU>
<TI>beta-Adrenergic blockade and emotional memory in PTSD</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>4</NO>
<PG>377-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schelling-2004" NAME="Schelling 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schelling G, Kilger E, Roozendaal B, de Quervain DJ, Briegel J, Dagge A et al</AU>
<TI>Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: A randomized study</TI>
<SO>Biological Psychiatry</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>6</NO>
<PG>627-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Southwick-1997" NAME="Southwick 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Southwick SM, Krystal JH, Bremner JD, Morgan CA 3rd, Nicolaou AL, Nagy LM et al</AU>
<TI>Noradrenergic and serotonergic function in posttraumatic stress disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>8</NO>
<PG>749-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-2002" NAME="Stein 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein MB, Kline NA, Matloff JL</AU>
<TI>Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>10</NO>
<PG>1777-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaiva-2003" NAME="Vaiva 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A et al</AU>
<TI>Immediate Treatment with propranolol decreases posttraumatic stress disorder two months after trauma</TI>
<SO>Biological Psychiatry</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>9</NO>
<PG>947-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Kolk-1989" NAME="van der Kolk 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van der Kolk BA, Greenberg MS, Orr SP, Pitman RK</AU>
<TI>Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>3</NO>
<PG>417-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zatzick-2004" NAME="Zatzick 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zatzick D, Roy-Byrne P, Russo J, Rivara F, Droesch R, Wagner A et al</AU>
<TI>A randomized effectiveness trial of stepped collaborative care for acutely injured trauma survivors</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>5</NO>
<PG>498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-12-18 14:42:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Fluoxetine_x002c_-Davidson" NAME="Fluoxetine, Davidson" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Fluoxetine_x002c_-Lilly" NAME="Fluoxetine, Lilly" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Nefazodone-1_x002c_-BMS" NAME="Nefazodone 1, BMS" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Nefazodone-2_x002c_-BMS" NAME="Nefazodone 2, BMS" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olanzapine_x002c_-Davidson" NAME="Olanzapine, Davidson" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Paroxetine-2-_x002d_-SB" NAME="Paroxetine 2 - SB" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Paroxetine-3-_x002d_-SB" NAME="Paroxetine 3 - SB" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Sertraline-2_x002c_-Pfizer" NAME="Sertraline 2, Pfizer" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Sertraline-3_x002c_-Pfizer" NAME="Sertraline 3, Pfizer" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sertraline-4_x002c_-Pfizer" NAME="Sertraline 4, Pfizer" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SKB650" MODIFIED="2013-12-18 14:42:49 +0000" MODIFIED_BY="[Empty name]" NAME="SKB650" YEAR="">
<REFERENCE MODIFIED="2013-12-18 14:42:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>
GlaxoSmithKline
</AU>
<TI>
A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder
</TI>
<SO>
GSK - clinical study register [www.gsk-clinicalstudyregister.com]
</SO>
<YR>
2001
</YR>
<PG>
Study ID: 29060/627
</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>SmithKline Beecham</AU>
<TI>Unpublished data</TI>
<SO>Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-18 14:38:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 14:38:51 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="29060/650"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Davis-2003" NAME="Davis 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Davis L &amp; Petty F</AU>
<TI>Gabaergic modulation in PTSD and treatment with anticonvulsants</TI>
<SO>19th Annual Meeting, International Society for Traumatic Stress Studies, October 29 - November 1, Chicago, IL</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-DVA-_x0028_unknown_x0029_" NAME="DVA (unknown)" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Study starts: March 2005&lt;br&gt;Expected date of completion: unknown&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Department of Veterans Affairs (sponsors)</AU>
<TI>CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder</TI>
<SO>http://clinicaltrials.gov/show/NCT00099983</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mechoulam-_x0028_THC_x0029_" NAME="Mechoulam (THC)" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Raphael Mechoulam</AU>
<TI>delta-9 tetrahydrocannabino (THC) for combat-related post traumatic stress disorder</TI>
<SO>http://www.medscape.com/</SO>
<PB>Reuters Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mithoefer-2005" NAME="Mithoefer 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;The study is expected to be complete in September, 2005&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Mithoefer, M</AU>
<TI>A Test of MDMA-assisted Psychotherapy in People with Posttraumatic Stress Disorder</TI>
<SO>Current controlled trials (http://clinicaltrials.gov/show/NCT00090064)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NIAAA-2005" NAME="NIAAA 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Expected date of completion: August 2005&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Institute on Alcohol Abuse and Alcoholism (sponsors)</AU>
<TI>Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone)</TI>
<SO>Current controlled trials (http://clinicaltrials.gov/show/NCT00006489)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Tucker-2004" NAME="Tucker 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tucker P, Davis L, Cohen J</AU>
<TI>Pharmacotherapy of PTSD: Trauma and neurotransmitters across the lifespan</TI>
<SO>20th Annual Meeting, International Society for Traumatic Stress Studies, November 14 - November 18, New Orleans, LA</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Albucher-2002" NAME="Albucher 2002" TYPE="JOURNAL_ARTICLE">
<AU>Albucher RC, Liberzon I</AU>
<TI>Psychopharmacological treatment in PTSD: a critical review</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>6</NO>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2003" NAME="Alderson 2003" TYPE="BOOK_SECTION">
<AU>Alderson P, Green S, Higgins JP</AU>
<TI>Assessment of study quality</TI>
<SO>Cochrane Reviewers&#8217; Handbook 4.2.1 [updated December] Section 8;</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allodi-1991" NAME="Allodi 1991" TYPE="JOURNAL_ARTICLE">
<AU>Allodi FA</AU>
<TI>Assessment and treatment of torture victims: A critical review</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1991</YR>
<VL>179</VL>
<NO>1</NO>
<PG>4-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2003" NAME="Als-Nielsen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Als-Nielsen B, Chen W, Gluud C, Kjaergard LL</AU>
<TI>Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>7</NO>
<PG>921-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1998" NAME="Altman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG</AU>
<TI>Confidence intervals for the number needed to treat</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7</NO>
<PG>1309-1312</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1980" NAME="APA 1980" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-III)</SO>
<YR>1980</YR>
<EN>3rd</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Asnis-2004" NAME="Asnis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Asnis GM, Kohn SR, Henderson M, Brown NL</AU>
<TI>SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations</TI>
<SO>Drugs</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bailar-1997" NAME="Bailar 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bailar JC 3rd</AU>
<TI>The promise and problems of meta-analysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>337</VL>
<NO>8</NO>
<PG>559-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baker-2003" NAME="Baker 2003" TYPE="JOURNAL_ARTICLE">
<AU>Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW</AU>
<TI>Quantitative analysis of sponsorship bias in economic studies of antidepressants</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>183</VL>
<PG>498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballenger-2000" NAME="Ballenger 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC et al</AU>
<TI>Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>Suppl 5</NO>
<PG>60-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballenger-2004" NAME="Ballenger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Marshall RD, Nemeroff CB et al</AU>
<TI>Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety</TI>
<SO>Jouornal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>Suppl 1</NO>
<PG>55-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Basoglu-1992" NAME="Basoglu 1992" TYPE="JOURNAL_ARTICLE">
<AU>Basoglu M, Marks IM, Senguen S</AU>
<TI>Amitriptyline for PTSD in a torture survivor: A case study</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>77-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1961" NAME="Beck 1961" TYPE="JOURNAL_ARTICLE">
<AU>Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J</AU>
<TI>An inventory for measuring depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1961</YR>
<VL>4</VL>
<PG>561-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlant-2002" NAME="Berlant 2002" TYPE="JOURNAL_ARTICLE">
<AU>Berlant J, van Kammen DP</AU>
<TI>Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>1</NO>
<PG>15-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlant-2004" NAME="Berlant 2004" TYPE="JOURNAL_ARTICLE">
<AU>Berlant JL</AU>
<TI>Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder</TI>
<SO>BMC Psychiatry</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>1</NO>
<PG>24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1999" NAME="Berlin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA, Rennie D</AU>
<TI>Measuring the quality of trials: The quality of quality scales</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>11</NO>
<PG>1083-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bisson-2005" NAME="Bisson 2005" TYPE="COCHRANE_REVIEW">
<AU>Bisson JI, Andrew M</AU>
<TI>Psychological treatment of post-traumatic stress disorder (PTSD)</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>New York</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CD003388"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blake-1990" NAME="Blake 1990" TYPE="JOURNAL_ARTICLE">
<AU>Blake DD, Weathers FW, Nagy LM, et al</AU>
<TI>A clinician rating scale for assessing current and lifetime PTSD: The CAPS-1</TI>
<SO>Behavior Therapy</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>187-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bleich-1986" NAME="Bleich 1986" TYPE="JOURNAL_ARTICLE">
<AU>Bleich A, Siegel B, Garb R, Lerer B</AU>
<TI>Post-traumatic stress disorder following combat exposure: clinical features and psychopharmacological treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>149</VL>
<PG>365-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonne-2004" NAME="Bonne 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bonne O, Grillon C, Vythilingam M, Neumeister A, Charney DS</AU>
<TI>Adaptive and maladaptive psychobiological responses to severe psychological stress: implications for the discovery of novel pharmacotherapy</TI>
<SO>Neuroscience Biobehavioral Review</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>1</NO>
<PG>65-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradley-2005" NAME="Bradley 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bradley R, Greene J, Russ E, Dutra L, Westen D</AU>
<TI>A multidimensional meta-analysis of psychotherapy for PTSD</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>2</NO>
<PG>214-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brady-1995" NAME="Brady 1995" TYPE="JOURNAL_ARTICLE">
<AU>Brady KT, Sonne SC, Roberts JM</AU>
<TI>Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>11</NO>
<PG>502-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bremner-2004" NAME="Bremner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bremner JD, Vermetten E</AU>
<TI>Neuroanatomical changes associated with pharmacotherapy in posttraumatic stress disorder</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>2004</YR>
<VL>1032</VL>
<PG>154-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breslau-1991" NAME="Breslau 1991" TYPE="JOURNAL_ARTICLE">
<AU>Breslau N, Davis GC, Andreski P</AU>
<TI>Traumatic events and post traumatic stress disorder in an urban population of young adults</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>3</NO>
<PG>216-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brom-1989" NAME="Brom 1989" TYPE="JOURNAL_ARTICLE">
<AU>Brom D, Kleber RJ, Defares PB</AU>
<TI>Brief psychotherapy for posttraumatic stress disorders</TI>
<SO>Journal of Consulting and Clinial Psychology</SO>
<YR>1989</YR>
<VL>57</VL>
<NO>5</NO>
<PG>607-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brophy-1991" NAME="Brophy 1991" TYPE="JOURNAL_ARTICLE">
<AU>Brophy MH</AU>
<TI>Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder</TI>
<SO>Military Medicine</SO>
<YR>1991</YR>
<VL>156</VL>
<PG>100-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunello-2001" NAME="Brunello 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brunello N, Davidson JR, Deahl M, Kessler RC, Mendlewicz J, Racagni G et al</AU>
<TI>Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment</TI>
<SO>Neuropsychobiology</SO>
<YR>2001</YR>
<VL>43</VL>
<NO>3</NO>
<PG>150-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burdon-1991" NAME="Burdon 1991" TYPE="JOURNAL_ARTICLE">
<AU>Burdon AP, Sutker PB, Foulks EF, Crane MU</AU>
<TI>Pilot program of treatment for PTSD</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>148</VL>
<NO>9</NO>
<PG>1269-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burstein-1984" NAME="Burstein 1984" TYPE="JOURNAL_ARTICLE">
<AU>Burstein A</AU>
<TI>Treatment of posttraumatic stress disorder with imipramine</TI>
<SO>Psychosomatics</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>9</NO>
<PG>681-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burton-1999" NAME="Burton 1999" TYPE="JOURNAL_ARTICLE">
<AU>Burton JK, Marshall RD</AU>
<TI>Categorizing fear: the role of trauma in a clinical formulation</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>5</NO>
<PG>761-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Canive-1997" NAME="Canive 1997" TYPE="JOURNAL_ARTICLE">
<AU>Canive JM, Lewine JD, Orrison WW Jr, Edgar CJ, Provencal SL, Davis JT et al</AU>
<TI>MRI reveals gross structural abnormalities in PTSD</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1997</YR>
<VL>821</VL>
<PG>512-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Canive-1998" NAME="Canive 1998" TYPE="JOURNAL_ARTICLE">
<AU>Canive JM, Clark RD, Calais LA, Qualls C, Tuason VB</AU>
<TI>Bupropion treatment in veterans with posttraumatic stress disorder: an open study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>5</NO>
<PG>379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Charney-1993" NAME="Charney 1993" TYPE="JOURNAL_ARTICLE">
<AU>Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M</AU>
<TI>Psychobiologic mechanisms of posttraumatic stress disiorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>4</NO>
<PG>294-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Charney-2004" NAME="Charney 2004" TYPE="JOURNAL_ARTICLE">
<AU>Charney D</AU>
<TI>Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>2</NO>
<PG>195-216</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1991" NAME="Chen 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chen C</AU>
<TI>The obsessive quality and clomipramine treatment of PTSD</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>148</VL>
<NO>8</NO>
<PG>1087-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connor-1998" NAME="Connor 1998" TYPE="JOURNAL_ARTICLE">
<AU>Connor KM, Davidson JR</AU>
<TI>The role of serotonin in posttraumatic stress disorder: Neurobiology and pharmacotherapy</TI>
<SO>CNS Spectrums</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>7S2</NO>
<PG>43-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connor-1999" NAME="Connor 1999" TYPE="JOURNAL_ARTICLE">
<AU>Connor KM, Davidson JR, Weisler RH, Ahearn E</AU>
<TI>A pilot study of mirtazapine in post-traumatic stress disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>1</NO>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Covi-1984" NAME="Covi 1984" TYPE="JOURNAL_ARTICLE">
<AU>Covi L, Lipman RS</AU>
<TI>Primary depression or primary anxiety A possible psychometric approach to a diagnostic dillema</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1984</YR>
<VL>7</VL>
<PG>S502-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creamer-2003" NAME="Creamer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Creamer M, Bell R, Failla S</AU>
<TI>Psychometric properties of the Impact of Event Scale&#8212; RPPsychometric properties of the Impact of Event Scale&#8212;Revised</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>12</NO>
<PG>1489&#8211;96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CSM-2004" NAME="CSM 2004" TYPE="OTHER">
<AU>Committee on Safety of Medicines</AU>
<TI>Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antridepressants</TI>
<SO>http://www.mhra.gov.uk/news/2004/SSRIfinal.pdf</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cyr-2000" NAME="Cyr 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cyr M, Farrar MK</AU>
<TI>Treatment for posttraumatic stress disorder</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>3</NO>
<PG>366-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1987" NAME="Davidson 1987" TYPE="JOURNAL_ARTICLE">
<AU>Davidson J, Walker I, Kilts C</AU>
<TI>A pilot study of phenelzine in the treatment of post-traumatic stress disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>150</VL>
<PG>252-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1989" NAME="Davidson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Nemeroff CB</AU>
<TI>Pharmacotherapy in posttraumatic stress disorder: historical and clinical considerations and future directions</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>3</NO>
<PG>422-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1990" NAME="Davidson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Roth S, Newman E</AU>
<TI>Fluoxetine in posttraumatic stress disorder</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1990</YR>
<VL>4</VL>
<PG>419-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1991" NAME="Davidson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Hughes D, Blazer DG, George LK</AU>
<TI>Posttraumatic stress disorder in the community : an epidemiological study</TI>
<SO>Psychological Medicine</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>3</NO>
<PG>713-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1992" NAME="Davidson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR</AU>
<TI>Drug therapy of posttraumatic stress disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>160</VL>
<PG>309-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1993" NAME="Davidson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Kudler HS, Saunders WB, Erickson L, Smith RD, Stein RM et al</AU>
<TI>Predicting response to amitriptyline in posttraumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>7</NO>
<PG>1024-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1997a" NAME="Davidson 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Malik ML, Sutherland SN</AU>
<TI>Response characteristics to antidepressants and placebo in post-traumatic stress disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>6</NO>
<PG>291-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1997b" NAME="Davidson 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR</AU>
<TI>Biological therapies for posttraumatic stress disorder: an overview</TI>
<SO>Joournal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>Suppl 9</NO>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1997c" NAME="Davidson 1997c" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Book SW, Colket L, Tupler LA, Roth S, David D et al</AU>
<TI>Assessment of a new self-rating scale for posttraumatic stress disorder</TI>
<SO>Psychological Medicine</SO>
<YR>1997</YR>
<VL>27</VL>
<PG>153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1998a" NAME="Davidson 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Weisler RH, Malik M, Tupler LA</AU>
<TI>Fluvoxamine in civilians with posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>1</NO>
<PG>93-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1998b" NAME="Davidson 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR, Weisler RH, Malik ML, Connor MK</AU>
<TI>Treatment of posttraumatic stress disorder with nefazodone</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>3</NO>
<PG>111-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-2000" NAME="Davidson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Davidson JR</AU>
<TI>Pharmacotherapy of posttraumatic stress disorder: Treatment options, long term follow-up, and predictors of outcome</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>Suppl 5</NO>
<PG>52-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2000" NAME="Davis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Davis LL, Nugent AL, Murray J, Kramer GL, Petty F</AU>
<TI>Nefazodone treatment for chronic posttraumatic stress disorder: an open trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>2</NO>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Boer-1992" NAME="De Boer 1992" TYPE="JOURNAL_ARTICLE">
<AU>De Boer M, Op van Velde W, Falger PJ, Hovens JE, De Groen JH, Van Duijn H</AU>
<TI>Fluvoxamine treatment for chronic PTSD: A pilot study</TI>
<SO>Psychotherapy &amp; Psychosomatics</SO>
<YR>1992</YR>
<VL>57</VL>
<NO>4</NO>
<PG>158-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ.</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis.</TI>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<ED>Egger M, Davey SG, Altman DG</ED>
<PB>BMJ Publication Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2002" NAME="Deeks 2002" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ</AU>
<TI>Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes</TI>
<SO>Statistics in medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1575-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2003" NAME="Deeks 2003" TYPE="BOOK_SECTION">
<AU>Deeks J, Higgins J, Altman D</AU>
<TI>Cochrane Reviewers&#8217; Handbook 4.2.1 [updated December 2003]</TI>
<SO>The Cochrane Library</SO>
<YR>2003</YR>
<NO>1</NO>
<ED>Alderson P, Green S, Higgins J</ED>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demartino-1995" NAME="Demartino 1995" TYPE="JOURNAL_ARTICLE">
<AU>Demartino R, Mollica RF, Wilk V</AU>
<TI>Monoamine oxidase inhibitors in posttraumatic stress disorder: promise and problems in Indochinese survivors of trauma</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1995</YR>
<VL>183</VL>
<NO>8</NO>
<PG>510-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dhansay-2005" NAME="Dhansay 2005" TYPE="COCHRANE_REVIEW">
<AU>Dhansay Y, Ipser JC, Stein DJ</AU>
<TI>Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders</TI>
<SO>The Cochrane Database of Systematic</SO>
<YR>2005</YR>
<NO>5</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>New York</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD005473. DOI: 10.1002/14651858.CD005473."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1992" NAME="Dickersin 1992" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Min YI, Meinert CL</AU>
<TI>Factors influencing the publication of research results : follow-up of applications submitted to two substantial review boards</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>267</VL>
<NO>3</NO>
<PG>374-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dillard-1993" NAME="Dillard 1993" TYPE="JOURNAL_ARTICLE">
<AU>Dillard ML, Bendfeldt F, Jernigan P</AU>
<TI>Use of thioridazine in post-traumatic stress disorder</TI>
<SO>Southern Medical Journal</SO>
<YR>1993</YR>
<VL>86</VL>
<NO>11</NO>
<PG>1276-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dominiak-1992" NAME="Dominiak 1992" TYPE="BOOK_SECTION">
<AU>Dominiak GM</AU>
<TI>Psychopharmacology of the abused</TI>
<SO>Sexual trauma and psychopathology: Clinical intervention with adult survivors</SO>
<YR>1992</YR>
<PG>81-111</PG>
<ED>Shapiro S, Dominiak GM, et al</ED>
<PB>Lexington Books/Macmillan</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dow-1997" NAME="Dow 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dow B, Kline N</AU>
<TI>Antidepressant treatment of posttraumatic stress disorder and major depression in veterans</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duffy-1992" NAME="Duffy 1992" TYPE="JOURNAL_ARTICLE">
<AU>Duffy JD</AU>
<TI>Rapid response to buspirone in a case of post-traumatic stress disorder</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1992</YR>
<VL>4</VL>
<PG>193-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duffy-1994" NAME="Duffy 1994" TYPE="JOURNAL_ARTICLE">
<AU>Duffy JD, Malloy PF</AU>
<TI>Efficacy of buspirone in the treatment of posttraumatic stress disorder: An open trial</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>6</VL>
<NO>1</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunner-1985" NAME="Dunner 1985" TYPE="CONFERENCE_PROC">
<AU>Dunner FJ, Edwards WP, Copeland PC</AU>
<TI>Clinical efficacy of alprazolam in PTSD patients</TI>
<SO>138th Annual Meeting of the American Psychiatric Association, Los Angeles, CA</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Easterbrook-1991" NAME="Easterbrook 1991" TYPE="JOURNAL_ARTICLE">
<AU>Eaterbrook PJ, Berline JA, Gopaian R, Matthews DR</AU>
<TI>Publication bias in clinical research</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8746</NO>
<PG>867-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: Methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falcon-1985" NAME="Falcon 1985" TYPE="JOURNAL_ARTICLE">
<AU>Falcon S, Ryan C, Chamberlain K, Curtis G</AU>
<TI>Tricyclics: possible treatment for post-traumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<NO>9</NO>
<PG>385-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Famularo-1988" NAME="Famularo 1988" TYPE="JOURNAL_ARTICLE">
<AU>Famularo R, Kinscherff R, Fenton T</AU>
<TI>Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study</TI>
<SO>American Journal of Diseases of Children Am J Dis Childhood</SO>
<YR>1988</YR>
<VL>142</VL>
<NO>11</NO>
<PG>1244-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faustman-1989" NAME="Faustman 1989" TYPE="JOURNAL_ARTICLE">
<AU>Faustman WO, White PA</AU>
<TI>Diagnostic and psychopharmacological treatment characteristics of 536 inpatients with posttraumatic stress disorder</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1989</YR>
<VL>177</VL>
<NO>3</NO>
<PG>154-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fesler-1991" NAME="Fesler 1991" TYPE="JOURNAL_ARTICLE">
<AU>Fesler FA</AU>
<TI>Valproate in combat-related posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<NO>9</NO>
<PG>361-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fichtner-1990" NAME="Fichtner 1990" TYPE="JOURNAL_ARTICLE">
<AU>Fichtner CG, Kuhlman DT, Gruenfeld MJ, Hughes JR</AU>
<TI>Decreased episodic violence and increased control of dissociation in a carbamazepine-treated case of multiple personality</TI>
<SO>Biological Psychiatry</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1045-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fichtner-1994" NAME="Fichtner 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fichtner CG, Arora RC, O'Connor FL, Crayton JW</AU>
<TI>Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: Preliminary observations on a possible predictor of clinical treatment response</TI>
<SO>Life Sciences</SO>
<YR>1994</YR>
<VL>54</VL>
<NO>3</NO>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foa-1999" NAME="Foa 1999" TYPE="JOURNAL_ARTICLE">
<AU>Foa EB, Davidson JR, Frances A</AU>
<TI>The expert consensus guideline series: treatment of posttraumatic stress disorder: The Expert Consensus Panel for PTSD</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>Suppl. 16</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ford-1996" NAME="Ford 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ford N</AU>
<TI>The use of anticonvulsants in posttraumatic stress disorder: case study and overview</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>4</NO>
<PG>857-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forster-1994" NAME="Forster 1994" TYPE="JOURNAL_ARTICLE">
<AU>Forster PL, Schoenfield FB, Marmar CR, Lang AJ</AU>
<TI>Lithium for irritability in post-traumatic stress disorder</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>1</NO>
<PG>143-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fossey-1994" NAME="Fossey 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fossey MD, Hamner MB</AU>
<TI>Clonazepam-related sexual dysfunction in male veterans with PTSD</TI>
<SO>Anxiety</SO>
<YR>1994</YR>
<VL>1</VL>
<NO>5</NO>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-1988" NAME="Friedman 1988" TYPE="JOURNAL_ARTICLE">
<AU>Friedman MJ</AU>
<TI>Toward rational pharmacotherapy for posttraumatic stress disorder: an interim report</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<NO>3</NO>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedman-1991" NAME="Friedman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Friedman MJ</AU>
<TI>Biological approaches to the diagnosis and treatment of post traumatic stress disorder</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1991</YR>
<VL>4</VL>
<PG>67-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gersons-2000" NAME="Gersons 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gersons BP, Carlier IV, Lamberts RD, van der Kolk BA</AU>
<TI>Randomized clinical trial of brief eclectic psychotherapy for police officers with posttraumatic stress disorder</TI>
<SO>Journal of Trauma Stress</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>2</NO>
<PG>333-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glover-1993" NAME="Glover 1993" TYPE="JOURNAL_ARTICLE">
<AU>Glover H</AU>
<TI>A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder</TI>
<SO>Israel Journal of Psychiatry and Related Sciences</SO>
<YR>1993</YR>
<VL>30</VL>
<NO>4</NO>
<PG>255-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glynn-1995" NAME="Glynn 1995" TYPE="JOURNAL_ARTICLE">
<AU>Glynn SM, Eth S, Randolph ET, et al</AU>
<TI>Behavioral family therapy for Vietnam combat veterans with posttraumatic stress disorder</TI>
<SO>Journal of Psychotherapy Practice and Research</SO>
<YR>1995</YR>
<VL>4</VL>
<PG>214-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-1998" NAME="Gupta 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gupta S, Popli A, Bathurst E, Hennig L, Droney T, Keller P</AU>
<TI>Efficacy of cyproheptadine for nightmares associated with posttraumatic stress disorder</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1998</YR>
<VL>39</VL>
<NO>3</NO>
<PG>160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gury-1999" NAME="Gury 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gury C, Cousin F</AU>
<TI>Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability</TI>
<SO>Encephale</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>5</NO>
<PG>470-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PB>U.S. National Institute of Health</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1959" NAME="Hamilton 1959" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>The assessment of anxiety states by rating</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>1959</YR>
<VL>32</VL>
<PG>50-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamner-1996" NAME="Hamner 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hamner MB</AU>
<TI>Clozapine treatment for a veteran with comorbid psychosis and PTSD (let)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>6</NO>
<PG>841</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamner-1997" NAME="Hamner 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hamner M, Ulmer H, Horne D</AU>
<TI>Buspirone potentiation of antidepressants in the treatment of PTSD</TI>
<SO>Depression and Anxiety</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>3</NO>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamner-1998" NAME="Hamner 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hamner MB, Frueh BC</AU>
<TI>Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>5</NO>
<PG>233-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamner-2003" NAME="Hamner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW</AU>
<TI>Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms</TI>
<SO>International Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hargrave-1993" NAME="Hargrave 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hargrave R</AU>
<TI>Serotonergic agents in the management of dementia and posttraumatic stress disorder</TI>
<SO>Psychosomatics</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>5</NO>
<PG>461-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harmon-1996" NAME="Harmon 1996" TYPE="JOURNAL_ARTICLE">
<AU>Harmon RJ, Riggs PD</AU>
<TI>Clonidine for posttraumatic stress disorder in preschool children</TI>
<SO>Journal of the American Academy of Child &amp; Adolescent Psychiatry</SO>
<YR>1996</YR>
<VL>35</VL>
<NO>9</NO>
<PG>1247-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harvey-2003" NAME="Harvey 2003" TYPE="JOURNAL_ARTICLE">
<AU>Harvey AG, Bryant RA, Tarrier N</AU>
<TI>Cognitive behaviour therapy for posttraumatic stress disorder</TI>
<SO>Clinical Psychology Review</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>501-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hertzberg-1996" NAME="Hertzberg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hertzberg MA, Feldman ME, Beckham JC, Davidson JR</AU>
<TI>Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>4</NO>
<PG>294-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hertzberg-1998" NAME="Hertzberg 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JR</AU>
<TI>Open trial of nefazodone for combat-related posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>9</NO>
<PG>460-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hertzberg-1999" NAME="Hertzberg 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM et al</AU>
<TI>A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>9</NO>
<PG>1226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hidalgo-1999" NAME="Hidalgo 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hidalgo R</AU>
<TI>Nefazodone in posttraumatic stress: results from six open-label trials</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>61-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JTP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>6</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogben-1981" NAME="Hogben 1981" TYPE="JOURNAL_ARTICLE">
<AU>Hogben GL, Cornfield RB</AU>
<TI>Treatment of traumatic war neurosis with phenelzine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1981</YR>
<VL>38</VL>
<NO>4</NO>
<PG>440-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hopewell-2002" NAME="Hopewell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hopewell S, Clarke M, Lusher A, Lefebvre C, Westby M</AU>
<TI>A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1625-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horowitz-1979" NAME="Horowitz 1979" TYPE="JOURNAL_ARTICLE">
<AU>Horowitz M, Wilner N, Alvarez W</AU>
<TI>Impact of Event Scale: a measure of subjective stress</TI>
<SO>Psychosomatic Medicine</SO>
<YR>1979</YR>
<VL>41</VL>
<NO>3</NO>
<PG>209-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horrigan-1996" NAME="Horrigan 1996" TYPE="CONFERENCE_PROC">
<AU>Horrigan JP</AU>
<TI>Guanfacine for PTSD nightmares</TI>
<SO>Journal of the American Academy of Child &amp; Adolescent Psychiatry</SO>
<YR>1996</YR>
<VL>35</VL>
<NO>8</NO>
<PG>975-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hull-2002" NAME="Hull 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hull A</AU>
<TI>Neuroimaging findings in post-traumatic stress disorder</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>181</VL>
<PG>102-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Irwin-1989" NAME="Irwin 1989" TYPE="JOURNAL_ARTICLE">
<AU>Irwin M, Van-Putten T, Guze B, Marder SR</AU>
<TI>Pharmacologic treatment of veterans with posttraumatic stress disorder and concomitant affective disiorder</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>2</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Izrayelit-1998" NAME="Izrayelit 1998" TYPE="JOURNAL_ARTICLE">
<AU>Izrayelit L</AU>
<TI>Schizoaffective disorder and PTSD successfully treated with olanzapine and supportive psychotherapy</TI>
<SO>Psychiatric Annals</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>8</NO>
<PG>424-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keane-1989" NAME="Keane 1989" TYPE="JOURNAL_ARTICLE">
<AU>Keane T</AU>
<TI>Post-traumatic stress disorder: current status and future directions</TI>
<SO>Behavior Therapy</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keck-1992" NAME="Keck 1992" TYPE="JOURNAL_ARTICLE">
<AU>Keck PE, McElroy SL, Friredman LM</AU>
<TI>Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>1S</NO>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-1995" NAME="Kessler 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB</AU>
<TI>Posttraumatic stress disorder in the National Comorbidity Survey</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>12</NO>
<PG>1048-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khouzam-1997" NAME="Khouzam 1997" TYPE="JOURNAL_ARTICLE">
<AU>Khouzam HR, Kissmeyer P</AU>
<TI>Antidepressant treatment, posttraumatic stress disorder, survivor guilt, and spiritual awakening</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>4</NO>
<PG>691-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kinzie-1989" NAME="Kinzie 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kinzie JD, Leung P</AU>
<TI>Clonidine in Cambodian patients with post traumatic stress disorder</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1989</YR>
<VL>177</VL>
<NO>9</NO>
<PG>546-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kitchner-1985" NAME="Kitchner 1985" TYPE="JOURNAL_ARTICLE">
<AU>Kitchner I, Greenstein R</AU>
<TI>Low dose lithium carbonate in the treatment of post traumatic stress disorder: brief communication</TI>
<SO>Military Medicine</SO>
<YR>1985</YR>
<VL>150</VL>
<NO>7</NO>
<PG>378-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kolb-1984" NAME="Kolb 1984" TYPE="BOOK_SECTION">
<AU>Kolb LC, Burris BC, Griffiths S</AU>
<TI>Propranolol and clonidine in the treatment of the chronic post-traumatic stress disorders of war</TI>
<SO>Post-traumatic Stress Disorder: Psychological and Biological Sequelae</SO>
<YR>1984</YR>
<PG>98-105</PG>
<ED>van der Kolk BA</ED>
<PB>American Psychiatric Press</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krakow-2000" NAME="Krakow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Krakow B, Hollifield M, Warner TD</AU>
<TI>Placebo effect in posttraumatic stress disorders</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>284</VL>
<NO>5</NO>
<PG>563</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kroll-1990" NAME="Kroll 1990" TYPE="JOURNAL_ARTICLE">
<AU>Kroll J, Paul L, Habenicht M, Chan S, Yang M, Vang T et al</AU>
<TI>Medication compliance, antidepressant blood levels, and side effects in Southeast Asian patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>4</NO>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LaPorta-1992" NAME="LaPorta 1992" TYPE="JOURNAL_ARTICLE">
<AU>LaPorta LD, Ware MR</AU>
<TI>Buspirone in the treatment of posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>2</NO>
<PG>133-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lerer-1987" NAME="Lerer 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lerer B, Bleich A, Kotler M, Garb R, Hertzberg M, Levin B</AU>
<TI>Posttraumatic stress disorder in Israeli combat veterans: effect of phenelzine treatment</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1987</YR>
<VL>44</VL>
<NO>11</NO>
<PG>976-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leyba-1998" NAME="Leyba 1998" TYPE="JOURNAL_ARTICLE">
<AU>Leyba CM, Wampler TP</AU>
<TI>Risperidone in PTSD</TI>
<SO>Psychiatric Services</SO>
<YR>1998</YR>
<VL>49</VL>
<NO>2</NO>
<PG>245-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liebowitz-1989" NAME="Liebowitz 1989" TYPE="JOURNAL_ARTICLE">
<AU>Liebowitz NR, El Mallakh RS</AU>
<TI>Trazodone for the treatment of anxiety symptoms in substance abusers</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>8</NO>
<PG>449-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipper-1986" NAME="Lipper 1986" TYPE="JOURNAL_ARTICLE">
<AU>Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL et al</AU>
<TI>Preliminary study of carbamazepine in post traumatic stress disorder</TI>
<SO>Psychosomatics</SO>
<YR>1986</YR>
<VL>27</VL>
<NO>12</NO>
<PG>849-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Loke-2005" NAME="Loke 2005" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Green S</AU>
<TI>Appendix 6b. Including adverse effects</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [Updated May 2005]</SO>
<YR>2005</YR>
<VL>Issue 3</VL>
<ED>Loke YK, Price D, Herxheimer A</ED>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Looff-1995" NAME="Looff 1995" TYPE="JOURNAL_ARTICLE">
<AU>Looff D, Grimley P, Kuller F, Martin A, Shonfield L</AU>
<TI>Carbamazepine for PTSD</TI>
<SO>Journal of the American Academy of Child &amp; Adolescent Psychiatry</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>6</NO>
<PG>703-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lowenstein-1988" NAME="Lowenstein 1988" TYPE="JOURNAL_ARTICLE">
<AU>Lowenstein RJ, Hornstein N, Farber B</AU>
<TI>Open trial of clonazepam in the treatment of post traumatic stress symptoms in multiple personality disorder</TI>
<SO>Dissociation</SO>
<YR>1988</YR>
<VL>1</VL>
<PG>3-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marmar-1996" NAME="Marmar 1996" TYPE="JOURNAL_ARTICLE">
<AU>Marmar CR, Schoenfeld F, Weiss DS, Metzler T, Zatzick D, Wu R et al</AU>
<TI>Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>Suppl 8</NO>
<PG>66-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-1996" NAME="Marshall 1996" TYPE="JOURNAL_ARTICLE">
<AU>Marshall RD, Stein DJ, Liebowitz MR, Yehuda R</AU>
<TI>Psychopharmacology of posttraumatic stress disorder</TI>
<SO>Psychiatric Annals</SO>
<YR>1996</YR>
<VL>26</VL>
<PG>217-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-1998a" NAME="Marshall 1998a" TYPE="BOOK_SECTION">
<AU>Marshall RD, Davidson JR, Yehuda R</AU>
<TI>Pharmacotherapy in the treatment of posttraumatic stress disorder and other trauma-related disorders</TI>
<SO>Psychological Trauma</SO>
<YR>1998</YR>
<PG>133-77</PG>
<ED>Yehuda R</ED>
<PB>American Psychiatric Press</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-1998b" NAME="Marshall 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D et al</AU>
<TI>An open trial of paroxetine in patients with noncombat-related posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>1</NO>
<PG>10-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall RD, Pierce D</AU>
<TI>Implications of recent findings in posttraumatic stress disorder and the role of pharmacotherapy</TI>
<SO>Harvard Review of Psychiatry</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>5</NO>
<PG>247-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDougle-1991" NAME="McDougle 1991" TYPE="JOURNAL_ARTICLE">
<AU>McDougle CJ, Southwick SM, Charney DS, St James RL</AU>
<TI>An open trial of fluoxetine in the treatment of posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>5</NO>
<PG>325-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McQuay-1997" NAME="McQuay 1997" TYPE="JOURNAL_ARTICLE">
<AU>McQuay HJ, Moore RA</AU>
<TI>Using numerical results from systematic reviews in clinical practice</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1997</YR>
<VL>126</VL>
<NO>9</NO>
<PG>712-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mellman-1998" NAME="Mellman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mellman TA, Byers PM, Augenstein JS</AU>
<TI>Pilot evaluation of hypnotic medication during acute traumatic stress response</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>3</NO>
<PG>563-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mellman-2002" NAME="Mellman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mellman TA, Bustamante V, David D, Fins AI</AU>
<TI>Hypnotic medication in the aftermath of trauma</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>12</NO>
<PG>1183-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milanes-1984" NAME="Milanes 1984" TYPE="JOURNAL_ARTICLE">
<AU>Milanes F, Mack C</AU>
<TI>Phenelzine treatment of post-Vietnam stress syndrome</TI>
<SO>VA Practitioner</SO>
<YR>1984</YR>
<VL>1</VL>
<PG>40-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-1999" NAME="Moncrieff 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moncrieff J, Churchill R, Drummond DC, McGuire H</AU>
<TI>Development of a quality assessment instrument for trials of treatments for depression and neurosis</TI>
<SO>International Journal of Methods in Psychiatric Research</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>3</NO>
<PG>126-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-1979" NAME="Montgomery 1979" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Asberg M</AU>
<TI>A new depression scale designed to be sensitive to change</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>382-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" NAME="Mulrow 1997" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1997</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagy-1993" NAME="Nagy 1993" TYPE="JOURNAL_ARTICLE">
<AU>Nagy LM, Morgan CA, Southwick SM, Charney DS</AU>
<TI>Open prospective trial of fluoxetine for posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>2</NO>
<PG>107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neal-1997" NAME="Neal 1997" TYPE="JOURNAL_ARTICLE">
<AU>Neal LA, Shapland W, Fox C</AU>
<TI>An open trial of moclobemide in the treatment of post-traumatic stress disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>4</NO>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2005" NAME="NICE 2005" TYPE="BOOK">
<AU>Guideline Development Group</AU>
<SO>Post-traumatic stress disorder: The management of PTSD in adults and children in primary and secondary care</SO>
<YR>2005</YR>
<VL>26</VL>
<PB>Gaskell and the British Psychological Society</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivera-1990" NAME="Olivera 1990" TYPE="JOURNAL_ARTICLE">
<AU>Olivera AT, Fero D</AU>
<TI>Affective disorders, DST, and treatment in PTSD patients: Clinical observations</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>407-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Onder-2005" NAME="Onder 2005" TYPE="OTHER">
<AU>Onder E, Tural U, Aker T</AU>
<TI>A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake</TI>
<SO>Eur Psychiatry</SO>
<YR>2005</YR>
<VL>[Epub ahead of print]</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Otto-1996" NAME="Otto 1996" TYPE="BOOK_SECTION">
<AU>Otto MW, Penava SJ, Pollock RA, Smoller JW</AU>
<TI>Cognitive-behavioral and pharmacological perspectives on the treatment of post traumatic stress disorder</TI>
<SO>Challenges in clinical practice: Pharmacologic and psychosocial strategies</SO>
<YR>1996</YR>
<PG>219-60</PG>
<ED>Pollack MH, Otto MW, Rosenbaum JR</ED>
<PB>Guilford Press</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Penava-1996" NAME="Penava 1996" TYPE="JOURNAL_ARTICLE">
<AU>Penava SJ, Otto MW, Pollack MH, Rosenbaum JF</AU>
<TI>Current status of pharmacotherapy for PTSD: An effect size analysis of controlled studies</TI>
<SO>Depression and Anxiety</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>5</NO>
<PG>240-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petty-2001" NAME="Petty 2001" TYPE="JOURNAL_ARTICLE">
<AU>Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL et al</AU>
<TI>Olanzapine treatment for post-traumatic stress disorder: an open-label study</TI>
<SO>International Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>331-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rapaport-2002" NAME="Rapaport 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rapaport MH, Endicott J, Clary CM</AU>
<TI>Posttraumatic stress disorder and quality of life: Results across 64 weeks of sertraline treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>1</NO>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robert-1999" NAME="Robert 1999" TYPE="JOURNAL_ARTICLE">
<AU>Robert R, Blakeney PE, Villarreal C, Rosenberg L, Meyer WJ 3rd</AU>
<TI>Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study</TI>
<SO>Journal of the American Academy of Child and Adolescent Psychiatry</SO>
<YR>1999</YR>
<VL>38</VL>
<NO>7</NO>
<PG>873-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K</AU>
<TI>Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>150-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-1998" NAME="Rose 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rose S, Bisson J</AU>
<TI>Brief early psychological interventions following trauma: A systematic review of the literature</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>4</NO>
<PG>697-710</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-2002" NAME="Rose 2002" TYPE="COCHRANE_REVIEW">
<AU>Rose S, Bisson J, Wessely S.</AU>
<TI>Psychological debriefng for preventing post traumatic stress disorder (PTSD) (Review)</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothbaum-1996" NAME="Rothbaum 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rothbaum BO, Ninan PT, Tomas L</AU>
<TI>Sertraline in the treatment of rape victims with posttraumatic stress disorder</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>4</NO>
<PG>865-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rubin-1993" NAME="Rubin 1993" NOTES="&lt;p&gt;abstr NR169&lt;/p&gt;" TYPE="CONFERENCE_PROC">
<AU>Rubin MR, Solt V, Chen C-J, et al</AU>
<TI>Anafranil's effect on the obsessions and sleep in PTSD</TI>
<SO>Proceedings and Abstracts of the 146th Annual Meeting of the American Psychiatric Association, San Francisco, CA</SO>
<YR>1993</YR>
<PG>102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sargent-1940" NAME="Sargent 1940" TYPE="JOURNAL_ARTICLE">
<AU>Sargent WW, Slater E</AU>
<TI>Acute war neuroses</TI>
<SO>Lancet</SO>
<YR>1940</YR>
<VL>140</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scherer-1994" NAME="Scherer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Scherer RW, Dickersin K, Langenberg P</AU>
<TI>Full publication of results initially presented in abstracts. A meta-analysis</TI>
<SO>JAMA</SO>
<YR>1994</YR>
<VL>272</VL>
<NO>2</NO>
<PG>158-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seedat-2001" NAME="Seedat 2001" TYPE="JOURNAL_ARTICLE">
<AU>Seedat S, Lockhat R, Kaminer D, Zungu-Dirwayi N, Stein DJ</AU>
<TI>An open trial of citalopram in adolescents with post-traumatic stress disorder</TI>
<SO>International Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shalev-1996" NAME="Shalev 1996" TYPE="JOURNAL_ARTICLE">
<AU>Shalev A, Bonne E, Eth S</AU>
<TI>Treatment of posttraumatic stress disorder: A review</TI>
<SO>Psychosomatic Medicine</SO>
<YR>1996</YR>
<VL>58</VL>
<NO>2</NO>
<PG>162-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shay-1992" NAME="Shay 1992" TYPE="JOURNAL_ARTICLE">
<AU>Shay J</AU>
<TI>Fluoxetine reduces explosiveness and elevates mood of Vietnam vets with PTSD</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>97-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheehan-1996" NAME="Sheehan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Sheehan DV, Harnett-Sheehan K, Raj BA</AU>
<TI>The measurement of disability</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>11 Suppl 3</VL>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherman-1998" NAME="Sherman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Sherman JJ</AU>
<TI>Effects of psychotherapeutic treatments for PTSD: A meta-analysis of controlled clinical trials</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>3</NO>
<PG>413-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silver-1990" NAME="Silver 1990" TYPE="JOURNAL_ARTICLE">
<AU>Silver JM, Sandberg DP, Hales RP</AU>
<TI>New approaches in the pharmacotherapy of posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<NO>10 Suppl</NO>
<PG>33-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1991" NAME="Simpson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Simpson MA</AU>
<TI>Buspirone, benzodiazepines, and post-traumatic stress disorder</TI>
<SO>Journal of Traumatic Stress</SO>
<YR>1991</YR>
<VL>4</VL>
<PG>305-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solomon-1992" NAME="Solomon 1992" TYPE="JOURNAL_ARTICLE">
<AU>Solomon SD, Gerrity ET, Muff AM</AU>
<TI>Efficacy of treatments for posttraumatic stress disorder: An empirical review</TI>
<SO>JAMA</SO>
<YR>1992</YR>
<VL>268</VL>
<NO>5</NO>
<PG>633-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solomon-1997" NAME="Solomon 1997" TYPE="JOURNAL_ARTICLE">
<AU>Solomon SD, Davidson JR</AU>
<TI>Trauma: Prevalence, impairment, service use, and cost</TI>
<SO>Journal of Clinial Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>Suppl 5</NO>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Southwick-1993" NAME="Southwick 1993" TYPE="JOURNAL_ARTICLE">
<AU>Southwick SM, Yehuda R</AU>
<TI>The interaction between pharmacotherapy and psychotherapy in the treatment of posttraumatic stress disorder</TI>
<SO>American Journal of Psychotherapy</SO>
<YR>1993</YR>
<VL>47</VL>
<NO>3</NO>
<PG>404-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1996" NAME="Spitzer 1996" TYPE="BOOK">
<AU>Spitzer R, Williams J, Gibbons M</AU>
<SO>Instructional manual for the structured clinical interview for DSM-IV.</SO>
<YR>1996</YR>
<PB>New York State Psychiatric Institute.</PB>
<CY>New York. NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1986" NAME="Stewart 1986" TYPE="JOURNAL_ARTICLE">
<AU>Stewart JT, Bartucci RJ</AU>
<TI>Posttraumatic stress disorder and partial complex seizures (let)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<NO>1</NO>
<PG>113-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Szymanski-1991" NAME="Szymanski 1991" TYPE="JOURNAL_ARTICLE">
<AU>Szymanski HV, Olympia J</AU>
<TI>Divalproex in posttraumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>148</VL>
<NO>8</NO>
<PG>1086-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2003" NAME="Taylor 2003" TYPE="JOURNAL_ARTICLE">
<AU>Taylor FB</AU>
<TI>Tiagabine for posttraumatic stress disorder: a case series of 7 women</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1421-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomson-1994" NAME="Thomson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thomson SG</AU>
<TI>Why sources of heterogeneity in meta-analysis should be investigated</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6965</NO>
<PG>1351-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ursano-2004" NAME="Ursano 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ursano RJ, Bell C, Eth S, Friedman M, Norwood A, Pfefferbaum B et al</AU>
<TI>Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>11 Suppl</NO>
<PG>3-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Kolk-1983" NAME="van der Kolk 1983" TYPE="JOURNAL_ARTICLE">
<AU>van der Kolk BA</AU>
<TI>Psychopharmacological issues in post traumatic stress disorder</TI>
<SO>Hospital and Community Psychiatry</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>8</NO>
<PG>683-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Kolk-1987" NAME="van der Kolk 1987" TYPE="JOURNAL_ARTICLE">
<AU>van der Kolk BA</AU>
<TI>The drug treatment of post traumatic stress disorder</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>2</NO>
<PG>203-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Etten-1998" NAME="van Etten 1998" TYPE="JOURNAL_ARTICLE">
<AU>van Etten ML, Taylor S</AU>
<TI>Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis</TI>
<SO>Clinical Psychology and Psychotherapy</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>126-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-1989" NAME="Walker 1989" TYPE="BOOK_SECTION">
<AU>Walker JI</AU>
<TI>Chemotherapy of traumatic war stress</TI>
<SO>Stressful life events.</SO>
<YR>1989</YR>
<PG>587-601</PG>
<EN>International Universities Press Stress and Health Series, Monograph 4</EN>
<ED>Miller TW, et al</ED>
<PB>International Universities Press</PB>
<CY>Madison, CT</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiss-1997" NAME="Weiss 1997" TYPE="BOOK_SECTION">
<AU>Weiss DS, Marmar CR</AU>
<TI>The Impact of Event Scale&#8212;Revised</TI>
<SO>Assessing psychological trauma and PTSD: A handbook for practitioners</SO>
<YR>1997</YR>
<PG>399-411</PG>
<ED>Wilson JP, Keane TM</ED>
<PB>Guilford Press</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wells-1991" NAME="Wells 1991" TYPE="JOURNAL_ARTICLE">
<AU>Wells GB, Chu C, Johnson R, et al</AU>
<TI>Buspirone in the treatment of post-traumatic stress disorder and dream anxiety disorder</TI>
<SO>Military Medicine</SO>
<YR>1991</YR>
<VL>11</VL>
<PG>340-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1983" NAME="White 1983" TYPE="JOURNAL_ARTICLE">
<AU>White NS</AU>
<TI>Post-traumatic stress disorder</TI>
<SO>Hospital and Community Psychiatry</SO>
<YR>1983</YR>
<VL>34</VL>
<NO>11</NO>
<PG>1061-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wise-1983" NAME="Wise 1983" TYPE="JOURNAL_ARTICLE">
<AU>Wise M</AU>
<TI>Post traumatic stress disorder: The human reaction to catastrophe</TI>
<SO>Drug Therapy</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>97-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolf-1988" NAME="Wolf 1988" TYPE="JOURNAL_ARTICLE">
<AU>Wolf ME, Alavi A, Mosnaim AD</AU>
<TI>Posttraumatic stress disorder in Vietnam veterans: clinical and EEG findings; possible therapeutic effects of carbamazepine</TI>
<SO>Biological Psychiatry</SO>
<YR>1988</YR>
<VL>23</VL>
<NO>6</NO>
<PG>642-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yehuda-1995" NAME="Yehuda 1995" TYPE="JOURNAL_ARTICLE">
<AU>Yehuda R, McFarlane AC</AU>
<TI>Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>12</NO>
<PG>1705-13</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-04-12 16:57:03 +0100" MODIFIED_BY="Sarah  R Davies">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-04-12 16:57:03 +0100" MODIFIED_BY="Sarah  R Davies" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Baker-1995-a">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, single-blind placebo run-in </P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 146 DSM-III-R PTSD, average age: 44 years (23-73), 81% male, mean duration of diagnosis: 12.8 years, MDD not present, 60% combat-related</P>
<P>SCREENING<BR/>Primary diagnosis: symptoms at least 6 months, CAPS &gt;= 45, MADRS &lt;= 22<BR/>Comorbidity: MADRS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: brofaromine up to 150 mg/d vs placebo x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS<BR/>Secondary outcomes: IES, DTS, CGI </P>
<P>NOTES: CGI (values not reported, CGI-C obtained from Davidson et al, 1997), ITT (LOCF 1 post-baseline assessment) values provided.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Not mentioned<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: total of 35<BR/>Quality rating score: 15<BR/>Single-blind placebo run-in excluded 28 placebo-responders<BR/>Obtained additional HAM-D and CAPS-2 summary statistics from Sudie Back</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brady-2000">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, single blind 2 week placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 187 DSM-III-R PTSD, 6% combat-related, mean age: 39.9 years (18-69), 27% male, 33% (62/187) with current major depression</P>
<P>SCREENING<BR/>Primary diagnosis: CAPS-1, 6-month duration, CAPS &gt;= 50 at end of placebo run-in<BR/>Comorbidity: No information</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline 50-200 mg/d (mean endpoint dose: 133.3 mg/d) versus placebo x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CGI-C, CGI-S, CAPS-2, IES. Responders defined as 30% or greater decrease on CAPS-2 and CGI-C of 1 or 2.<BR/>Secondary outcomes: DTS, HAM-D, Q-LES-Q</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No<BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 30/94(32%) on sertraline, 28/93(30%) on placebo. <BR/>Quality rating score: 31</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brady-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, fixed dose, double-blind, 4 day tapering of medication at end of trial, single blind 1 week placebo run-in</P>
<P>BLINDING<BR/>Participants: unclear<BR/>Assessors: unclear<BR/>Administrators: unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: unclear</P>
<P>RANDOMISATION<BR/>Method: urn randomisation by gender, depressive disorder, trauma type, and age of index trauma</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 94 DSM-IV PTSD with concurrent alcoholism (LOCF sample), no war veterans, mean age: 36.7 years, 54% male, </P>
<P>SCREENING<BR/>Primary diagnosis: CAPS, SCID, CAPS &gt;= 30% decrease after placebo run-in grounds for exclusion<BR/>Comorbidity: TLFB</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline (50 mg/d - 150 mg/d) versus placebo (50 mg/d - 150 mg/d) x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes: OCDS, CAPS, HAM-D, SID, IES (not clear whether primary or secondary)</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: unclear<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: information not provided, 3 patients excluded as responders during placebo run-in<BR/>Quality rating score: 22</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Braun-1990">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, crossover, 2 week titrated placebo washout, flexible dose, double-blind, single centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 16 DSM-III PTSD, 25% combat-veterans, mean age: 37.7 years (19-56), 13% (2/16) MDD, described as chronic and treatment-refractory</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: alprazolam 1.5mg to 6 mg/d (max avg: 4.65 mg/d) in divided doses vs placebo x 5 weeks each phase of crossover</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcomes: DSM based PTSD scale, IES, HAM-D, HAM-A, Visual Analogue (not clear which outcomes are secondary or primary). </P>
<P>Data estimation: Observed cases for patients who completed 5 weeks of both phases</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Unclear</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 3/7 (43%) on alprazolam, 3/9 (33%) on placebo.<BR/>Quality Rating Scale score: 14</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Butterfield-2001">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 15 DSM-IV PTSD, mean age: 43.2 years (26-73), 14 women, 53.3% (8/15) MDD, most common comorbid diagnosis: GAD - 64.3% (9/15), baseline severity on TOP-8: olanzapine (19.3), placebo (21.8)</P>
<P>SCREENING<BR/>Primary diagnosis: SIP<BR/>Comorbidity: MINI </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: olanzapine 5 mg/d - 20mg/d (max. mean 14.1 mg/d) versys placebo (max. mean: 13.9mg/d) x 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: TOP-8, SPRINT, <BR/>Secondary outcomes: IES, DTS, CGI-I, SDS, BAS, AIMS</P>
<P>Data estimation: ITT (General linear model)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No<BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 3/15 (20%) on olanzapine and 1/5 (20%) on placebo.<BR/>Quality rating score: 24<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chung-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, non-blinded, single centre</P>
<P>BLINDING<BR/>Participants: No<BR/>Assessors: No<BR/>Administrators: No </P>
<P>ALLOCATION CONCEALMENT<BR/>Method: None</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 113 DSM-IV Korean war veterans, mean age: 59.8 , mean duration of diagnosis:34.5, 17% (17/100) MDD, baseline severity on CAPS-2: mirtazapine (103.2), sertaline (88.8)</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: mirtazapine 15 mg/d - 34.1 mg/d (mean daily dose) versus sertraline 50mg/d - 101.5mg/d (mean daily dose) x 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAPS-2, HAM-D (17 item), CGI-I, CGI-S (no distinction made between primary and secondary outcomes) </P>
<P>Data estimation: completer values<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 12.1% (7/58) on mirtazapine, 10.9% (6/55) on sertraline<BR/>Quality rating score: 27<BR/>Patients taking antidepressants were placed on 7 day washout priot to entering trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Conner-1999">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, single centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear </P>
<P>ALLOCATION CONCEALMENT<BR/>Method: randomisation only known to hospital pharmacy</P>
<P>RANDOMISATION<BR/>Method: computer generated randomisation into groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 54 DSM-III PTSD, none combat-related, duration of diagnosis: 6 years (median), median age: 37 years (18-55), 91% female, baseline severity on DGRP: fluoxetine (4.2) placebo (4.6)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: fluoxetine (20-60 mg/d; median: 30 mg/d) vs placebo (20-60 mg/d; median: 40 mg/d) x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: DGRP(change, severity)<BR/>Secondary outcomes: SIP, DTS, SDS. VS. </P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 6/27(22%) on fluoxetine and 12/27(44%) on placebo.<BR/>Quality rating score: 28<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davidson-1990">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: balanced randomization, placebo-controlled, parallel arms, flexible dose, double-blind, single centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 46 DSM-III PTSD, chronic, combat veterans, presumably all males, inpatients included, 20% (9/46) MDD, most common comorbid diagnosis: GAD (16), baseline severity on IES: amitriptyline (33.1) placebo (36.8)</P>
<P>SCREENING<BR/>Primary diagnosis: SI-PTSD<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: amitriptyline (50-300 mg/d) vs placebo x 8 weeks, ongoing supportive psychotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CGI-I , SI-PTSD, CGI-S<BR/>Secondary outcomes: HAM-D, HAM-A, IES, NI, EPI</P>
<P>Data estimation: completer values<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 8/25 (32%) on amitriptyline, 5/21 (24%) on placebo.<BR/>Quality rating score: 24</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davidson-2001a">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, multicentre, 1 week single-blind placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: computer generated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 208 DSM-III-R PTSD, 5% war trauma, mean age: 37.1 (18-69), 78% male, duration of diagnosis: 12.3 years, 40% (83/208) MDD, baseline severity on CAPS-2: sertraline (73.9) placebo (73.5)</P>
<P>SCREENING<BR/>Primary diagnosis: CAPS-1, CAPS-2 &gt;= 50, minimum 6 months duration<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline 25 mg/d to between 50-200 mg/d (avg: 146.3 mg/d) vs. placebo x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS-2, IES, CGI-S, CGI-I<BR/>Secondary outcomes: DTS, HAM-D, HAM-A, PSQI</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 30% on sertraline and 27% on placebo (not clear which sample was used as denominator)<BR/>Quality rating score: 33</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-16 13:05:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2001b">
<CHAR_METHODS MODIFIED="2016-02-16 12:56:16 +0000" MODIFIED_BY="[Empty name]">
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, relapse prevention study for participants undergoing acute and continuation treatment in <LINK REF="STD-Brady-2000" TYPE="STUDY">Brady 2000</LINK> and <LINK REF="STD-Davidson-2001a" TYPE="STUDY">Davidson 2001a</LINK>
</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-16 12:56:41 +0000" MODIFIED_BY="[Empty name]">
<P>SAMPLE</P>
<P>96 DSM-III-R PTSD, mean age=43.4 years, SD=10.3, 30% male</P>
<P>SCREENING</P>
<P>Responders (CGI &#8804; 2, &#8805;30% improvement on total severity score for CAPS) in last two sessions of 28 week continuation treatment with sertraline </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-16 12:51:12 +0000" MODIFIED_BY="[Empty name]">
<P>Sertraline 50-200 mg/d (avg 137 mg/day) vs. placebo (avg 145 mg/day) x 28 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-16 13:05:06 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Rates and times to event for 1) relapse, 2) relapse or discontinuation because of clinical deterioration (self-<BR/>rated), and 3) acute exacerbation of PTSD. <BR/>Secondary outcomes: CAPS, HAM-D, QLES</P>
<P>Data estimation: Not applicable for primary outcomes (Kaplan Meier survival analysis)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-16 13:05:31 +0000" MODIFIED_BY="[Empty name]">
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes (as reported in acute and continuation phase studies)<BR/>Medication provided by industry: No (as reported in acute and continuation phase studies)<BR/>Any of the authors work for industry: Yes<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davidson-2003">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, fixed dose, double-blind, single centre, 1 week single-blind placeb run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 29 DSM-IV PTSD, 15% (4/26) war trauma, mean age: 46.5 years, 73% (19/26) MDD, baseline severity on SPRINT: mirtrazapine (21.7), placebo (25)</P>
<P>SCREENING<BR/>Primary diagnosis: SIP =&lt; 20<BR/>Comorbidity: MINI<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: mirtrazapine 15 mg/d - 45 mg/d (mean end dose: 38.8 mg/d) versus placebo (mean end dose: 43.3 mg/d) x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: SPRINT(Clinical Global Improvement &amp; Total Scores)<BR/>Secondary outcomes: DTS, HADS, SIP, ASEX</P>
<P>Data estimation: LOCF (1 post-baseline assessment)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 18% (3/17) on mitrazapine and 33% (3/9) on placebo<BR/>Quality rating score: 27</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davidson-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: Randomised, double-blind, placebo-controlled, parallel flexible dose trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 538 DSM-IV PTSD, 65.4% females, average age: 32 years</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline (25 mg/d -200 mg/d), venlafaxine (37.5 mg/d - 300 mg/d) versus placebo x mean duration of 84 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAPS, CGI-S, DTS, GAF (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Unclear <BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Unclear </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 40.5% (218/538) dropout rate ?<BR/>Quality rating score: Not calculated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davis-2001">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, multi-centre</P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Yes<BR/>Administrators: Yes (self-administered)</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: randomisation log kept by pharmacist</P>
<P>RANDOMISATION<BR/>Method: No information</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 42 DSM-IV PTSD, 98% (40/41) combat veterans, mean age: 53.8 years (32-75), 98% (40/41) male, average duration of illness: 29.9 years, 39% (16/41) MDD, baseline severity on CAPS: nefazodone (81) and placebo (83.2)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID<BR/>Comorbidity: SCID</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: nefazodone 200 mg/d - 600 mg/d (avg final dose: 435mg/d) versus placebo x 12 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS<BR/>Secondary outcomes: HAM-A, HAM-D, PTSD checklist, CADSS, GAFS, CGI</P>
<P>Data estimation: LOCF (excluded 1 patient due to compromise of blind)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 46% (12/26) on nefazodone and 40% (6/15) on placebo<BR/>Quality rating score: 25</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Eli-Lilly-2006">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: Randomised, double blind, placebo-controlled, parallel fixed dose trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 411 PTSD</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: fluoxetine 20 mg/d (N = 163) and 40 mg/d (N = 160) versus placebo (N = 88) x mean of 84 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>TOP-8,CGI-S (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: ITT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 259 (63%) dropouts in total<BR/>Quality rating score: Not calculated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hertzberg-1999">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arms, flexible dose, double blind, multi-centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 15 DSM-IV PTSD, 71% (10/14) war combat, mean age: 43.4 years (29-53), 64% (9/14) male, baseline severity on SI-PTSD: lamotrigine (44.8) and placebo (43)</P>
<P>SCREENING<BR/>Primary diagnosis: SIP<BR/>Comorbidity: MINI<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: lamotrigine 25 mg/d -500mg/d (avg. max. dose: 380 mg/d) versus placebo x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ITT(LOCF) values provided.<BR/>Primary outcomes: SIP, DGRP<BR/>Secondary outcomes: None</P>
<P>Data estimation: LOCF (excluded 1 patient)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 27% (3/11) on lamotrigine and 75% (3/4) on placebo<BR/>Quality rating score: 23</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hertzberg-2000">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arms, flexible dose, double blind, single centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 12 DSM-IV PTSD, male Vietnam combat veterans, mean age: 46 years (44-48), 66% (8/12) MDD, baseline severity on DTS: fluoxetine (106) and placebo (111)</P>
<P>SCREENING<BR/>Primary diagnosis: SIP<BR/>Comorbidity: SCID - DSM-III-R <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: fluoxetine 10 mg/d - 60 mg/d (mean endpoint dose: 48 mg/d) vs placebo x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>DTS, SDS, SIP, DGRP (no distinction between primary and secondary outcomes)</P>
<P>Data estimation: Presumably LOCF (not clear in text)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 1/6 (17%) on fluoxetine and 0/6 (0%) on placebo<BR/>Quality rating score: 21</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kaplan-1996">
<CHAR_METHODS>
<P>Description: random-assignment, placebo-controlled, crossover, fixed dose, double-blind, 2 week washout period</P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: Unclear<BR/>Administrators: Yes (self administered) </P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Identical capsules used for medication and placebo</P>
<P>RANDOMISATION<BR/>Method: pre-arranged random code</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 17 DSM-III-R PTSD, 23% (3/13) combat-related, mean age for OC: 39.7 year (25-56), 62% male, duration of diagnosis for OC: 0.5-28 years, no comorbid major depression, baseline severity on IES for OC: inositol (35.8) and placebo (34.9)</P>
<P>SCREENING<BR/>Primary diagnosis: No information<BR/>Comorbidity: No information</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: inositol 12 g/d versus placebo x 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IES , SCL-90 (1 centre), HAM-A, HAM-D (other centre)<BR/>(no distinction between primary and secondary outcomes)</P>
<P>Data estimation: Completer values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No information<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No information </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 4/17 (24%)<BR/>Quality rating score: 13</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Katz-1994">
<CHAR_METHODS>
<P>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, multi-centre, 2 week single-blind placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 64 DSM-III-R PTSD, 17% (8/45) combat-related, median age: 39 (22-62), 76% male, duration of diagnosis: 2.8 years, baseline severity on CAPS: brofaromine (80.6) and placebo (82.9)</P>
<P>SCREENING<BR/>Primary diagnosis: CAPS &gt; 36, response of &gt;= 20% decrease on CAPS during placebo run-in <BR/>Comorbidity: HAM-D &gt; 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: brofaromine 50 mg/d -150 mg/d versus placebo x 14 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS<BR/>Secondary outcomes: CGI</P>
<P>Data estimation: LOCF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 30% (10/33) on brofaromine and 29% (9/31) on placebo<BR/>Quality rating score: 24<BR/>CGI-C values obtained from Davidson et al, 1997</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kosten-1991">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, comparator and placebo-controlled, parallel arm, flexible dose, double-blind, multi-centre</P>
<P>BLINDING<BR/>Participants: Yes<BR/>Assessors: No<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 60 DSM-III-PTSD, all combat veterans, mean age: 39 years, all males, no subjects with comorbid major depression, baseline severity on IES: imipramine (36.5), phenelzine (30.6) and placebo (33)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID<BR/>Comorbidity: SADS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: imipramine 50 mg/d - 300 mg/d (avg max. dose: 225 mg/d) versus phenelzine 15 mg/d - 75 mg/d (avg max. dose: 68 mg/d) versus placebo x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: IES<BR/>Secondary outcomes: Combat Scale; CAS; HAM-D; HAM-A; RSD</P>
<P>Data estimation: LOCF (completers of 3 or more weeks)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 52% (12/23) on impramine, 21% (4/19) on phenelzine and 12/18 (67%) on placebo<BR/>Quality rating score: 26</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marshall-2001">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, comparator and placebo-controlled, parallel arm, fixed dose, double-blind, 1 week placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 563 DSM-IV PTSD, mean age: 41.8 years, 57% (315 /551) female, average duration of diagnosis: 15.7 years, approximately 45% (248/551) comorbid MDD, baseline severity on CAPS-2:: paroxetine 20mg/d (75.3), paroxetine 40mg/d (74.3), and placebo ( 74.4)</P>
<P>
<BR/>SCREENING<BR/>Primary diagnosis: MINI, CAPS-1, CAPS-2 &gt;= 50<BR/>Comorbidity: No information</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: paroxetine (25 mg/d) or paroxetine (50 mg/d) versus placebo x 12 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS-2, CGI-I<BR/>Secondary outcomes: DTS, TOP-8, SDS, MADRS</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No information<BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 35% (66/188) on 20mg/d paroxetine, 40% (74/187) on 40mg/d paroxetine, and 36% (68/188) placebo<BR/>Quality rating score: 26</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Marshall-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, 1 week single-blind placebo run-in, single centre, with maintenance phase</P>
<P>BLINDING<BR/>Participants: No<BR/>Assessors: Yes<BR/>Administrators: Yes</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 63 DSM-IV PTSD, no combat-related trauma, mean age: 39.8 years, 67% (35/52) female, 62.5% (30/48) MDD, baseline severity on CAPS: paroxetine (82.8) and placebo (84.2)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID, minimum duration of 3 months PTSD<BR/>Comorbidity: SCID I</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: paroxetine 10 mg/d - 6 mg/d versus placebo x 10 weeks, followed by 12 week double-blind maintenance phase for responders to paroxetine or placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CGI, CAPS<BR/>Secondary outcomes: CAPS-2, IPP, DES, HAM-A, HAM-D, CAP-2 (items 22 &amp; 23)</P>
<P>Data estimation: Mixed-effects model regression (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 32% (8/25) on paroxetine and 52% (14/27) on placebo<BR/>Quality rating score: 21<BR/>7 patients removed as responders during placebo run-in<BR/>Assessments made in either Spanish or English</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-16 13:25:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martenyi-2002a">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, fixed dose, double-blind, multi-centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: computer drug-labelled emergency codes</P>
<P>RANDOMISATION<BR/>Method: computer generated random sequence<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 301 DSM-IV PTSD, acute, 46% combat-related, mean age: 37.9 years, 81% male, baseline severity on CAPS: fluoxetine ( 80.5) and placebo (81.3)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID-I [modified], CAPS-DX =&gt; 50, CGI-S &gt;= 4<BR/>Comorbidity: MADRS &gt; 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-16 13:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>Description: fluoxetine 20 mg/d - 80 mg/d, (avg dose: 57.8 mg/d) versus placebo x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: TOPS-8<BR/>Secondary outcomes: CAPS-2, CGI-S, CGI-I, DTS, MADRS, HAM-A, SCL-90-R, DES<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-16 13:11:52 +0000" MODIFIED_BY="[Empty name]">
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Not mentioned<BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: not provided<BR/>Quality rating score: 31<BR/>The patient-rated scales, the DTS and SCL-90-R, were translated into other languages<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-02-16 13:24:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martenyi-2002b">
<CHAR_METHODS MODIFIED="2016-02-16 13:24:15 +0000" MODIFIED_BY="[Empty name]">
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, relapse prevention component of <LINK REF="STD-Martenyi-2002b" TYPE="STUDY">Martenyi 2002b</LINK>
</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: unclear</P>
<P>RANDOMISATION<BR/>Method: unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-02-16 13:24:47 +0000" MODIFIED_BY="[Empty name]">
<P>131 DSM-IV PTSD, 81% male, avg age = 38.2 years, 47% trauma combat related. Patients required to present with 50% decrease after 12 weeks of acute treatment with fluoxetine on the TOP-8 score, a CGI&#8211;S score &lt;= 2, and failed diagnostic criteria for PTSD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-02-16 13:21:30 +0000" MODIFIED_BY="[Empty name]">
<P>Fluoxetine max avg dose at endpoint: 53 mg/d vs placebo x 24 weeks. Responders to 12 weeks of acute treatment with placebo maintained on placebo. No discontinuation taper of fluoxetine from the acute to relapse prevention phase</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-02-16 13:14:03 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Time to relapse on TOPS-8 (&gt;= 40% increase for 12 week acute baseline) and CGI-S (&gt;= 2 on CGI-S from 12 week acute baseline)<BR/>Secondary outcomes: CAPS-2, CGI-I, DTS, MADRS, HAM-A, SCL-90-R</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-16 13:14:26 +0000" MODIFIED_BY="[Empty name]">
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Not mentioned<BR/>Any of the authors work for industry: No</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McRae-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, multi-centre, 1 week single-blind placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: randomisation sequence kept by research pharmacist</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 37 DSM-IV PTSD, mean age: 40.3 years (18-65), 77% (26/26) female, average duration of diagnosis: 22 years, baseline severity on CAPS: nefazedone (68.85) and placebo (73.77)</P>
<P>SCREENING<BR/>Primary diagnosis: MINI; CAPS-1, minimal 3 month duration, CAPS-2 &gt;= 50 after placebo run-in + CAPS not &gt;30% decrease during run-in<BR/>Comorbidity: MINI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: nafazedone 100 mg/d-600 mg/d (avg: 463 mg/d) versus sertraline 50 mg/d-200 mg/d (avg: 153 mg/d) x 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS-2, CGI-I<BR/>Secondary outcomes: DTS, MADRS, HAM-A, TOP-8, PSQI, SDS</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 14 dropouts in total<BR/>Quality rating score: 33<BR/>3 patients excluded during run-in</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pfizer588">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: Randomised placebo-controlled, double-blind, parallel, flexible dose trial</P>
<P>BLINDING<BR/>Participants: Unclear <BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 193 DSM-III-R PTSD, physical/sexual assault, 74.6% female, average age: 37 years, average duration of illness: 10.5 years, baseline severity on CPS-2: &lt; 50 (except for one participant)</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline (mean completer dose: 156 mg/d) versus placebo x mean of 74 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAPS-2, CGI-I, IES, DTS, CGI-S (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: <BR/>Medication provided by industry: <BR/>Any of the authors work for industry: </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 50 (25.9%) dropped out in total<BR/>Quality rating score: Not calculated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-12 16:57:03 +0100" MODIFIED_BY="Sarah  R Davies" STUDY_ID="STD-Pfizer589">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: Randomised, double-blind, placebo-controlled, parallel flexible dose trial</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-12 16:57:03 +0100" MODIFIED_BY="Sarah  R Davies">
<P>SAMPLE<BR/>Description: 169 DSM-III-R PTSD, predominantly war-trauma sample (71%), 79.9% female, average age: 45 years, average duration of illness: 18 years</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline (mean completer dose: 156 mg/d) versus placebo x mean duration of 72 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAPS-2, CGI-I, CGI-S, IES, DTS (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 26 on sertraline, 14 on placebo<BR/>Quality rating score: Not calculated<BR/>Prevalence of patients with drug abuse history higher at baseline in medication than placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reich-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, single-centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 21 DSM-III-R PTSD, mean age: 27.9 years (18-56), 100% female, all suffered childhood physical, sexual, emotion or verbal abuse, 9 participants on concurrent medication, baseline severity on CAPS-2: risperidone (63.5) and placebo (65.6)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID, CAPS-1<BR/>Comorbidity: None</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: risperidone mean dose of 0.5 mg q.h.s. (avg dose: 1.4 mg/d) at start to 8 mg/d versus placebo x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS-1, CAPS-2<BR/>Secondary outcomes: None</P>
<P>Data estimation: LOCF and random effects time series modeling methods</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 75% (9/12) on risperidone and 78% (7/9) on placebo<BR/>Quality rating score: 26</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Reist-1989">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, crossover, flexible dose, double-blind, 4 day switched cross-over, multi-centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 27 DSM-III PTSD, combat veterans, mean age 38.4 years (28-64), all males, 33% (6/18) major depression, most prevalent comorbidity: 50% (9/18) dysthymic disorder, baseline severity on IES: desipramine (55.2) and placebo (56.2)</P>
<P>SCREENING<BR/>Primary diagnosis: Not mentioned<BR/>Comorbidity: SCID, SCID - DSM-III-R for personality disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: desipramine 50 mg/d -200 mg/d (max avg: 165 mg/d) versus placebo x 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D, HAM-A, BDI, IES<BR/>(no distinction between primary and secondary outcomes)</P>
<P>Data estimation: Completer values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No information<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 33% (9/27)<BR/>Quality rating score: 12<BR/>ongoing recreational and group therapies</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Saygin-2002">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible-dose, single centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 60 DSM-IV PTSD, earthquake survivors, mean age: 41.5 years, 76% (41/54) male, 9% (5/54) MDD, baseline severity on TOP-8: nefazadone (15.75) and sertraline (19.27)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID-1<BR/>Comorbidity: Not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: nefazadone 200 mg/d - 400 mg/d (avg: 332.4 mg/d) versus sertraline 50 mg/d-100 mg/d (avg: 68.3 mg/d) x 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PDS, TOP-8, CGI (no distinction between primary and secondary outcomes)</P>
<P>Data estimation: Completer values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 20% (6/30) on nefazadone and 0% on sertraline<BR/>Quality rating score: 25<BR/>Not clear whether study was blinded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shestatzky-1988">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, crossover, flexible-dose, double-blind, single centre, 2 week placebo washout</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Claimed, but method not mentioned</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 13 DSM-III PTSD, mean age: 38.5 years (31-50), average duration of diagnosis: 5.6 years, 2% (2/10) MDD, baseline severity on IES: phenelzine (34) and placebo (36)</P>
<P>SCREENING<BR/>Primary diagnosis: Not mentioned<BR/>Comorbidity: Not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: phenelzine 30 mg/d - 75 mg/d (avg. max dose: 66 mg/d) versus placebo x 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CGI-I, CGI-S, CAPS-2. ITT(LOCF) values provided.<BR/>Primary outcomes: CAPS-2, CGI-I, CGI-S<BR/>Secondary outcomes: MADRS</P>
<P>Data estimation:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 54% (7/13) on phenelzine and 0% (0/13) on placebo<BR/>Quality rating score: 14<BR/>much of descriptive data for 4 week completers in both phases; supportive psychotherapy provided to patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SKB627">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: Randomised, double-blind, placebo-controlled, parallel flexible dose trial, placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 322 DSM-IV PTSD, 53.7% female</P>
<P>SCREENING<BR/>Primary diagnosis: Unclear<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: paroxetine 20 mg/d - 50 mg/d versus placebo x mean duration of 84 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAPS-2, CGI-I (no distinction made between primary and secondary outcomes)</P>
<P>Data estimation: ITT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Yes <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: Not provided<BR/>Quality rating score: Not calculated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smajkic-2001">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, single centre</P>
<P>BLINDING<BR/>Participants: No<BR/>Assessors: No<BR/>Administrators: No </P>
<P>ALLOCATION CONCEALMENT<BR/>Method: None</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 32 DSM-IV PTSD, bosnian refugees, no combat-related trauma, mean age: 51.34 years (24-63), 56% female, baseline severity on PSS-Sev: sertraline (41.9), venlaxafine (37.8) and paroxetine (37.3)</P>
<P>SCREENING<BR/>Primary diagnosis: PSS<BR/>Comorbidity: SCID, BDI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline 50 mg/d - 100 mg/d versus venlafaxine 75 mg/d - 150 mg/d versus paroxetine (max dose 20mg/d) x 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: PSS<BR/>Secondary outcomes: GAF, BDI</P>
<P>Data estimation: Completer values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: No <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 0% sertraline, 62% (8/13) venlafaxine and 0% paroxetine<BR/>Quality rating score: 17<BR/>Scales translated into Bosnian. Participants received concurrent case management and supportive therapy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tucker-2001">
<CHAR_METHODS>
<P>Description: random-assignment, placebo-controlled, parallel arm, flexible-dose, double-blind, multi-centre, 1 week placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 323 DSM-IV PTSD, 7% (21/307) combat-related, mean age: 40.8 years, 66% female, average duration of diagnosis: 14.9 years, 35% (108/307) with comorbid major depression, baseline severity on CAPS-2: paroxetine (73.2) and placebo (74.3)</P>
<P>SCREENING<BR/>Primary diagnosis: CAPS-1; MINI, CAPS-2 &lt; 50 after placebo run-in<BR/>Comorbidity: Not mentioned<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: paroxetine 20 mg/d -50 mg/d (mean dose: 27.6 mg/d) versus placebo x 12 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS-2 (score &lt; 20 = 'remission'), CGI-I<BR/>Secondary outcomes: DTS, TOP-8, SDS, MADRS</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 46% (70/151) on paroxetine and 42% (66/156) on placebo<BR/>Quality rating score: 27</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tucker-2003">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible-dose, double-blind, single centre, 1-2 week taper at end</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: Unclear</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 59 DSM-IV PTSD, mean age: 38.5 years, 72% (42/58) female, 3% (2/58) combat related, 78% (45/58) major depression, baseline severity on CAPS: citalopramine (91), sertraline (83.9) and placebo (94.2)</P>
<P>SCREENING<BR/>Primary diagnosis: SCID-IV, CAPS-I &gt;=50<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: citalopram 20 mg/d - 50 mg/d (final avg: 36.2 mg/d)) versus sertraline 50 mg/d - 200 mg/d (final avg: 134.1mg/d)) versus placebo x 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS<BR/>Secondary outcomes: IES (revised), BDI (revised)</P>
<P>Data estimation: LOCF (2 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Yes</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: +-20% (5/58) on citalopramine, +- 26% (6/23) on sertraline and +- 30% (3/10) on placebo<BR/>Quality rating score: 26</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-der-Kolk-1994">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible-dose, double-blind, multi-centre</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 64 DSM-II-R PTSD, 44% (28/64) combat-related trauma, mean age: 40.4 years (22-55), 66% (42/64) male, 54.8% (34/64) MDD</P>
<P>SCREENING<BR/>Primary diagnosis: CAPS &gt;= 45<BR/>Comorbidity: Not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: fluoxetine 20 mg/d - 60 mg/d (avg. dose: 40 mg/d) versus placebo x 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CAPS, BDHI, HAM-D, DES, DESI, acoustic startle response, rorschach inkblot test (no distinction between primary and secondary outcomes)</P>
<P>Data estimation: Completer values</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 36% (12/33) on fluoxetine and 13% (4/31) on placebo<BR/>Quality rating score: 22<BR/>Supportive psychotherapy was permitted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-der-Kolk-2004">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible-dose, double-blind, multi-centre, 6 month follow-up</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Yes<BR/>Administrators: Unclear </P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 59 DSM-IV PTSD, mean age: 34.9 years (18-65), 86% (51/59) female, average duration of diagnosis: 13.3 years, baseline severity on CAPS: fluoxetine (73.7) and placebo (70.3)</P>
<P>
<BR/>SCREENING<BR/>Primary diagnosis: Trauma incident &gt;= 1 year ago, GAF &lt; 40<BR/>Comorbidity: Not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: fluoxetine 10 mg/d - 60 mg/d versus Eye Movement Desensitization and Reprocessing (EMDR) versus placebo x 5 weeks <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS<BR/>Secondary outcomes: BDI</P>
<P>Data estimation: LOCF<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: No<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: No</P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 13% (4/30) on fluoxetine and 10% (3/29) on placebo<BR/>Quality rating score: 28</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zohar-2002">
<CHAR_METHODS>
<P>DESIGN<BR/>Description: random-assignment, placebo-controlled, parallel arm, flexible dose, double-blind, mutli-centre, 1 week single blind placebo run-in</P>
<P>BLINDING<BR/>Participants: Unclear<BR/>Assessors: Unclear<BR/>Administrators: Unclear</P>
<P>ALLOCATION CONCEALMENT<BR/>Method: No information</P>
<P>RANDOMISATION<BR/>Method: Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>SAMPLE <BR/>Description: 51 PTSD, 76% (32/42) combat-related trauma, mean age: 40 years, 88% (37/42) male, baseline severity on CAPS-2: sertraline (91.2) and placebo (93.3)</P>
<P>SCREENING<BR/>Primary diagnosis: minimum 6 month PTSD, CAPS-1, CGI-S &gt;=4, CAPS-2 &gt;=50 required after placebo run-in<BR/>Comorbidity: Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Description: sertraline 50 mg/d - 200 mg/d (120 mg/d) versus placebo (avg:147 mg/d) x 10 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: CAPS-2, CGI-I, CGI-S<BR/>Secondary outcomes: MADRS</P>
<P>Data estimation: LOCF (1 post-baseline assessment)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>INDUSTRY SUPPORT<BR/>Industry funded: Yes<BR/>Medication provided by industry: Unclear <BR/>Any of the authors work for industry: Yes </P>
<P>ADDITIONAL INFORMATION<BR/>Drop-out rates: 26% (6/23) on fluoxetine and 26% (5/19) on placebo<BR/>Quality rating score: 30</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Acronyms for scales: AIMS: Abnormal Involuntary Movement Scale; ASEX: Arizona Sexual Experience Scale; ASI: Addiction Severity Index; BAS: Barnes Akathisia Scale; BDHI: Buss-Durkee Hostility Inventory; BDI: Beck Depression Inventory; CADSS: Clinician Administered Dissociative States Scale; CAPS-2: Clinician Administered PTSD Scale - part 2; CAS: Covi Anxiety Scale; CES: Combat Exposure Scale; CES-D: Center for Epidemiologic Studies Depression Scale (self-rated); CGI-I: Clinical Impression - Improvement Scale; CS: Columbia Scale; DESI: Disorders of Extreme Stress Inventory; DES: Dissociative Experiences Scale; DGRP: Duke Global Rating for PTSD; DTS: Davidson Trauma Scale; EPI: Eyesenck Personality Inventory; HADS: Hospital Anxiety and Depression Scale; HAM-A: Hamilton Anxeity Scale; IPP: Inventory of Personal Problems; MADRS: Montgomery-Asberg Depression Rating Scale; MISS: Mississippi Scale for Combat-Related PTSD; NI: Newcastle Index; OCDS: Obsessive Compulsive Drinking Scale; PDS: Posttraumatic Stress Disorder Scale PSQI: Pittsburgh Sleep Quality Index; PSS: PTSD Symptoms Scale; RSD: Raskin Scale for Depression; SADS: Schedule for Affective Disorders and Schizophrenia; SAS: Simpson-Angus Scale; SCID: Structured Clinical Interview for DSM; SCID-P: Structured Clinical Interview for DSM, Psychotic screen; SCL-90-R: Hopkins 90-item Symptom Checklist-Revised; SDS: Sheehan Disability Scale; SI-PTSD: DSM based PTSD scale; SIP: Structured Interview for PTSD; SPRINT: Short PTSD Rating Interview scale; TLFB: Time-Line Follow-Back; VS: Vulnerability to the effects of stress scale; VAS: Visual Analog Scale; UKUSERS: UKU Side Effect Rating Scale; SPRINT: Short PTSD Rating Interview; TOP-8: Treatment Outcome PTSD Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aerni-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>All 3 patients received concurrent medication. In addition, one of the patients was treated with concurrent psychotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bartzokis-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Augmentation trial of adjunctive risperidone for chronic, combat-related PTSD. To be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bremner-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Coupland-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eftekhari-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of treatment of chronic PTSD with prolonged exposure or sertraline. No placebo or other medication used as control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frank-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>An extension of this database was subsequently published (Kosten et al, 1991).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frommberger-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open label comparison of paroxetine and CBT. No placebo or alternative medication control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gelpin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of prophlactic treatment of recent trauma survivors with benzodiazepines. To be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamner-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Buspirone potentiation of antidepressants for combat-veteran PTSD sufferers. May be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamner-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamner-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Risperidone augmentation of medication for war-veteran PTSD sample with psychotic symptoms. May be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heresco_x002d_Levy-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Augmentation trial of d-cycloserine for PTSD. May be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jacobs_x002d_Rebhun-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of treatment for sleep disorders associated with PTSD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kanter-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kellner-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial. Not a treatment study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kline-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open uncontrolled trial of sertraline for treatment-resistant combat veteran PTSD patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monnelly-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Augmentation of risperidone for irritable aggression symptoms in combat-veteran PTSD sufferers. May be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morgan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nagy-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The poster presentation provided neither response rates, nor means/standard deviations before and after medication/placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Otto-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Augmentation trial and comparison group receives medication and cognitive-behaviour therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pitman-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pitman-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were allowed to continue with concommitant psychiatric treatments</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pivac-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Open, non-randomised trial of olanzapine versus fluphenazine for psychotic combat-related PTSD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Randall-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raskind-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial classified as an augmentation trial for treatment resistant PTSD. To be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reist-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reist-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schelling-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of hydrocortisone for post-operative complications in cardiac surgery. As trials is concerned with the development of PTSD following surgery, and diagnosis with PTSD does not fall within its inclusion criteria, this is better considered a prophylaxis trial, and will be included in an upcoming protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Southwick-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stein-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Augmentation trial of adjunctive olanzapine for SSRI resistant combated-related PTSD. To be included in an upcoming review of pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vaiva-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Kolk-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy impact assessment trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zatzick-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacotherapy component of collaborative care intervention non-randomised as only offered to patients with persistent PTSD symptoms</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Fluoxetine_x002c_-Davidson">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Fluoxetine_x002c_-Lilly">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Nefazodone-1_x002c_-BMS">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Nefazodone-2_x002c_-BMS">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Olanzapine_x002c_-Davidson">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Paroxetine-2-_x002d_-SB">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Paroxetine-3-_x002d_-SB">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Sertraline-2_x002c_-Pfizer">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Sertraline-3_x002c_-Pfizer">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Sertraline-4_x002c_-Pfizer">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-SKB650">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Davis-2003">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-DVA-_x0028_unknown_x0029_">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Mechoulam-_x0028_THC_x0029_">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Mithoefer-2005">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-NIAAA-2005">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Tucker-2004">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-02-12 15:28:45 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-02-12 15:28:45 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Baker-1995-a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brady-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brady-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Braun-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Butterfield-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chung-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Conner-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2001a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2001b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Davis-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eli-Lilly-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hertzberg-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hertzberg-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kaplan-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Katz-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kosten-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Marshall-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2002a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Martenyi-2002b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-McRae-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pfizer588">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pfizer589">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reich-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Reist-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SKB627">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saygin-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shestatzky-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smajkic-2001">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tucker-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tucker-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zohar-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-der-Kolk-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-der-Kolk-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-01-24 11:27:15 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-01-24 11:27:15 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Medication versus Placebo: Primary global and PTSD symptom outcomes</NAME>
<CONT_OUTCOME CHI2="22.03527370400613" CI_END="-3.3613713124631595" CI_START="-8.157855110063817" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.759613211263488" ESTIMABLE="YES" I2="27.389147895670952" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.14205631266274577" P_Q="0.9957337484505602" P_Z="2.513324553531035E-6" Q="0.008550755961651866" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="6.273619197503241" TOTALS="YES" TOTAL_1="1270" TOTAL_2="1237" UNITS="" WEIGHT="99.99999999999997" Z="4.707045800761145">
<NAME>CAPS: Total score</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="20.131899285062183" CI_END="-2.5827504168885387" CI_START="-8.596048122514878" DF="11" EFFECT_SIZE="-5.589399269701708" ESTIMABLE="YES" I2="45.360346561230955" ID="CMP-001.01.01" NO="1" P_CHI2="0.043564311596470895" P_Z="2.6885269222447114E-4" STUDIES="12" TAU2="11.430633211215191" TOTAL_1="964" TOTAL_2="945" WEIGHT="82.3507670481006" Z="3.6435985045542547">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="-0.2675583461650568" CI_START="-16.732441653834943" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="43.4" MEAN_2="51.9" ORDER="332" SD_1="28.1" SD_2="28.7" SE="4.200302515133641" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="6.260345938500939"/>
<CONT_DATA CI_END="9.339431733377683" CI_START="-9.619431733377684" EFFECT_SIZE="-0.14000000000000057" ESTIMABLE="YES" MEAN_1="32.56" MEAN_2="32.7" ORDER="333" SD_1="15.69" SD_2="28.75" SE="4.836533634367892" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="5.0470258530100045"/>
<CONT_DATA CI_END="-0.2782851153780168" CI_START="-13.321714884621985" EFFECT_SIZE="-6.800000000000001" ESTIMABLE="YES" MEAN_1="-33.0" MEAN_2="-26.2" ORDER="334" SD_1="23.8" SD_2="23.46" SE="3.3274666963599526" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="8.631755213198241"/>
<CONT_DATA CI_END="-7.989096645353667" CI_START="-18.810903354646335" EFFECT_SIZE="-13.400000000000002" ESTIMABLE="YES" MEAN_1="-38.7" MEAN_2="-25.3" ORDER="335" SD_1="27.2" SD_2="25.8" SE="2.760715705659313" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="10.77521421918625"/>
<CONT_DATA CI_END="13.00529270362274" CI_START="-27.40529270362273" EFFECT_SIZE="-7.199999999999996" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="62.8" ORDER="336" SD_1="33.4" SD_2="40.8" SE="10.309012238489842" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="1.3302914175779472"/>
<CONT_DATA CI_END="8.441343414053849" CI_START="-7.441343414053849" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-27.4" MEAN_2="-27.9" ORDER="337" SD_1="27.12" SD_2="28.42" SE="4.0517802759102475" STUDY_ID="STD-Pfizer588" TOTAL_1="94" TOTAL_2="94" WEIGHT="6.598495256526958"/>
<CONT_DATA CI_END="10.754204583788948" CI_START="-6.154204583788946" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="-13.1" MEAN_2="-15.4" ORDER="338" SD_1="27.12" SD_2="28.42" SE="4.313448946243214" STUDY_ID="STD-Pfizer589" TOTAL_1="84" TOTAL_2="82" WEIGHT="6.017953430319863"/>
<CONT_DATA CI_END="1.22911303151119" CI_START="-12.629113031511189" EFFECT_SIZE="-5.699999999999999" ESTIMABLE="YES" MEAN_1="-36.5" MEAN_2="-30.8" ORDER="339" SD_1="26.1" SD_2="25.37" SE="3.5353267132289923" STUDY_ID="STD-SKB627" TOTAL_1="109" TOTAL_2="103" WEIGHT="7.975826130318784"/>
<CONT_DATA CI_END="-5.253722783701645" CI_START="-16.346277216298358" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-35.5" MEAN_2="-24.7" ORDER="340" SD_1="24.6" SD_2="24.98" SE="2.8297852715900307" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="10.483877310873604"/>
<CONT_DATA CI_END="25.509284608808002" CI_START="-15.949284608808" EFFECT_SIZE="4.780000000000001" ESTIMABLE="YES" MEAN_1="60.28" MEAN_2="55.5" ORDER="341" SD_1="26.15" SD_2="29.07" SE="10.576359959834953" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="1.2674140677768426"/>
<CONT_DATA CI_END="10.510415961147347" CI_START="-12.310415961147344" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="42.7" MEAN_2="43.6" ORDER="343" SD_1="22.1" SD_2="22.6" SE="5.821747772485234" STUDY_ID="STD-van-der-Kolk-2004" TOTAL_1="30" TOTAL_2="29" WEIGHT="3.7275823388706253"/>
<CONT_DATA CI_END="-1.1621075670776149" CI_START="-9.237892432922383" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="-18.7" MEAN_2="-13.5" ORDER="342" SD_1="6.7" SD_2="6.6" SE="2.060187056891231" STUDY_ID="STD-Zohar-2002" TOTAL_1="23" TOTAL_2="19" WEIGHT="14.234985871940534"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4404318762409116" CI_END="5.809036772527354" CI_START="-15.93415224832415" DF="1" EFFECT_SIZE="-5.0625577378983975" ESTIMABLE="YES" I2="30.57637667602196" ID="CMP-001.01.02" NO="2" P_CHI2="0.23006973729562763" P_Z="0.3614039097877587" STUDIES="2" TAU2="18.83657685126333" TOTAL_1="89" TOTAL_2="89" WEIGHT="6.116931550930694" Z="0.9126932416785701">
<NAME>MAOIs</NAME>
<CONT_DATA CI_END="12.802022321866549" CI_START="-12.202022321866554" EFFECT_SIZE="0.29999999999999716" ESTIMABLE="YES" MEAN_1="54.9" MEAN_2="54.6" ORDER="344" SD_1="33.9" SD_2="34.2" SE="6.378700027388721" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" WEIGHT="3.1882212148508864"/>
<CONT_DATA CI_END="2.325765142167416" CI_START="-23.925765142167425" EFFECT_SIZE="-10.800000000000004" ESTIMABLE="YES" MEAN_1="46.3" MEAN_2="57.1" ORDER="345" SD_1="29.7" SD_2="23.7" SE="6.696942007966361" STUDY_ID="STD-Katz-1994" TOTAL_1="33" TOTAL_2="31" WEIGHT="2.9287103360798077"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.34341936244356736" CI_END="0.5181599954033205" CI_START="-11.533025587174883" DF="2" EFFECT_SIZE="-5.507432795885782" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" NO="4" P_CHI2="0.8422236817536396" P_Z="0.07322585560224135" STUDIES="3" TAU2="0.0" TOTAL_1="217" TOTAL_2="203" WEIGHT="11.532301400968699" Z="1.7914204130779878">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="2.1259176231891788" CI_START="-11.725917623189172" EFFECT_SIZE="-4.799999999999997" ESTIMABLE="YES" MEAN_1="42.2" MEAN_2="47.0" ORDER="346" SD_1="33.58" SD_2="33.28" SE="3.5336963729027318" STUDY_ID="STD-Davidson-2004" TOTAL_1="179" TOTAL_2="179" WEIGHT="7.980725790358995"/>
<CONT_DATA CI_END="10.057709663791236" CI_START="-21.25770966379124" EFFECT_SIZE="-5.600000000000001" ESTIMABLE="YES" MEAN_1="-19.1" MEAN_2="-13.5" ORDER="347" SD_1="24.0" SD_2="25.0" SE="7.988774175085488" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="2.136033836430756"/>
<CONT_DATA CI_END="8.550333731474097" CI_START="-30.550333731474097" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-29.6" MEAN_2="-18.6" ORDER="348" SD_1="31.5" SD_2="12.3" SE="9.974843357166067" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="1.4155417741789478"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="20.131899285062183" CI_END="-2.5827504168885382" CI_START="-8.596048122514878" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.589399269701708" ESTIMABLE="YES" I2="45.360346561230955" I2_Q="70.9312210311432" ID="CMP-001.02" MODIFIED="2016-01-24 11:27:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.043564311596470895" P_Q="0.016030483274076635" P_Z="2.6885269222447146E-4" Q="10.320350927756847" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="11.430633211215195" TOTALS="YES" TOTAL_1="964" TOTAL_2="945" UNITS="" WEIGHT="100.00000000000001" Z="3.6435985045542543">
<NAME>CAPS: Individual SSRI agents</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="25.509284608808002" CI_START="-15.949284608808" DF="0" EFFECT_SIZE="4.780000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2016-01-24 11:27:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6513040428914245" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="10" WEIGHT="1.9087159516808048" Z="0.4519513346891225">
<NAME>Citalopram versus placebo</NAME>
<CONT_DATA CI_END="25.509284608808002" CI_START="-15.949284608808" EFFECT_SIZE="4.780000000000001" ESTIMABLE="YES" MEAN_1="60.28" MEAN_2="55.5" MODIFIED="2016-01-24 11:27:15 +0000" MODIFIED_BY="[Empty name]" ORDER="349" SD_1="26.15" SD_2="29.07" SE="10.576359959834953" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="1.9087159516808048"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.510415961147347" CI_START="-12.310415961147344" DF="0" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.8771423857167263" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="5.192146574973105" Z="0.15459275035129175">
<NAME>Fluoxetine versus placebo</NAME>
<CONT_DATA CI_END="10.510415961147347" CI_START="-12.310415961147344" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="42.7" MEAN_2="43.6" ORDER="350" SD_1="22.1" SD_2="22.6" SE="5.821747772485234" STUDY_ID="STD-van-der-Kolk-2004" TOTAL_1="30" TOTAL_2="29" WEIGHT="5.192146574973105"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.0605506660648203" CI_END="-7.1075714249290645" CI_START="-13.874622023758642" DF="3" EFFECT_SIZE="-10.491096724343853" ESTIMABLE="YES" I2="1.9784239070505187" ID="CMP-001.02.03" NO="3" P_CHI2="0.38238358697907127" P_Z="1.2234160717175779E-9" STUDIES="4" TAU2="0.2612660939168708" TOTAL_1="468" TOTAL_2="472" WEIGHT="36.291429820201685" Z="6.077144374122606">
<NAME>Paroxetine versus placebo</NAME>
<CONT_DATA CI_END="-7.989096645353667" CI_START="-18.810903354646335" EFFECT_SIZE="-13.400000000000002" ESTIMABLE="YES" MEAN_1="-38.7" MEAN_2="-25.3" ORDER="351" SD_1="27.2" SD_2="25.8" SE="2.760715705659313" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="12.351635319858701"/>
<CONT_DATA CI_END="13.00529270362274" CI_START="-27.40529270362273" EFFECT_SIZE="-7.199999999999996" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="62.8" ORDER="352" SD_1="33.4" SD_2="40.8" SE="10.309012238489842" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="1.999260030656702"/>
<CONT_DATA CI_END="1.22911303151119" CI_START="-12.629113031511189" EFFECT_SIZE="-5.699999999999999" ESTIMABLE="YES" MEAN_1="-36.5" MEAN_2="-30.8" ORDER="353" SD_1="26.1" SD_2="25.37" SE="3.5353267132289923" STUDY_ID="STD-SKB627" TOTAL_1="109" TOTAL_2="103" WEIGHT="9.834258851431859"/>
<CONT_DATA CI_END="-5.253722783701645" CI_START="-16.346277216298358" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-35.5" MEAN_2="-24.7" ORDER="354" SD_1="24.6" SD_2="24.98" SE="2.8297852715900307" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="12.106275618254418"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.1984815370982345" CI_END="-0.6547407523165956" CI_START="-6.903818799437881" DF="5" EFFECT_SIZE="-3.779279775877238" ESTIMABLE="YES" I2="19.335082792862416" ID="CMP-001.02.04" NO="4" P_CHI2="0.2873822248584207" P_Z="0.017755856060340684" STUDIES="6" TAU2="2.992013158845923" TOTAL_1="441" TOTAL_2="434" WEIGHT="56.607707653144416" Z="2.3706704228577324">
<NAME>Sertraline versus placebo</NAME>
<CONT_DATA CI_END="-0.2675583461650568" CI_START="-16.732441653834943" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="43.4" MEAN_2="51.9" ORDER="355" SD_1="28.1" SD_2="28.7" SE="4.200302515133641" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="8.094253159527836"/>
<CONT_DATA CI_END="9.339431733377683" CI_START="-9.619431733377684" EFFECT_SIZE="-0.14000000000000057" ESTIMABLE="YES" MEAN_1="32.56" MEAN_2="32.7" ORDER="356" SD_1="15.69" SD_2="28.75" SE="4.836533634367892" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="6.757824525584075"/>
<CONT_DATA CI_END="-0.2782851153780168" CI_START="-13.321714884621985" EFFECT_SIZE="-6.800000000000001" ESTIMABLE="YES" MEAN_1="-33.0" MEAN_2="-26.2" ORDER="357" SD_1="23.8" SD_2="23.46" SE="3.3274666963599526" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="10.457677098542549"/>
<CONT_DATA CI_END="8.441343414053849" CI_START="-7.441343414053849" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-27.4" MEAN_2="-27.9" ORDER="358" SD_1="27.12" SD_2="28.42" SE="4.0517802759102475" STUDY_ID="STD-Pfizer588" TOTAL_1="94" TOTAL_2="94" WEIGHT="8.450494857980091"/>
<CONT_DATA CI_END="10.754204583788948" CI_START="-6.154204583788946" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="-13.1" MEAN_2="-15.4" ORDER="359" SD_1="27.12" SD_2="28.42" SE="4.313448946243214" STUDY_ID="STD-Pfizer589" TOTAL_1="84" TOTAL_2="82" WEIGHT="7.834662150124506"/>
<CONT_DATA CI_END="-1.1621075670776149" CI_START="-9.237892432922383" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="-18.7" MEAN_2="-13.5" ORDER="360" SD_1="6.7" SD_2="6.6" SE="2.060187056891231" STUDY_ID="STD-Zohar-2002" TOTAL_1="23" TOTAL_2="19" WEIGHT="15.012795861385356"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.302796945174087" CI_END="1.7343861747160818" CI_START="1.2779960545808255" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.488804449350781" ESTIMABLE="YES" EVENTS_1="383" EVENTS_2="244" I2="26.392998450782954" I2_Q="14.996430486915814" ID="CMP-001.03" LOG_CI_END="0.23914580298764765" LOG_CI_START="0.10652951307400799" LOG_EFFECT_SIZE="0.17283765803082776" METHOD="MH" NO="3" P_CHI2="0.17775783194870332" P_Q="0.3169866612657085" P_Z="3.2419749587109935E-7" Q="3.529263555853645" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017658698179318876" TOTALS="YES" TOTAL_1="644" TOTAL_2="628" WEIGHT="100.00000000000003" Z="5.108808052664898">
<NAME>Clinical Global Impressions scale improvement item (CGI-I)</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9939564960710814" CI_END="1.8157435860476707" CI_START="1.3927436181265183" DF="6" EFFECT_SIZE="1.5902406395329143" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="184" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.25905451872960605" LOG_CI_START="0.14387117709824593" LOG_EFFECT_SIZE="0.201462847913926" NO="1" P_CHI2="0.6774945187524843" P_Z="7.071710673631914E-12" STUDIES="7" TAU2="0.0" TOTAL_1="498" TOTAL_2="501" WEIGHT="69.07916880990652" Z="6.856198483942226">
<NAME>SSRIs</NAME>
<DICH_DATA CI_END="2.3347996176444" CI_START="1.1451586885446934" EFFECT_SIZE="1.6351501668520578" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3682496135164242" LOG_CI_START="0.05886567251347047" LOG_EFFECT_SIZE="0.21355764301494734" ORDER="361" O_E="0.0" SE="0.18173365842034228" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" VAR="0.033027122602841644" WEIGHT="11.972434456075115"/>
<DICH_DATA CI_END="1.9490540424429341" CI_START="0.983130100611921" EFFECT_SIZE="1.3842592592592593" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.2898238811952842" LOG_CI_START="-0.007389006848286702" LOG_EFFECT_SIZE="0.14121743717349877" ORDER="362" O_E="0.0" SE="0.17458432166431703" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="26" VAR="0.030479685370989718" WEIGHT="12.60600424051623"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="363" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="0.5123867859114052"/>
<DICH_DATA CI_END="2.0215879295543435" CI_START="1.2987281738680632" EFFECT_SIZE="1.620337372297458" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.3056926358451822" LOG_CI_START="0.11351826197173107" LOG_EFFECT_SIZE="0.2096054489084566" ORDER="364" O_E="0.0" SE="0.11288417849175787" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" VAR="0.01274283775375905" WEIGHT="19.960592402390162"/>
<DICH_DATA CI_END="5.156229672423908" CI_START="1.1588523051895705" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7123322537637644" LOG_CI_START="0.06402808900199841" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="365" O_E="0.0" SE="0.3808170755384335" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="22" VAR="0.145021645021645" WEIGHT="3.730215066101431"/>
<DICH_DATA CI_END="1.9836458889032347" CI_START="1.2243543979684224" EFFECT_SIZE="1.5584240655516892" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.29746414653726916" LOG_CI_START="0.08790714559085233" LOG_EFFECT_SIZE="0.19268564606406074" ORDER="366" O_E="0.0" SE="0.12309481967980966" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" VAR="0.015152334632004856" WEIGHT="18.494774933063276"/>
<DICH_DATA CI_END="8.007343704622013" CI_START="0.8750617775006169" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.903488470422633" LOG_CI_START="-0.057961285628493536" LOG_EFFECT_SIZE="0.42276359239706973" ORDER="367" O_E="0.0" SE="0.5647603459574805" STUDY_ID="STD-Zohar-2002" TOTAL_1="17" TOTAL_2="15" VAR="0.31895424836601305" WEIGHT="1.8027609258488941"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3697090176014663" CI_END="1.7249764235056047" CI_START="0.7855543952415285" DF="1" EFFECT_SIZE="1.1640716520785308" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="51" I2="57.800726056561835" ID="CMP-001.03.02" LOG_CI_END="0.23678316363457347" LOG_CI_START="-0.10482373712264648" LOG_EFFECT_SIZE="0.06597971325596351" NO="2" P_CHI2="0.1237102786696962" P_Z="0.44898094856803206" STUDIES="2" TAU2="0.04737096679239777" TOTAL_1="87" TOTAL_2="91" WEIGHT="24.26983951727661" Z="0.7571150430820756">
<NAME>MAOIs</NAME>
<DICH_DATA CI_END="1.3211022699534605" CI_START="0.7218305942998562" EFFECT_SIZE="0.976530612244898" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.12093643877823436" LOG_CI_START="-0.14156471460953687" LOG_EFFECT_SIZE="-0.010314137915651268" ORDER="368" O_E="0.0" SE="0.1541944769016426" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" VAR="0.023775936706971187" WEIGHT="14.645541557977532"/>
<DICH_DATA CI_END="2.2223360012474958" CI_START="0.9640513489267248" EFFECT_SIZE="1.4637096774193548" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.3468097217766995" LOG_CI_START="-0.01589983335690695" LOG_EFFECT_SIZE="0.16545494420989623" ORDER="369" O_E="0.0" SE="0.2130573881267348" STUDY_ID="STD-Katz-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.04539345063538612" WEIGHT="9.624297959299074"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.525336515954691E-31" CI_END="9.142381322469094" CI_START="0.9844262323516123" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="100.0" ID="CMP-001.03.03" LOG_CI_END="0.9610593314567514" LOG_CI_START="-0.006816822017426501" LOG_EFFECT_SIZE="0.47712125471966244" NO="3" P_CHI2="0.0" P_Z="0.053315624394273425" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="1.7801368444785397" Z="1.9323556472642212">
<NAME>TCAs</NAME>
<DICH_DATA CI_END="9.142381322469094" CI_START="0.9844262323516123" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9610593314567514" LOG_CI_START="-0.006816822017426501" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="370" O_E="0.0" SE="0.5685352436149611" STUDY_ID="STD-Davidson-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.3232323232323232" WEIGHT="1.7801368444785397"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2885258173026424" CI_END="3.2038161436760437" CI_START="0.7299720735587487" DF="2" EFFECT_SIZE="1.5292796715121126" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="6" I2="12.607496717809006" ID="CMP-001.03.04" LOG_CI_END="0.5056675854153172" LOG_CI_START="-0.13669375430601946" LOG_EFFECT_SIZE="0.18448691555464886" NO="4" P_CHI2="0.3184589408688082" P_Z="0.2602468914142674" STUDIES="3" TAU2="0.06002296169194498" TOTAL_1="37" TOTAL_2="18" WEIGHT="4.870854828338363" Z="1.125807821071096">
<NAME>Other medication</NAME>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="371" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.2" WEIGHT="2.7880009953328195"/>
<DICH_DATA CI_END="10.385741110674171" CI_START="0.8163474914378822" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.0164374925699402" LOG_CI_START="-0.08812493745935067" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="372" O_E="0.0" SE="0.6488254390714155" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" VAR="0.4209744503862151" WEIGHT="1.383462853072818"/>
<DICH_DATA CI_END="12.184256768115382" CI_START="0.328292490557773" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.0857990426425488" LOG_CI_START="-0.4837390513145864" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="373" O_E="0.0" SE="0.9219544457292886" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="10" TOTAL_2="4" VAR="0.8499999999999999" WEIGHT="0.6993909799327258"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.993956496071082" CI_END="1.815743586047671" CI_START="1.3927436181265183" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5902406395329143" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="184" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2590545187296061" LOG_CI_START="0.14387117709824593" LOG_EFFECT_SIZE="0.201462847913926" METHOD="MH" NO="4" P_CHI2="0.6774945187524843" P_Q="0.5614375164167398" P_Z="7.071710673631862E-12" Q="1.1545102346975964" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="498" TOTAL_2="501" WEIGHT="99.99999999999999" Z="6.856198483942227">
<NAME>CGI-I: Individual SSRI agents</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9387876574472235" CI_END="1.8908634105831317" CI_START="0.9621775651882786" DF="1" EFFECT_SIZE="1.348831476685832" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="18" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.2766601580504774" LOG_CI_START="-0.016744773632294048" LOG_EFFECT_SIZE="0.1299576922090917" NO="1" P_CHI2="0.3325899824545817" P_Z="0.08251935082411616" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="15.411486456702168" Z="1.7362516354643664">
<NAME>fluoxetine versus placebo</NAME>
<DICH_DATA CI_END="1.9490540424429341" CI_START="0.983130100611921" EFFECT_SIZE="1.3842592592592593" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.2898238811952842" LOG_CI_START="-0.007389006848286702" LOG_EFFECT_SIZE="0.14121743717349877" ORDER="374" O_E="0.0" SE="0.17458432166431703" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="26" VAR="0.030479685370989718" WEIGHT="15.019105644197486"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="375" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="0.3923808125046816"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2679751837919155" CI_END="1.903483059530172" CI_START="1.3841324672834043" DF="2" EFFECT_SIZE="1.6231674909323623" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="134" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2795490160674833" LOG_CI_START="0.1411776559135174" LOG_EFFECT_SIZE="0.2103633359905004" NO="2" P_CHI2="0.5304722967926252" P_Z="2.5317870403054555E-9" STUDIES="3" TAU2="0.0" TOTAL_1="355" TOTAL_2="364" WEIGHT="69.29261125945548" Z="5.9593916219412435">
<NAME>paroxetine versus placebo</NAME>
<DICH_DATA CI_END="2.0215879295543435" CI_START="1.2987281738680632" EFFECT_SIZE="1.620337372297458" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.3056926358451822" LOG_CI_START="0.11351826197173107" LOG_EFFECT_SIZE="0.2096054489084566" ORDER="376" O_E="0.0" SE="0.11288417849175787" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" VAR="0.01274283775375905" WEIGHT="35.92430692714061"/>
<DICH_DATA CI_END="5.156229672423908" CI_START="1.1588523051895705" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7123322537637644" LOG_CI_START="0.06402808900199841" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="377" O_E="0.0" SE="0.3808170755384335" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="22" VAR="0.145021645021645" WEIGHT="3.156615790149603"/>
<DICH_DATA CI_END="1.9836458889032347" CI_START="1.2243543979684224" EFFECT_SIZE="1.5584240655516892" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.29746414653726916" LOG_CI_START="0.08790714559085233" LOG_EFFECT_SIZE="0.19268564606406074" ORDER="378" O_E="0.0" SE="0.12309481967980966" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" VAR="0.015152334632004856" WEIGHT="30.211688542165273"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6652987067893188" CI_END="2.4012842046075633" CI_START="1.218799184683272" DF="1" EFFECT_SIZE="1.7107551638877252" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="32" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.3804435641337881" LOG_CI_START="0.08593215502907837" LOG_EFFECT_SIZE="0.23318785958143323" NO="3" P_CHI2="0.4146958227547375" P_Z="0.0019110702938062482" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="105" WEIGHT="15.295902283842338" Z="3.1037154574144052">
<NAME>sertraline versus placebo</NAME>
<DICH_DATA CI_END="2.3347996176444" CI_START="1.1451586885446934" EFFECT_SIZE="1.6351501668520578" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3682496135164242" LOG_CI_START="0.05886567251347047" LOG_EFFECT_SIZE="0.21355764301494734" ORDER="379" O_E="0.0" SE="0.18173365842034228" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" VAR="0.033027122602841644" WEIGHT="13.860656893840583"/>
<DICH_DATA CI_END="8.007343704622013" CI_START="0.8750617775006169" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.903488470422633" LOG_CI_START="-0.057961285628493536" LOG_EFFECT_SIZE="0.42276359239706973" ORDER="380" O_E="0.0" SE="0.5647603459574805" STUDY_ID="STD-Zohar-2002" TOTAL_1="17" TOTAL_2="15" VAR="0.31895424836601305" WEIGHT="1.4352453900017554"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-01-24 11:26:20 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Medication versus Placebo: Secondary measures of PTSD</NAME>
<CONT_OUTCOME CHI2="7.349954947039047" CI_END="-0.00928097323023952" CI_START="-0.871402335551946" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4403416543910928" ESTIMABLE="YES" I2="31.972372129787455" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.19588745528206497" P_Q="0.7786952662985509" P_Z="0.0452671944219629" Q="0.5002710158888238" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.09093831683124494" TOTALS="YES" TOTAL_1="85" TOTAL_2="62" UNITS="" WEIGHT="100.00000000000001" Z="2.002163085659096">
<NAME>Symptom severity: Other measures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.384913519583831" CI_END="1.046483178891107" CI_START="-1.6612806751731095" DF="1" EFFECT_SIZE="-0.3073987481410012" ESTIMABLE="YES" I2="77.19453312969992" ID="CMP-002.01.01" NO="1" P_CHI2="0.03625836545055483" P_Z="0.6563128069268538" STUDIES="2" TAU2="0.7493576754159339" TOTAL_1="31" TOTAL_2="28" WEIGHT="37.02360110320495" Z="0.4450096151071325">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="-0.3089255906128978" CI_START="-1.5180437617136289" EFFECT_SIZE="-0.9134846761632633" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="20.5" ORDER="381" SD_1="9.8" SD_2="12.6" SE="0.30845418095385957" STUDY_ID="STD-Conner-1999" TOTAL_1="25" TOTAL_2="22" WEIGHT="25.99414742110563"/>
<CONT_DATA CI_END="1.63546484716168" CI_START="-0.6756951642508435" EFFECT_SIZE="0.4798848414554182" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="42.0" ORDER="382" SD_1="8.0" SD_2="11.0" SE="0.589592469464403" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" WEIGHT="11.02945368209932"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MAOIs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.07352091414619233" CI_START="-1.3295128505303955" DF="0" EFFECT_SIZE="-0.6279959681921016" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="1.0" P_Z="0.07933556991271132" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="22.082205642360616" Z="1.7545543251791988">
<NAME>TCAs</NAME>
<CONT_DATA CI_END="0.07352091414619233" CI_START="-1.3295128505303955" EFFECT_SIZE="-0.6279959681921016" ESTIMABLE="YES" MEAN_1="15.2" MEAN_2="20.3" ORDER="383" SD_1="8.3" SD_2="7.5" SE="0.3579233536288266" STUDY_ID="STD-Davidson-1990" TOTAL_1="17" TOTAL_2="16" WEIGHT="22.082205642360616"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.2883277395112023" CI_END="0.31747276427948795" CI_START="-0.9222768181964693" DF="2" EFFECT_SIZE="-0.30240202695849067" ESTIMABLE="YES" I2="12.599932017290078" ID="CMP-002.01.04" NO="4" P_CHI2="0.31849048192303864" P_Z="0.338993371899734" STUDIES="3" TAU2="0.03888454592556357" TOTAL_1="37" TOTAL_2="18" WEIGHT="40.89419325443444" Z="0.9561561303482781">
<NAME>Other medications</NAME>
<CONT_DATA CI_END="1.246872568968152" CI_START="-0.9048852188033977" EFFECT_SIZE="0.17099367508237717" ESTIMABLE="YES" MEAN_1="19.2" MEAN_2="17.0" ORDER="384" SD_1="8.7" SD_2="17.5" SE="0.5489278896817341" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" WEIGHT="12.331231619101233"/>
<CONT_DATA CI_END="0.05291246903843383" CI_START="-1.6285599254015404" EFFECT_SIZE="-0.7878237281815532" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="19.4" ORDER="385" SD_1="8.8" SD_2="8.2" SE="0.4289549215452972" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" WEIGHT="17.5930727246075"/>
<CONT_DATA CI_END="1.1629438955398088" CI_START="-1.1561186829695158" EFFECT_SIZE="0.003412606285146431" ESTIMABLE="YES" MEAN_1="34.3" MEAN_2="34.25" ORDER="386" SD_1="15.22" SD_2="7.59" SE="0.5916084675029221" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="10" TOTAL_2="4" WEIGHT="10.96988891072571"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.283846944021597" CI_END="-0.10798372891502359" CI_START="-0.5086744670378586" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3083290979764411" ESTIMABLE="YES" I2="34.873822211750166" I2_Q="66.65063159691083" ID="CMP-002.02" MODIFIED="2016-01-24 11:26:20 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13898170726764092" P_Q="0.02934850771396791" P_Z="0.0025582860951716344" Q="8.99567261286456" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.02731997878604703" TOTALS="YES" TOTAL_1="459" TOTAL_2="423" UNITS="" WEIGHT="99.99999999999999" Z="3.0163608485219786">
<NAME>Self-rated scales: Total score</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8394935068596792" CI_END="-0.057061357696209375" CI_START="-0.3414961533179106" DF="4" EFFECT_SIZE="-0.19927875550705998" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" MODIFIED="2016-01-24 11:26:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7652494594454393" P_Z="0.006026187647891078" STUDIES="5" TAU2="0.0" TOTAL_1="396" TOTAL_2="375" WEIGHT="78.55616214891047" Z="2.746353046040623">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="0.09194481844114744" CI_START="-0.4891298279928621" EFFECT_SIZE="-0.19859250477585733" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="24.5" ORDER="387" SD_1="17.6" SD_2="17.5" SE="0.1482360520441835" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="21.196746340673567"/>
<CONT_DATA CI_END="-0.001539601485437303" CI_START="-0.5843237286009366" EFFECT_SIZE="-0.29293166504318696" ESTIMABLE="YES" MEAN_1="43.2" MEAN_2="52.2" ORDER="388" SD_1="29.9" SD_2="31.3" SE="0.1486721520682079" STUDY_ID="STD-Conner-1999" TOTAL_1="93" TOTAL_2="90" WEIGHT="21.141214124983286"/>
<CONT_DATA CI_END="0.013889191122096467" CI_START="-0.4014421358218592" EFFECT_SIZE="-0.19377647234988138" ESTIMABLE="YES" MEAN_1="46.8" MEAN_2="53.4" ORDER="389" SD_1="34.72" SD_2="33.24" SE="0.10595381604458964" STUDY_ID="STD-Davidson-2004" TOTAL_1="179" TOTAL_2="179" WEIGHT="27.106970154698363"/>
<CONT_DATA CI_END="1.1693408300009513" CI_START="-1.0941284444261778" EFFECT_SIZE="0.037606192787386646" ESTIMABLE="YES" MEAN_1="103.0" MEAN_2="102.0" ORDER="390" SD_1="23.0" SD_2="26.0" SE="0.5774262415741018" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.8964556135720163"/>
<CONT_DATA CI_END="0.9593366000235214" CI_START="-0.5115864100934434" EFFECT_SIZE="0.223875094965039" ESTIMABLE="YES" MEAN_1="24.7" MEAN_2="20.57" MODIFIED="2016-01-24 11:26:20 +0000" MODIFIED_BY="[Empty name]" ORDER="391" SD_1="17.09" SD_2="20.31" SE="0.37524235693089714" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="6.2147759149832495"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3645289665281869" CI_START="-1.751039764056276" DF="0" EFFECT_SIZE="-1.0577843652922314" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="0.0027846984443806273" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="6.854778543365964" Z="2.9905562410022752">
<NAME>MAOIs</NAME>
<CONT_DATA CI_END="-0.3645289665281869" CI_START="-1.751039764056276" EFFECT_SIZE="-1.0577843652922314" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="31.3" ORDER="392" SD_1="11.3" SD_2="15.0" SE="0.3537082335350826" STUDY_ID="STD-Kosten-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="6.854778543365964"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.17734781885746864" CI_START="-1.618681350902147" DF="0" EFFECT_SIZE="-0.8980145848798078" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.03" NO="3" P_CHI2="1.0" P_Z="0.014594473405788108" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="6.4292292029153035" Z="2.442288623451733">
<NAME>TCAs</NAME>
<CONT_DATA CI_END="-0.17734781885746864" CI_START="-1.618681350902147" EFFECT_SIZE="-0.8980145848798078" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="33.7" ORDER="393" SD_1="11.5" SD_2="6.6" SE="0.3676938819829684" STUDY_ID="STD-Davidson-1990" TOTAL_1="17" TOTAL_2="16" WEIGHT="6.4292292029153035"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3105712130175022" CI_END="0.33157820621969036" CI_START="-1.2009887315685304" DF="1" EFFECT_SIZE="-0.43470526267442" ESTIMABLE="YES" I2="23.697393162057395" ID="CMP-002.02.04" NO="4" P_CHI2="0.25229138879458335" P_Z="0.2661945955356795" STUDIES="2" TAU2="0.07501094517013224" TOTAL_1="27" TOTAL_2="14" WEIGHT="8.159830104808252" Z="1.1118687709151436">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="1.1103177467600542" CI_START="-1.0369330126110696" EFFECT_SIZE="0.0366923670744924" ESTIMABLE="YES" MEAN_1="57.4" MEAN_2="56.0" ORDER="394" SD_1="35.6" SD_2="36.6" SE="0.5477781164114146" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" WEIGHT="3.1916052516834506"/>
<CONT_DATA CI_END="0.07945500087670576" CI_START="-1.5973884504409046" EFFECT_SIZE="-0.7589667247820994" ESTIMABLE="YES" MEAN_1="54.1" MEAN_2="82.6" ORDER="395" SD_1="40.0" SD_2="27.7" SE="0.42777404700911276" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" WEIGHT="4.968224853124801"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.647184324634933" CI_END="-1.103626181436252" CI_START="-3.0219007174404187" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0627634494383353" ESTIMABLE="YES" I2="7.484335944952304" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.3729273968448821" P_Q="0.8504559711576726" P_Z="2.4957231414878303E-5" Q="0.03554610706572617" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1657043888808002" TOTALS="YES" TOTAL_1="662" TOTAL_2="642" UNITS="" WEIGHT="100.00000000000001" Z="4.215186089000938">
<NAME>CAPS subscale: Re-experiencing/intrusion</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.285148505350465" CI_END="-0.8263189989554145" CI_START="-3.105731094718536" DF="6" EFFECT_SIZE="-1.9660250468369753" ESTIMABLE="YES" I2="27.58126186724039" ID="CMP-002.03.01" NO="1" P_CHI2="0.2179481596600099" P_Z="7.222435637636537E-4" STUDIES="7" TAU2="0.6268070158579626" TOTAL_1="624" TOTAL_2="618" WEIGHT="94.73886944804426" Z="3.380993100516202">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="0.6651403442227903" CI_START="-3.6651403442227903" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="10.0" ORDER="396" SD_1="7.0" SD_2="7.9" SE="1.104683739752945" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="17.277963263803123"/>
<CONT_DATA CI_END="2.150640908396115" CI_START="-3.9906409083961147" EFFECT_SIZE="-0.9199999999999999" ESTIMABLE="YES" MEAN_1="6.38" MEAN_2="7.3" ORDER="397" SD_1="5.45" SD_2="9.12" SE="1.5666823128470413" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="9.139685735839254"/>
<CONT_DATA CI_END="0.940501400272765" CI_START="-2.940501400272765" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-7.5" MEAN_2="-6.5" ORDER="398" SD_1="6.93" SD_2="7.14" SE="0.990069927600299" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="20.897887692682055"/>
<CONT_DATA CI_END="-2.207322443793217" CI_START="-5.892677556206783" EFFECT_SIZE="-4.05" ESTIMABLE="YES" MEAN_1="-11.35" MEAN_2="-7.3" ORDER="399" SD_1="9.25" SD_2="8.8" SE="0.940158885949736" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="22.816038310639165"/>
<CONT_DATA CI_END="4.250237089431741" CI_START="-4.450237089431741" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="10.9" ORDER="400" SD_1="7.9" SD_2="8.1" SE="2.2195495038408133" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="4.702924991598059"/>
<CONT_DATA CI_END="-0.5157674742462235" CI_START="-4.684232525753776" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="-10.5" MEAN_2="-7.9" ORDER="401" SD_1="8.6" SD_2="10.0" SE="1.063403481999637" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="18.470656269779095"/>
<CONT_DATA CI_END="9.63048362842811" CI_START="-6.310483628428108" EFFECT_SIZE="1.6600000000000001" ESTIMABLE="YES" MEAN_1="12.76" MEAN_2="11.1" ORDER="402" SD_1="10.02" SD_2="11.19" SE="4.066648005421664" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="1.4337131837034978"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MAOIs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>TCAs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.34323089993381783" CI_END="1.763324148663031" CI_START="-6.521982485477567" DF="1" EFFECT_SIZE="-2.379329168407268" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.04" NO="4" P_CHI2="0.5579703810392586" P_Z="0.2602910460091641" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="24" WEIGHT="5.26113055195576" Z="1.1257035335850545">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="4.195432309409611" CI_START="-6.7954323094096125" EFFECT_SIZE="-1.3000000000000003" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-3.1" ORDER="403" SD_1="8.0" SD_2="9.0" SE="2.8038435158793122" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="2.9833138770733574"/>
<CONT_DATA CI_END="2.504804693170686" CI_START="-10.104804693170685" EFFECT_SIZE="-3.8" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-3.3" ORDER="404" SD_1="9.6" SD_2="4.9" SE="3.2167961977373976" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="2.2778166748824025"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.353825579136675" CI_END="-2.7024735403150197" CI_START="-5.413104521677266" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.057789030996143" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="0.6076629305326195" P_Q="0.4025678251003011" P_Z="4.408300662439188E-9" Q="0.7006439771708228" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="662" TOTAL_2="642" UNITS="" WEIGHT="99.99999999999997" Z="5.86809522380448">
<NAME>CAPS subscale: Avoidance/numbing</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.652929863328651" CI_END="-2.800737454331596" CI_START="-5.583304022776883" DF="6" EFFECT_SIZE="-4.192020738554239" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="0.46316912662987897" P_Z="3.5159988833535017E-9" STUDIES="7" TAU2="0.0" TOTAL_1="624" TOTAL_2="618" WEIGHT="94.89638524737911" Z="5.905490106281253">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="-0.37516453757428314" CI_START="-7.824835462425719" EFFECT_SIZE="-4.100000000000001" ESTIMABLE="YES" MEAN_1="18.5" MEAN_2="22.6" ORDER="405" SD_1="13.4" SD_2="12.3" SE="1.9004611777597675" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="13.23934860075573"/>
<CONT_DATA CI_END="4.104366934861742" CI_START="-5.144366934861742" EFFECT_SIZE="-0.5199999999999996" ESTIMABLE="YES" MEAN_1="13.43" MEAN_2="13.95" ORDER="406" SD_1="9.8" SD_2="12.74" SE="2.359414239923875" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="8.589665065767196"/>
<CONT_DATA CI_END="-0.770625242647569" CI_START="-7.429374757352431" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="-14.7" MEAN_2="-10.6" ORDER="407" SD_1="11.9" SD_2="12.24" SE="1.6986918043464643" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="16.571256489343245"/>
<CONT_DATA CI_END="-3.1373447921788578" CI_START="-8.262655207821144" EFFECT_SIZE="-5.700000000000001" ESTIMABLE="YES" MEAN_1="-16.8" MEAN_2="-11.1" ORDER="408" SD_1="12.9" SD_2="12.2" SE="1.307501172488393" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="27.970514067140666"/>
<CONT_DATA CI_END="6.084448443006062" CI_START="-10.284448443006065" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="20.7" MEAN_2="22.8" ORDER="409" SD_1="14.9" SD_2="15.2" SE="4.175815733127725" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="2.7422179530663056"/>
<CONT_DATA CI_END="-1.8268613918508216" CI_START="-7.373138608149178" EFFECT_SIZE="-4.6" ESTIMABLE="YES" MEAN_1="-15.0" MEAN_2="-10.4" ORDER="410" SD_1="12.3" SD_2="12.49" SE="1.4148926357950153" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="23.88568221128989"/>
<CONT_DATA CI_END="11.918446423335357" CI_START="-7.758446423335361" EFFECT_SIZE="2.0799999999999983" ESTIMABLE="YES" MEAN_1="26.08" MEAN_2="24.0" ORDER="411" SD_1="11.62" SD_2="14.07" SE="5.019707760417931" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="1.8977008600160938"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MAOIs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>TCAs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.517386372010563E-4" CI_END="4.437421517806861" CI_START="-7.561202804266605" DF="1" EFFECT_SIZE="-1.5618906432298716" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.04" NO="4" P_CHI2="0.9873410764549887" P_Z="0.6098646086281538" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="24" WEIGHT="5.103614752620862" Z="0.5102667316433884">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="6.0258623518040135" CI_START="-9.225862351804015" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-6.1" ORDER="412" SD_1="12.0" SD_2="12.0" SE="3.8908175925454973" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="3.158659998371655"/>
<CONT_DATA CI_END="8.2181959323045" CI_START="-11.2181959323045" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-10.4" MEAN_2="-8.9" ORDER="413" SD_1="14.9" SD_2="7.4" SE="4.958354341692189" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="1.9449547542492072"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.60301180887708" CI_END="-2.0997125879085257" CI_START="-4.1016635304207805" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.100688059164653" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.8910495933792519" P_Q="0.771424163782138" P_Z="1.2686742678842802E-9" Q="0.08439754118658153" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="662" TOTAL_2="642" UNITS="" WEIGHT="100.0" Z="6.0713145304447655">
<NAME>CAPS subscale: Hyperarousal</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1989927578713386" CI_END="-2.042093530220603" CI_START="-4.093154059236632" DF="6" EFFECT_SIZE="-3.0676237947286173" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="0.7834887658372973" P_Z="4.552511183192578E-9" STUDIES="7" TAU2="0.0" TOTAL_1="624" TOTAL_2="618" WEIGHT="95.26862733684139" Z="5.862754483087412">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="0.19134829542850262" CI_START="-5.991348295428507" EFFECT_SIZE="-2.900000000000002" ESTIMABLE="YES" MEAN_1="16.4" MEAN_2="19.3" ORDER="414" SD_1="10.2" SD_2="11.1" SE="1.5772475003687136" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="10.48457891633063"/>
<CONT_DATA CI_END="0.8026682159761336" CI_START="-6.202668215976132" EFFECT_SIZE="-2.6999999999999993" ESTIMABLE="YES" MEAN_1="12.75" MEAN_2="15.45" ORDER="415" SD_1="6.59" SD_2="10.19" SE="1.787108458933293" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="8.16674259853116"/>
<CONT_DATA CI_END="0.5949303717792693" CI_START="-4.39493037177927" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="-10.8" MEAN_2="-8.9" ORDER="416" SD_1="8.91" SD_2="9.18" SE="1.2729470497718132" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="16.096446513000373"/>
<CONT_DATA CI_END="-1.66124821775672" CI_START="-5.438751782243282" EFFECT_SIZE="-3.5500000000000007" ESTIMABLE="YES" MEAN_1="-10.55" MEAN_2="-7.0" ORDER="417" SD_1="9.5" SD_2="9.0" SE="0.9636665760909453" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="28.086465939368072"/>
<CONT_DATA CI_END="1.4759352992628614" CI_START="-9.35593529926286" EFFECT_SIZE="-3.9399999999999995" ESTIMABLE="YES" MEAN_1="13.06" MEAN_2="17.0" ORDER="418" SD_1="8.4" SD_2="11.4" SE="2.763283071517164" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="3.4158590007276275"/>
<CONT_DATA CI_END="-1.7602639085759488" CI_START="-5.6397360914240515" EFFECT_SIZE="-3.7" ESTIMABLE="YES" MEAN_1="-10.0" MEAN_2="-6.3" ORDER="419" SD_1="8.6" SD_2="8.74" SE="0.9896794567269818" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="26.629412037457705"/>
<CONT_DATA CI_END="7.515961250286423" CI_START="-5.435961250286417" EFFECT_SIZE="1.0400000000000027" ESTIMABLE="YES" MEAN_1="21.44" MEAN_2="20.4" ORDER="420" SD_1="9.22" SD_2="8.67" SE="3.304122576418738" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="2.389122331425826"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MAOIs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>TCAs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.31962150981915993" CI_END="0.8353683695802538" CI_START="-8.368276502392886" DF="1" EFFECT_SIZE="-3.766454066406316" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.04" NO="4" P_CHI2="0.571835318965572" P_Z="0.10867616304141409" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="24" WEIGHT="4.7313726631586155" Z="1.6041719171631155">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="2.5954323094096123" CI_START="-8.39543230940961" EFFECT_SIZE="-2.8999999999999995" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-4.2" ORDER="421" SD_1="8.0" SD_2="9.0" SE="2.8038435158793122" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="3.3177460825801792"/>
<CONT_DATA CI_END="2.618914208939924" CI_START="-14.218914208939925" EFFECT_SIZE="-5.8" ESTIMABLE="YES" MEAN_1="-12.1" MEAN_2="-6.3" ORDER="422" SD_1="12.1" SD_2="7.5" SE="4.295443322095327" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="1.4136265805784365"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.992927385806075" CI_END="0.12511025966588002" CI_START="-0.9799906677295751" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4274402040318475" ESTIMABLE="YES" I2="66.64045119795998" I2_Q="66.64045119795996" ID="CMP-002.06" NO="6" P_CHI2="0.029385099432433726" P_Q="0.029385099432433615" P_Z="0.12947318346311415" Q="8.992927385806073" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.199309294417797" TOTALS="YES" TOTAL_1="139" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="1.5161826122458453">
<NAME>Self-rated subscale: Re-experiencing/Intrusion</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_SUBGROUP CHI2="3.5088090053604274E-32" CI_END="0.10932601315230761" CI_START="-0.4715032125012648" DF="0" EFFECT_SIZE="-0.1810885996744786" ESTIMABLE="YES" I2="100.0" ID="CMP-002.06.01" NO="1" P_CHI2="0.0" P_Z="0.22165494812740894" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="90" WEIGHT="35.91994402368141" Z="1.2221393748683758">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="0.10932601315230761" CI_START="-0.4715032125012648" EFFECT_SIZE="-0.1810885996744786" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="11.7" ORDER="423" SD_1="9.2" SD_2="9.5" SE="0.14817344355178952" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="35.91994402368141"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3773334931363794" CI_START="-1.7663509811594884" DF="0" EFFECT_SIZE="-1.071842237147934" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" NO="2" P_CHI2="1.0" P_Z="0.0024877137770434113" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="24.464479302218884" Z="3.024831868616243">
<NAME>MAOIs</NAME>
<CONT_DATA CI_END="-0.3773334931363794" CI_START="-1.7663509811594884" EFFECT_SIZE="-1.071842237147934" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="15.4" ORDER="424" SD_1="7.2" SD_2="9.0" SE="0.35434770714653474" STUDY_ID="STD-Kosten-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="24.464479302218884"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.03786852299793586" CI_START="-1.4562431235599709" DF="0" EFFECT_SIZE="-0.7470558232789534" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.03" NO="3" P_CHI2="1.0" P_Z="0.038958939447445246" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="24.067129686282943" Z="2.0646203160821885">
<NAME>TCAs</NAME>
<CONT_DATA CI_END="-0.03786852299793586" CI_START="-1.4562431235599709" EFFECT_SIZE="-0.7470558232789534" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="15.6" ORDER="425" SD_1="6.0" SD_2="3.9" SE="0.3618369040834405" STUDY_ID="STD-Davidson-1990" TOTAL_1="17" TOTAL_2="16" WEIGHT="24.067129686282943"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6066135062876497" CI_START="-0.5824310172731055" DF="0" EFFECT_SIZE="0.5120912445072721" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.04" NO="4" P_CHI2="1.0" P_Z="0.3591409836528531" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="5" WEIGHT="15.548446987816755" Z="0.9170031812783197">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="1.6066135062876497" CI_START="-0.5824310172731055" EFFECT_SIZE="0.5120912445072721" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="9.6" ORDER="426" SD_1="12.4" SD_2="11.5" SE="0.5584399868639575" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" WEIGHT="15.548446987816755"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.279159333149438" CI_END="-0.07952231377285984" CI_START="-0.8981145752708688" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4888184445218643" ESTIMABLE="YES" I2="43.172770309051046" I2_Q="43.17277030905103" ID="CMP-002.07" NO="7" P_CHI2="0.15246049702168085" P_Q="0.15246049702168085" P_Z="0.019244214320683833" Q="5.279159333149436" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.07471741744826353" TOTALS="YES" TOTAL_1="139" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="2.3407661941208686">
<NAME>Self-rated subscale: Avoidance/numbing</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10467833371043714" CI_START="-0.4762142949939797" DF="0" EFFECT_SIZE="-0.18576798064177127" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="1.0" P_Z="0.20999365110091672" STUDIES="1" TAU2="0.0" TOTAL_1="93" TOTAL_2="90" WEIGHT="45.1079742422629" Z="1.2535829636904368">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="0.10467833371043714" CI_START="-0.4762142949939797" EFFECT_SIZE="-0.18576798064177127" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="12.8" ORDER="427" SD_1="9.6" SD_2="9.7" SE="0.14818961809666498" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="45.1079742422629"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.14040907415403725" CI_START="-1.488177385693965" DF="0" EFFECT_SIZE="-0.8142932299240011" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" NO="2" P_CHI2="1.0" P_Z="0.017868207237500645" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="22.603351296313743" Z="2.368337925503384">
<NAME>MAOIs</NAME>
<CONT_DATA CI_END="-0.14040907415403725" CI_START="-1.488177385693965" EFFECT_SIZE="-0.8142932299240011" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="15.7" ORDER="428" SD_1="6.2" SD_2="7.7" SE="0.34382476468214523" STUDY_ID="STD-Kosten-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="22.603351296313743"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.17725694502135902" CI_START="-1.6185741656052626" DF="0" EFFECT_SIZE="-0.8979155553133108" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.03" NO="3" P_CHI2="1.0" P_Z="0.014604247851955748" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="20.774924492086868" Z="2.4420469337893738">
<NAME>TCAs</NAME>
<CONT_DATA CI_END="-0.17725694502135902" CI_START="-1.6185741656052626" EFFECT_SIZE="-0.8979155553133108" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="18.0" ORDER="429" SD_1="6.2" SD_2="3.9" SE="0.3676897208195737" STUDY_ID="STD-Davidson-1990" TOTAL_1="17" TOTAL_2="16" WEIGHT="20.774924492086868"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7817457136685984" CI_START="-1.3796991831188548" DF="0" EFFECT_SIZE="-0.2989767347251282" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.04" NO="4" P_CHI2="1.0" P_Z="0.587670590361197" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="5" WEIGHT="11.513749969336489" Z="0.5422147315877284">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="0.7817457136685984" CI_START="-1.3796991831188548" EFFECT_SIZE="-0.2989767347251282" ESTIMABLE="YES" MEAN_1="23.0" MEAN_2="27.8" ORDER="430" SD_1="14.6" SD_2="16.2" SE="0.5513991363710391" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" WEIGHT="11.513749969336489"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.014368492120244" CI_START="-1.1332358401847225" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.05943367403223922" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9136136137739211" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="0.108481677765158">
<NAME>Self-rated subscale: Hyperarousal</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.014368492120244" CI_START="-1.1332358401847225" DF="0" EFFECT_SIZE="-0.05943367403223922" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.04" NO="4" P_CHI2="1.0" P_Z="0.9136136137739211" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="5" WEIGHT="100.0" Z="0.108481677765158">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="1.014368492120244" CI_START="-1.1332358401847225" EFFECT_SIZE="-0.05943367403223922" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="18.6" ORDER="431" SD_1="10.5" SD_2="12.3" SE="0.54786831524584" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Medication versus Placebo: Comorbid symptoms</NAME>
<CONT_OUTCOME CHI2="8.178971823400873" CI_END="-0.09893440587007457" CI_START="-0.5733282579412036" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33613133190563904" ESTIMABLE="YES" I2="26.641145983247092" I2_Q="63.04721861134844" ID="CMP-003.01" NO="1" P_CHI2="0.22528254329158337" P_Q="0.043625754081626944" P_Z="0.0054785348045877655" Q="8.118468724850356" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.02638275093453899" TOTALS="YES" TOTAL_1="245" TOTAL_2="214" UNITS="" WEIGHT="100.0" Z="2.7774613930357295">
<NAME>Depression Scale (typically Hamilton Depression)</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.06050309855051819" CI_END="0.022633701947433416" CI_START="-0.3930672634595336" DF="3" EFFECT_SIZE="-0.18521678075605008" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.996112989453777" P_Z="0.08071796662792177" STUDIES="4" TAU2="0.0" TOTAL_1="192" TOTAL_2="172" WEIGHT="74.34862178703185" Z="1.7465353695241888">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="0.0894704923646428" CI_START="-0.4916409360288627" EFFECT_SIZE="-0.20108522183210994" ESTIMABLE="YES" MEAN_1="13.7" MEAN_2="15.8" ORDER="432" SD_1="10.4" SD_2="10.4" SE="0.14824543536953697" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="30.285900262558698"/>
<CONT_DATA CI_END="0.2616973941326447" CI_START="-0.548739959598968" EFFECT_SIZE="-0.14352128273316164" ESTIMABLE="YES" MEAN_1="8.93" MEAN_2="10.09" ORDER="433" SD_1="7.42" SD_2="8.62" SE="0.20674802193413735" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="21.187080087727207"/>
<CONT_DATA CI_END="0.3358104177328066" CI_START="-0.7554159816520877" EFFECT_SIZE="-0.2098027819596405" ESTIMABLE="YES" MEAN_1="13.01" MEAN_2="14.88" ORDER="434" SD_1="9.45" SD_2="8.11" SE="0.27837919675880496" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="14.09936287659077"/>
<CONT_DATA CI_END="0.5584158554763363" CI_START="-0.9109038299061889" EFFECT_SIZE="-0.1762439872149263" ESTIMABLE="YES" MEAN_1="13.65" MEAN_2="16.0" ORDER="435" SD_1="11.06" SD_2="17.21" SE="0.37483333800323154" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="8.776278560155157"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24728682740065716" CI_START="-1.0567266981106778" DF="0" EFFECT_SIZE="-0.40471993535501033" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="0.22375350563479335" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="10.68690258974763" Z="1.2166077753068585">
<NAME>MAOIs</NAME>
<CONT_DATA CI_END="0.24728682740065716" CI_START="-1.0567266981106778" EFFECT_SIZE="-0.40471993535501033" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="12.6" ORDER="436" SD_1="7.1" SD_2="6.4" SE="0.33266262436382177" STUDY_ID="STD-Kosten-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="10.68690258974763"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.4138775542544122" CI_START="-1.9035785176971014" DF="0" EFFECT_SIZE="-1.1587280359757568" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="1.0" P_Z="0.002295879626299705" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="8.57461549706867" Z="3.0490216145673945">
<NAME>TCAs</NAME>
<CONT_DATA CI_END="-0.4138775542544122" CI_START="-1.9035785176971014" EFFECT_SIZE="-1.1587280359757568" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="20.0" ORDER="437" SD_1="8.4" SD_2="10.1" SE="0.38003273917104097" STUDY_ID="STD-Davidson-1990" TOTAL_1="17" TOTAL_2="16" WEIGHT="8.57461549706867"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.011941475679266067" CI_START="-1.7773269628499233" DF="0" EFFECT_SIZE="-0.8946342192645947" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.04" NO="4" P_CHI2="1.0" P_Z="0.046980130870090765" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="8" WEIGHT="6.389860126151859" Z="1.986479283803257">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="-0.011941475679266067" CI_START="-1.7773269628499233" EFFECT_SIZE="-0.8946342192645947" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="13.0" ORDER="438" SD_1="6.0" SD_2="3.7" SE="0.45036171610697767" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="8" WEIGHT="6.389860126151859"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.9775234284188326" CI_END="-0.06565034967778194" CI_START="-0.6036773242179768" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3346638369478794" ESTIMABLE="YES" I2="74.92956281550644" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.01852268566352977" P_Q="1.0" P_Z="0.014757511137845007" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.04220798764116899" TOTALS="YES" TOTAL_1="442" TOTAL_2="445" UNITS="" WEIGHT="100.0" Z="2.4382757682601124">
<NAME>Depression Scale - Change scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.9775234284188326" CI_END="-0.06565034967778194" CI_START="-0.6036773242179768" DF="2" EFFECT_SIZE="-0.3346638369478794" ESTIMABLE="YES" I2="74.92956281550644" ID="CMP-003.02.01" NO="1" P_CHI2="0.01852268566352977" P_Z="0.014757511137845007" STUDIES="3" TAU2="0.04220798764116899" TOTAL_1="442" TOTAL_2="445" WEIGHT="100.0" Z="2.4382757682601124">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="-0.3496815476820774" CI_START="-0.7657640798008827" EFFECT_SIZE="-0.55772281374148" ESTIMABLE="YES" MEAN_1="-11.75" MEAN_2="-5.7" ORDER="439" SD_1="11.05" SD_2="10.6" SE="0.1061454535391495" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="35.229168487433526"/>
<CONT_DATA CI_END="0.202122759908272" CI_START="-0.3379051498966422" EFFECT_SIZE="-0.06789119499418513" ESTIMABLE="YES" MEAN_1="-11.4" MEAN_2="-10.7" ORDER="440" SD_1="10.39" SD_2="10.15" SE="0.13776475334868024" STUDY_ID="STD-SKB627" TOTAL_1="108" TOTAL_2="103" WEIGHT="30.788742456669663"/>
<CONT_DATA CI_END="-0.1196902706027026" CI_START="-0.5705550043808965" EFFECT_SIZE="-0.34512263749179956" ESTIMABLE="YES" MEAN_1="-9.6" MEAN_2="-5.1" ORDER="441" SD_1="13.52" SD_2="12.49" SE="0.11501862721319304" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="33.98208905589681"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MAOIs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>TCAs</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other medication</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.017314378871664" CI_END="2.8772965532228123" CI_START="-7.220727671796373" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1717155592867807" ESTIMABLE="YES" I2="80.03456890383352" I2_Q="87.21041507756182" ID="CMP-003.03" NO="3" P_CHI2="0.006679885841222366" P_Q="0.005170390159108584" P_Z="0.3992099462355272" Q="7.818862035511334" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="15.691226194006516" TOTALS="YES" TOTAL_1="140" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.8430330896456657">
<NAME>Anxiety - Hamilton Anxiety Scale</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2777316296577688" CI_END="3.1399214581766843" CI_START="-1.9705341632056455" DF="1" EFFECT_SIZE="0.5846936474855193" ESTIMABLE="YES" I2="21.736303869393698" ID="CMP-003.03.01" NO="1" P_CHI2="0.25832133194510076" P_Z="0.6538040164715251" STUDIES="2" TAU2="0.914011577708005" TOTAL_1="123" TOTAL_2="131" WEIGHT="70.58337332277782" Z="0.44848388322409505">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="3.760415836872323" CI_START="-0.9604158368723241" EFFECT_SIZE="1.3999999999999995" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="6.4" ORDER="442" SD_1="7.92" SD_2="9.18" SE="1.204315923910328" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="38.713747173233564"/>
<CONT_DATA CI_END="2.939913296932045" CI_START="-5.939913296932045" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="12.3" MEAN_2="13.8" ORDER="443" SD_1="7.3" SD_2="9.0" SE="2.265303511673436" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="31.86962614954425"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1486072203165542E-31" CI_END="-2.463556245565905" CI_START="-12.736443754434099" DF="0" EFFECT_SIZE="-7.600000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-003.03.03" NO="3" P_CHI2="0.0" P_Z="0.0037315352942280866" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="29.416626677222187" Z="2.9000076696343653">
<NAME>TCAs</NAME>
<CONT_DATA CI_END="-2.463556245565904" CI_START="-12.736443754434099" EFFECT_SIZE="-7.600000000000001" ESTIMABLE="YES" MEAN_1="10.2" MEAN_2="17.8" ORDER="444" SD_1="6.6" SD_2="8.3" SE="2.620682724248869" STUDY_ID="STD-Davidson-1990" TOTAL_1="17" TOTAL_2="16" WEIGHT="29.416626677222187"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other medication</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.14276549091631" CI_END="-0.21756713591273102" CI_START="-1.2790697334265073" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7483184346696191" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.7055471975525349" P_Q="0.7055471975525349" P_Z="0.005720293387327251" Q="0.14276549091631" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="2.7633981948891244">
<NAME>Anxiety - Other scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.006531375520170135" CI_START="-1.3358460391204745" DF="0" EFFECT_SIZE="-0.6711887073203223" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="1.0" P_Z="0.04779080034890581" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="63.76561189633105" Z="1.9792239252291448">
<NAME>MAOIs</NAME>
<CONT_DATA CI_END="-0.006531375520170135" CI_START="-1.3358460391204745" EFFECT_SIZE="-0.6711887073203223" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.0" ORDER="445" SD_1="1.7" SD_2="3.8" SE="0.33911711492807234" STUDY_ID="STD-Kosten-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="63.76561189633105"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.002332230793949397" CI_START="-1.7657718561372477" DF="0" EFFECT_SIZE="-0.8840520434655986" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.04" NO="4" P_CHI2="1.0" P_Z="0.04939707903719479" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="8" WEIGHT="36.23438810366895" Z="1.9651482713101627">
<NAME>Other medication</NAME>
<CONT_DATA CI_END="-0.002332230793949397" CI_START="-1.7657718561372477" EFFECT_SIZE="-0.8840520434655986" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="13.8" ORDER="446" SD_1="5.8" SD_2="3.7" SE="0.4498653136621604" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="8" WEIGHT="36.23438810366895"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Medication versus Placebo: Quality of Life Scales</NAME>
<CONT_OUTCOME CHI2="2.8024014691340757" CI_END="-1.406150273993495" CI_START="-3.679049910101159" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.542600092047327" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.5914182810893182" P_Q="0.8195411555672069" P_Z="1.1595195314127998E-5" Q="0.052045658739133346" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="375" TOTAL_2="377" UNITS="" WEIGHT="100.0" Z="4.385063491879526">
<NAME>Sheehan Disability Scale</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.7503558103949417" CI_END="-1.4138229556527129" CI_START="-3.7049433444595072" DF="3" EFFECT_SIZE="-2.55938315005611" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="0.4317376481478281" P_Z="1.1927733240883212E-5" STUDIES="4" TAU2="0.0" TOTAL_1="365" TOTAL_2="372" WEIGHT="98.41577072394495" Z="4.378904592928105">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="-1.5136500157198007" CI_START="-10.8863499842802" EFFECT_SIZE="-6.2" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="14.0" ORDER="447" SD_1="7.4" SD_2="9.2" SE="2.391038825838398" STUDY_ID="STD-Conner-1999" TOTAL_1="25" TOTAL_2="24" WEIGHT="5.880727942611671"/>
<CONT_DATA CI_END="5.24938647738509" CI_START="-7.24938647738509" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="25.0" ORDER="448" SD_1="6.0" SD_2="5.0" SE="3.188521078284832" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" WEIGHT="3.3069357734203693"/>
<CONT_DATA CI_END="-0.5878466560906037" CI_START="-3.8121533439093964" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-4.5" ORDER="449" SD_1="7.9" SD_2="7.9" SE="0.8225423306886536" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="49.692154868840476"/>
<CONT_DATA CI_END="-0.7926004813286294" CI_START="-4.4073995186713715" EFFECT_SIZE="-2.6000000000000005" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-4.6" ORDER="450" SD_1="8.6" SD_2="7.5" SE="0.9221595564652758" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="39.53595213907243"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.529033120593295" CI_START="-10.529033120593295" DF="0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.04" NO="4" P_CHI2="1.0" P_Z="0.7447192360964346" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="5" WEIGHT="1.5842292760550576" Z="0.32561027715190155">
<NAME>Other medications</NAME>
<CONT_DATA CI_END="7.529033120593295" CI_START="-10.529033120593295" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="13.6" ORDER="451" SD_1="7.8" SD_2="8.7" SE="4.606734201145101" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" WEIGHT="1.5842292760550576"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Medication versus Placebo: Drop-out Rate</NAME>
<DICH_OUTCOME CHI2="12.329588613443894" CI_END="2.001924080931722" CI_START="1.0411642501762342" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4437215052194183" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.3014476036839585" LOG_CI_START="0.017519247587659086" LOG_EFFECT_SIZE="0.15948342563580878" METHOD="MH" NO="1" P_CHI2="0.7797816721683047" P_Q="0.5873516507020875" P_Z="0.027676928747906112" Q="1.9286287964771165" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1143" TOTAL_2="973" WEIGHT="100.00000000000001" Z="2.2018355241083394">
<NAME>Drop-out rate due to treatment emergent adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4371004454516303" CI_END="2.05286271922745" CI_START="0.9852825101000637" DF="7" EFFECT_SIZE="1.4221989076395976" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="43" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.3123599078336048" LOG_CI_START="-0.006439226369358868" LOG_EFFECT_SIZE="0.152960340732123" NO="1" P_CHI2="0.841842247391238" P_Z="0.060000792307540456" STUDIES="10" TAU2="0.0" TOTAL_1="901" TOTAL_2="748" WEIGHT="79.32010297738053" Z="1.88078778599863">
<NAME>SSRIs</NAME>
<DICH_DATA CI_END="3.3045302152932625" CI_START="0.2962105091691747" EFFECT_SIZE="0.9893617021276596" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5191097272384174" LOG_CI_START="-0.5283995373299445" LOG_EFFECT_SIZE="-0.004644905045763525" ORDER="452" O_E="0.0" SE="0.6153121272619422" STUDY_ID="STD-Brady-2000" TOTAL_1="94" TOTAL_2="93" VAR="0.3786090139556166" WEIGHT="7.346860445516515"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="453" O_E="0.0" SE="0.0" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="454" O_E="0.0" SE="0.0" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.604586134193781" CI_START="0.6742934999148922" EFFECT_SIZE="1.944" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7485435480153657" LOG_CI_START="-0.1711510268348542" LOG_EFFECT_SIZE="0.28869626059025577" ORDER="455" O_E="0.0" SE="0.5402331458285875" STUDY_ID="STD-Davidson-2001a" TOTAL_1="100" TOTAL_2="108" VAR="0.29185185185185186" WEIGHT="9.530820418979225"/>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.14577691612966426" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898837" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="456" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="1.1682667873575423"/>
<DICH_DATA CI_END="2.458739111178717" CI_START="0.7845534879681667" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.3907124496064093" LOG_CI_START="-0.1053774424689462" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="457" O_E="0.0" SE="0.2914056582896344" STUDY_ID="STD-Marshall-2001" TOTAL_1="188" TOTAL_2="188" VAR="0.08491725768321515" WEIGHT="32.75644627295049"/>
<DICH_DATA CI_END="8.42560757513579" CI_START="0.01529416000590024" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9256012278834127" LOG_CI_START="-1.8154743705799352" LOG_EFFECT_SIZE="-0.4449365713482612" ORDER="458" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" VAR="2.5924908424908426" WEIGHT="1.0729401791344437"/>
<DICH_DATA CI_END="2.588738242770285" CI_START="0.1701678455239827" EFFECT_SIZE="0.6637168141592921" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.4130881394779135" LOG_CI_START="-0.7691224996613528" LOG_EFFECT_SIZE="-0.17801718009171966" ORDER="459" O_E="0.0" SE="0.6944363814674492" STUDY_ID="STD-Martenyi-2002a" TOTAL_1="226" TOTAL_2="75" VAR="0.48224188790560474" WEIGHT="5.768033965334435"/>
<DICH_DATA CI_END="3.7092113540353777" CI_START="0.8416435241923985" EFFECT_SIZE="1.7668711656441718" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5692815805046979" LOG_CI_START="-0.07487181379415193" LOG_EFFECT_SIZE="0.24720488335527305" ORDER="460" O_E="0.0" SE="0.37837889242187145" STUDY_ID="STD-Tucker-2001" TOTAL_1="163" TOTAL_2="160" VAR="0.14317058623040219" WEIGHT="19.428485013466133"/>
<DICH_DATA CI_END="21.92517990465492" CI_START="0.2801243576712541" EFFECT_SIZE="2.4782608695652173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3409431656083564" LOG_CI_START="-0.5526491262985592" LOG_EFFECT_SIZE="0.3941470196548985" ORDER="461" O_E="0.0" SE="1.11230548569914" STUDY_ID="STD-Zohar-2002" TOTAL_1="23" TOTAL_2="19" VAR="1.2372234935163997" WEIGHT="2.2482498946417384"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8317224043805302" CI_END="3.5686116854065983" CI_START="0.2926059774457912" DF="2" EFFECT_SIZE="1.0218596333806664" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.55249929324561" LOG_CI_START="-0.5337168062175188" LOG_EFFECT_SIZE="0.0093912435140456" NO="2" P_CHI2="0.40017189869446157" P_Z="0.9729640345743513" STUDIES="3" TAU2="0.0" TOTAL_1="97" TOTAL_2="99" WEIGHT="6.8325853431170565" Z="0.03389104445546761">
<NAME>MAOIs</NAME>
<DICH_DATA CI_END="8.950115223043012" CI_START="0.2696707387028318" EFFECT_SIZE="1.5535714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9518286264231361" LOG_CI_START="-0.5691661751982999" LOG_EFFECT_SIZE="0.1913312256124181" ORDER="462" O_E="0.0" SE="0.8934398755181265" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" VAR="0.7982348111658455" WEIGHT="3.484673369335946"/>
<DICH_DATA CI_END="72.98606354122126" CI_START="0.13426702924773704" EFFECT_SIZE="3.130434782608696" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8632399408743792" LOG_CI_START="-0.8720306200470282" LOG_EFFECT_SIZE="0.4956046604136756" ORDER="463" O_E="0.0" SE="1.6067114672928786" STUDY_ID="STD-Katz-1994" TOTAL_1="22" TOTAL_2="23" VAR="2.5815217391304346" WEIGHT="1.0774991923498134"/>
<DICH_DATA CI_END="2.7641482675461964" CI_START="0.03607729471700059" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.44156133466820857" LOG_CI_START="-1.442766035806579" LOG_EFFECT_SIZE="-0.5006023505691853" ORDER="464" O_E="0.0" SE="1.1068632249878072" STUDY_ID="STD-Kosten-1991" TOTAL_1="19" TOTAL_2="18" VAR="1.2251461988304093" WEIGHT="2.2704127814312964"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0063541756012584615" CI_END="43.884422492590986" CI_START="0.6780565310359721" DF="1" EFFECT_SIZE="5.454916982122021" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="1.6423103875295408" LOG_CI_START="-0.1687340965554872" LOG_EFFECT_SIZE="0.7367881454870266" NO="3" P_CHI2="0.9364654539935127" P_Z="0.11076898371059168" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="48" WEIGHT="2.457872215041122" Z="1.5947462826902392">
<NAME>TCAs</NAME>
<DICH_DATA CI_END="108.54233570712026" CI_START="0.32321803292818774" EFFECT_SIZE="5.923076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0355991628653425" LOG_CI_START="-0.49050441713405196" LOG_EFFECT_SIZE="0.7725473728656451" ORDER="465" O_E="0.0" SE="1.4838457473060338" STUDY_ID="STD-Davidson-1990" TOTAL_1="25" TOTAL_2="21" VAR="2.201798201798202" WEIGHT="1.2633253977021215"/>
<DICH_DATA CI_END="99.51175693739407" CI_START="0.25122659642848294" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9978743940260948" LOG_CI_START="-0.5999343853540574" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="466" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Reist-1989" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="1.1945468173390001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.436951903902928" CI_END="5.426522666855162" CI_START="0.5271908121360667" DF="4" EFFECT_SIZE="1.6913937719567693" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="26.429365742069727" ID="CMP-005.01.04" LOG_CI_END="0.7345216214195227" LOG_CI_START="-0.27803216721787316" LOG_EFFECT_SIZE="0.2282447271008248" NO="4" P_CHI2="0.24532749442714752" P_Z="0.37690666243134374" STUDIES="6" TAU2="0.4668767659250589" TOTAL_1="93" TOTAL_2="78" WEIGHT="11.389439464461297" Z="0.8836102334490208">
<NAME>Other medication</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="467" O_E="0.0" SE="0.0" STUDY_ID="STD-Braun-1990" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="137.256201398033" CI_START="0.3853564461549281" EFFECT_SIZE="7.2727272727272725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.1375319755053948" LOG_CI_START="-0.41413737183795785" LOG_EFFECT_SIZE="0.8616973018337185" ORDER="468" O_E="0.0" SE="1.4988632055964644" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="15" VAR="2.246590909090909" WEIGHT="1.2381371159701293"/>
<DICH_DATA CI_END="29.263900365324957" CI_START="0.38416664875584966" EFFECT_SIZE="3.3529411764705883" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.466332209494314" LOG_CI_START="-0.4154803409058791" LOG_EFFECT_SIZE="0.5254259342942175" ORDER="469" O_E="0.0" SE="1.1053860072274302" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="19" VAR="1.2218782249742002" WEIGHT="2.2764851129131647"/>
<DICH_DATA CI_END="21.624247320368667" CI_START="0.35682395176122583" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.334940999822427" LOG_CI_START="-0.4475460013570019" LOG_EFFECT_SIZE="0.44369749923271273" ORDER="470" O_E="0.0" SE="1.0470416879457554" STUDY_ID="STD-Davis-2001" TOTAL_1="27" TOTAL_2="15" VAR="1.0962962962962963" WEIGHT="2.537258949376902"/>
<DICH_DATA CI_END="1.7852962458414374" CI_START="0.07406692601672672" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.25171029174182985" LOG_CI_START="-1.130375679402355" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="471" O_E="0.0" SE="0.8118441408859887" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="11" TOTAL_2="4" VAR="0.6590909090909091" WEIGHT="4.220339790125769"/>
<DICH_DATA CI_END="50.84896561093882" CI_START="0.10473062181301512" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7062821227645535" LOG_CI_START="-0.9799263179389023" LOG_EFFECT_SIZE="0.3631779024128256" ORDER="472" O_E="0.0" SE="1.5778921350154418" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" VAR="2.4897435897435893" WEIGHT="1.1172184960753313"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.437100445451631" CI_END="2.05286271922745" CI_START="0.9852825101000637" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4221989076395976" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.3123599078336048" LOG_CI_START="-0.006439226369358868" LOG_EFFECT_SIZE="0.152960340732123" METHOD="MH" NO="2" P_CHI2="0.8418422473912379" P_Q="0.6992798922211191" P_Z="0.060000792307540456" Q="0.7154087088707093" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="901" TOTAL_2="748" WEIGHT="100.00000000000001" Z="1.88078778599863">
<NAME>Drop-out rate due to treatment emergent adverse effect: SSRI medications</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8003468764335959" CI_END="2.9604570302609963" CI_START="0.24733985432175606" DF="1" EFFECT_SIZE="0.8557096532063744" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.4713587618693045" LOG_CI_START="-0.6067058993383885" LOG_EFFECT_SIZE="-0.06767356873454199" NO="1" P_CHI2="0.37098973149466163" P_Z="0.8056308149207659" STUDIES="3" TAU2="0.0" TOTAL_1="259" TOTAL_2="108" WEIGHT="8.744694588545833" Z="0.24606642291087044">
<NAME>Fluoxetine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="473" O_E="0.0" SE="0.0" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="61.7381697935959" CI_START="0.14577691612966426" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7905537508292086" LOG_CI_START="-0.8363112413898837" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="474" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="1.4728508202904043"/>
<DICH_DATA CI_END="2.588738242770285" CI_START="0.1701678455239827" EFFECT_SIZE="0.6637168141592921" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.4130881394779135" LOG_CI_START="-0.7691224996613528" LOG_EFFECT_SIZE="-0.17801718009171966" ORDER="475" O_E="0.0" SE="0.6944363814674492" STUDY_ID="STD-Martenyi-2002a" TOTAL_1="226" TOTAL_2="75" VAR="0.48224188790560474" WEIGHT="7.271843768255429"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0411683877043831" CI_END="2.3093775674282884" CI_START="0.9428328147194731" DF="2" EFFECT_SIZE="1.4755869856258639" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="29" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.36349494289789935" LOG_CI_START="-0.025565310530842347" LOG_EFFECT_SIZE="0.16896481618352854" NO="2" P_CHI2="0.5941734184916936" P_Z="0.08868342749347406" STUDIES="3" TAU2="0.0" TOTAL_1="376" TOTAL_2="375" WEIGHT="67.14296813348624" Z="1.7023838927550634">
<NAME>Paroxetine</NAME>
<DICH_DATA CI_END="2.458739111178717" CI_START="0.7845534879681667" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.3907124496064093" LOG_CI_START="-0.1053774424689462" LOG_EFFECT_SIZE="0.14266750356873154" ORDER="476" O_E="0.0" SE="0.2914056582896344" STUDY_ID="STD-Marshall-2001" TOTAL_1="188" TOTAL_2="188" VAR="0.08491725768321515" WEIGHT="41.29652514734071"/>
<DICH_DATA CI_END="8.42560757513579" CI_START="0.01529416000590024" EFFECT_SIZE="0.358974358974359" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9256012278834127" LOG_CI_START="-1.8154743705799352" LOG_EFFECT_SIZE="-0.4449365713482612" ORDER="477" O_E="0.0" SE="1.6101213750804138" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" VAR="2.5924908424908426" WEIGHT="1.3526711878329392"/>
<DICH_DATA CI_END="3.7092113540353777" CI_START="0.8416435241923985" EFFECT_SIZE="1.7668711656441718" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5692815805046979" LOG_CI_START="-0.07487181379415193" LOG_EFFECT_SIZE="0.24720488335527305" ORDER="478" O_E="0.0" SE="0.37837889242187145" STUDY_ID="STD-Tucker-2001" TOTAL_1="163" TOTAL_2="160" VAR="0.14317058623040219" WEIGHT="24.493771798312586"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8866825767912316" CI_END="3.258552770436749" CI_START="0.7307964096570994" DF="2" EFFECT_SIZE="1.543158664983407" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="0.5130247585444203" LOG_CI_START="-0.13620359496747486" LOG_EFFECT_SIZE="0.18841058178847275" NO="3" P_CHI2="0.6418881257249837" P_Z="0.25529159739628626" STUDIES="4" TAU2="0.0" TOTAL_1="266" TOTAL_2="265" WEIGHT="24.11233727796794" Z="1.1375903489553278">
<NAME>Sertraline</NAME>
<DICH_DATA CI_END="3.3045302152932625" CI_START="0.2962105091691747" EFFECT_SIZE="0.9893617021276596" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5191097272384174" LOG_CI_START="-0.5283995373299445" LOG_EFFECT_SIZE="-0.004644905045763525" ORDER="479" O_E="0.0" SE="0.6153121272619422" STUDY_ID="STD-Brady-2000" TOTAL_1="94" TOTAL_2="93" VAR="0.3786090139556166" WEIGHT="9.262293125882096"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="480" O_E="0.0" SE="0.0" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.604586134193781" CI_START="0.6742934999148922" EFFECT_SIZE="1.944" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7485435480153657" LOG_CI_START="-0.1711510268348542" LOG_EFFECT_SIZE="0.28869626059025577" ORDER="481" O_E="0.0" SE="0.5402331458285875" STUDY_ID="STD-Davidson-2001a" TOTAL_1="100" TOTAL_2="108" VAR="0.29185185185185186" WEIGHT="12.01564302267371"/>
<DICH_DATA CI_END="21.92517990465492" CI_START="0.2801243576712541" EFFECT_SIZE="2.4782608695652173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3409431656083564" LOG_CI_START="-0.5526491262985592" LOG_EFFECT_SIZE="0.3941470196548985" ORDER="482" O_E="0.0" SE="1.11230548569914" STUDY_ID="STD-Zohar-2002" TOTAL_1="23" TOTAL_2="19" VAR="1.2372234935163997" WEIGHT="2.834401129412131"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Medication versus Placebo: Extension data</NAME>
<DICH_OUTCOME CHI2="0.39664786269755187" CI_END="0.6959611013765379" CI_START="0.12055677600939313" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2896598463886595" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.1574150332768209" LOG_CI_START="-0.9188083746620047" LOG_EFFECT_SIZE="-0.5381117039694129" METHOD="MH" NO="2" P_CHI2="0.5288259392054789" P_Q="1.0" P_Z="0.005598861679086885" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="108" WEIGHT="100.0" Z="2.770393440848265">
<NAME>Relapse data: Number of participants to relapse</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.39664786269755187" CI_END="0.6959611013765379" CI_START="0.12055677600939313" DF="1" EFFECT_SIZE="0.2896598463886595" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="22" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="-0.1574150332768209" LOG_CI_START="-0.9188083746620047" LOG_EFFECT_SIZE="-0.5381117039694129" NO="1" P_CHI2="0.5288259392054789" P_Z="0.005598861679086885" STUDIES="2" TAU2="0.0" TOTAL_1="107" TOTAL_2="108" WEIGHT="100.0" Z="2.770393440848265">
<NAME>SSRIs</NAME>
<DICH_DATA CI_END="0.8464186374065252" CI_START="0.04809066159129094" EFFECT_SIZE="0.20175438596491227" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.07241478241463443" LOG_CI_START="-1.317939248223125" LOG_EFFECT_SIZE="-0.6951770153188798" ORDER="483" O_E="0.0" SE="0.7316272366614481" STUDY_ID="STD-Davidson-2001a" TOTAL_1="38" TOTAL_2="46" VAR="0.5352784134248666" WEIGHT="37.36918474928096"/>
<DICH_DATA CI_END="1.0880450077541433" CI_START="0.11872941269787504" EFFECT_SIZE="0.35942028985507246" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.03664686063328409" LOG_CI_START="-0.9254416804553621" LOG_EFFECT_SIZE="-0.44439740991103904" ORDER="484" O_E="0.0" SE="0.5651355714505565" STUDY_ID="STD-Martenyi-2002a" TOTAL_1="69" TOTAL_2="62" VAR="0.31937821411874706" WEIGHT="62.63081525071904"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="22.769697533015268" CI_START="-3.529697533015268" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.620000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.15161160595013906" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="1.4338621465578185">
<NAME>Continuation trials: Symptom severity on the CAPS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="22.769697533015268" CI_START="-3.529697533015268" DF="0" EFFECT_SIZE="9.620000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" NO="1" P_CHI2="1.0" P_Z="0.15161160595013906" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="5" WEIGHT="100.0" Z="1.4338621465578185">
<NAME>SSRIs</NAME>
<CONT_DATA CI_END="22.769697533015268" CI_START="-3.529697533015268" EFFECT_SIZE="9.620000000000001" ESTIMABLE="YES" MEAN_1="18.37" MEAN_2="8.75" ORDER="485" SD_1="19.57" SD_2="7.14" SE="6.709152635833314" STUDY_ID="STD-Marshall-2004" TOTAL_1="11" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Subgroup analyses - Methodological criteria</NAME>
<CONT_OUTCOME CHI2="21.480623663655447" CI_END="-2.2883085309087488" CI_START="-8.95154118422489" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.6199248575668195" ESTIMABLE="YES" I2="39.48034189530726" I2_Q="27.44092626340007" ID="CMP-007.01" NO="1" P_CHI2="0.06395043023560698" P_Q="0.24041033463483963" P_Z="9.458470159677267E-4" Q="1.3781873837449283" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="14.133555010451884" TOTALS="YES" TOTAL_1="959" TOTAL_2="936" UNITS="" WEIGHT="99.99999999999999" Z="3.306158103655743">
<NAME>Single versus multi-centre trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8615066763409667" CI_END="3.54711739023324" CI_START="-7.946191242751777" DF="5" EFFECT_SIZE="-2.199536926259268" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.01" NO="1" P_CHI2="0.8679571422045133" P_Z="0.4531475636831511" STUDIES="6" TAU2="0.0" TOTAL_1="167" TOTAL_2="135" WEIGHT="24.658725620892838" Z="0.7501779158286559">
<NAME>Single centre trials</NAME>
<CONT_DATA CI_END="9.339431733377683" CI_START="-9.619431733377684" EFFECT_SIZE="-0.14000000000000057" ESTIMABLE="YES" MEAN_1="32.56" MEAN_2="32.7" ORDER="486" SD_1="15.69" SD_2="28.75" SE="4.836533634367892" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="7.699916054991168"/>
<CONT_DATA CI_END="10.057709663791236" CI_START="-21.25770966379124" EFFECT_SIZE="-5.600000000000001" ESTIMABLE="YES" MEAN_1="-19.1" MEAN_2="-13.5" ORDER="487" SD_1="24.0" SD_2="25.0" SE="7.988774175085488" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="3.7065938317831795"/>
<CONT_DATA CI_END="13.00529270362274" CI_START="-27.40529270362273" EFFECT_SIZE="-7.199999999999996" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="62.8" ORDER="488" SD_1="33.4" SD_2="40.8" SE="10.309012238489842" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="2.399682540766174"/>
<CONT_DATA CI_END="8.550333731474097" CI_START="-30.550333731474097" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-29.6" MEAN_2="-18.6" ORDER="489" SD_1="31.5" SD_2="12.3" SE="9.974843357166067" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="2.5428265799176466"/>
<CONT_DATA CI_END="25.509284608808002" CI_START="-15.949284608808" EFFECT_SIZE="4.780000000000001" ESTIMABLE="YES" MEAN_1="60.28" MEAN_2="55.5" ORDER="490" SD_1="26.15" SD_2="29.07" SE="10.576359959834953" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="2.2933352892155328"/>
<CONT_DATA CI_END="10.510415961147347" CI_START="-12.310415961147344" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="42.7" MEAN_2="43.6" ORDER="491" SD_1="22.1" SD_2="22.6" SE="5.821747772485234" STUDY_ID="STD-van-der-Kolk-2004" TOTAL_1="30" TOTAL_2="29" WEIGHT="6.016371324219138"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="16.822527523113543" CI_END="-2.2208684291291423" CI_START="-10.751351688373633" DF="7" EFFECT_SIZE="-6.486110058751388" ESTIMABLE="YES" I2="58.38913034689791" ID="CMP-007.01.02" NO="2" P_CHI2="0.018577148329636972" P_Z="0.002877805648289509" STUDIES="8" TAU2="20.778146868875908" TOTAL_1="792" TOTAL_2="801" WEIGHT="75.34127437910715" Z="2.9804975236635287">
<NAME>Multi-centre trials</NAME>
<CONT_DATA CI_END="12.802022321866549" CI_START="-12.202022321866554" EFFECT_SIZE="0.29999999999999716" ESTIMABLE="YES" MEAN_1="54.9" MEAN_2="54.6" ORDER="492" SD_1="33.9" SD_2="34.2" SE="6.378700027388721" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" WEIGHT="5.270646683811616"/>
<CONT_DATA CI_END="-0.2675583461650568" CI_START="-16.732441653834943" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="43.4" MEAN_2="51.9" ORDER="493" SD_1="28.1" SD_2="28.7" SE="4.200302515133641" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="9.093126635239207"/>
<CONT_DATA CI_END="-0.2782851153780168" CI_START="-13.321714884621985" EFFECT_SIZE="-6.800000000000001" ESTIMABLE="YES" MEAN_1="-33.0" MEAN_2="-26.2" ORDER="494" SD_1="23.8" SD_2="23.46" SE="3.3274666963599526" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="11.463491680769284"/>
<CONT_DATA CI_END="2.325765142167416" CI_START="-23.925765142167425" EFFECT_SIZE="-10.800000000000004" ESTIMABLE="YES" MEAN_1="46.3" MEAN_2="57.1" ORDER="495" SD_1="29.7" SD_2="23.7" SE="6.696942007966361" STUDY_ID="STD-Katz-1994" TOTAL_1="33" TOTAL_2="31" WEIGHT="4.898802856328639"/>
<CONT_DATA CI_END="-7.989096645353667" CI_START="-18.810903354646335" EFFECT_SIZE="-13.400000000000002" ESTIMABLE="YES" MEAN_1="-38.7" MEAN_2="-25.3" ORDER="496" SD_1="27.2" SD_2="25.8" SE="2.760715705659313" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="13.281666570148746"/>
<CONT_DATA CI_END="8.441343414053849" CI_START="-7.441343414053849" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-27.4" MEAN_2="-27.9" ORDER="497" SD_1="27.12" SD_2="28.42" SE="4.0517802759102475" STUDY_ID="STD-Pfizer588" TOTAL_1="94" TOTAL_2="94" WEIGHT="9.457922820794902"/>
<CONT_DATA CI_END="10.754204583788948" CI_START="-6.154204583788946" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="-13.1" MEAN_2="-15.4" ORDER="498" SD_1="27.12" SD_2="28.42" SE="4.313448946243214" STUDY_ID="STD-Pfizer589" TOTAL_1="84" TOTAL_2="82" WEIGHT="8.82557698154853"/>
<CONT_DATA CI_END="-5.253722783701645" CI_START="-16.346277216298358" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-35.5" MEAN_2="-24.7" ORDER="499" SD_1="24.6" SD_2="24.98" SE="2.8297852715900307" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="13.05004015046623"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.302796945174094" CI_END="1.7581110522094718" CI_START="1.2657857628934988" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4917747616421382" ESTIMABLE="YES" EVENTS_1="383" EVENTS_2="244" I2="26.392998450782983" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.2450463040930008" LOG_CI_START="0.10236020657666628" LOG_EFFECT_SIZE="0.17370325533483355" METHOD="MH" NO="2" P_CHI2="0.17775783194870265" P_Q="0.34052575264948237" P_Z="1.8236620007480347E-6" Q="0.908451467022665" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.017658698179318907" TOTALS="SUB" TOTAL_1="644" TOTAL_2="628" WEIGHT="200.0" Z="4.772043392870344">
<NAME>Single versus multi-centre trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.9763373462972655" CI_END="2.597344277750192" CI_START="1.2022967347841136" DF="5" EFFECT_SIZE="1.767138518693217" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="30" I2="16.336717452909024" ID="CMP-007.02.01" LOG_CI_END="0.41452951913928293" LOG_CI_START="0.08001166764592393" LOG_EFFECT_SIZE="0.2472705933926034" NO="1" P_CHI2="0.30852848862165705" P_Z="0.003760872238423224" STUDIES="6" TAU2="0.042392828681239995" TOTAL_1="103" TOTAL_2="85" WEIGHT="100.00000000000001" Z="2.8975521355396006">
<NAME>Single centre trials</NAME>
<DICH_DATA CI_END="1.9490540424429341" CI_START="0.983130100611921" EFFECT_SIZE="1.3842592592592593" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.2898238811952842" LOG_CI_START="-0.007389006848286702" LOG_EFFECT_SIZE="0.14121743717349877" ORDER="500" O_E="0.0" SE="0.17458432166431703" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="26" VAR="0.030479685370989718" WEIGHT="52.98464744715326"/>
<DICH_DATA CI_END="9.142381322469094" CI_START="0.9844262323516123" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9610593314567514" LOG_CI_START="-0.006816822017426501" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="501" O_E="0.0" SE="0.5685352436149611" STUDY_ID="STD-Davidson-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.3232323232323232" WEIGHT="10.560336031143489"/>
<DICH_DATA CI_END="10.385741110674171" CI_START="0.8163474914378822" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.0164374925699402" LOG_CI_START="-0.08812493745935067" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="502" O_E="0.0" SE="0.6488254390714155" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" VAR="0.4209744503862151" WEIGHT="8.332751663897758"/>
<DICH_DATA CI_END="12.184256768115382" CI_START="0.328292490557773" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.0857990426425488" LOG_CI_START="-0.4837390513145864" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="503" O_E="0.0" SE="0.9219544457292886" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="10" TOTAL_2="4" VAR="0.8499999999999999" WEIGHT="4.326709428347833"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="504" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="3.193494183290025"/>
<DICH_DATA CI_END="5.156229672423908" CI_START="1.1588523051895705" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7123322537637644" LOG_CI_START="0.06402808900199841" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="505" O_E="0.0" SE="0.3808170755384335" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="22" VAR="0.145021645021645" WEIGHT="20.602061246167647"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.325984000854394" CI_END="1.7227419869855038" CI_START="1.1980176542456478" DF="6" EFFECT_SIZE="1.4366194047550866" ESTIMABLE="YES" EVENTS_1="318" EVENTS_2="214" I2="41.89415750108128" ID="CMP-007.02.02" LOG_CI_END="0.2362202385512756" LOG_CI_START="0.07846321795727787" LOG_EFFECT_SIZE="0.15734172825427672" NO="2" P_CHI2="0.11157861263525726" P_Z="9.244569815785591E-5" STUDIES="7" TAU2="0.022599126672707328" TOTAL_1="541" TOTAL_2="543" WEIGHT="100.0" Z="3.9096088336673875">
<NAME>Multi-centre trials</NAME>
<DICH_DATA CI_END="1.3211022699534605" CI_START="0.7218305942998562" EFFECT_SIZE="0.976530612244898" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.12093643877823436" LOG_CI_START="-0.14156471460953687" LOG_EFFECT_SIZE="-0.010314137915651268" ORDER="506" O_E="0.0" SE="0.1541944769016426" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" VAR="0.023775936706971187" WEIGHT="18.516891379999684"/>
<DICH_DATA CI_END="2.3347996176444" CI_START="1.1451586885446934" EFFECT_SIZE="1.6351501668520578" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3682496135164242" LOG_CI_START="0.05886567251347047" LOG_EFFECT_SIZE="0.21355764301494734" ORDER="507" O_E="0.0" SE="0.18173365842034228" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" VAR="0.033027122602841644" WEIGHT="15.437352374566217"/>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="508" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.2" WEIGHT="3.8577061113303786"/>
<DICH_DATA CI_END="2.2223360012474958" CI_START="0.9640513489267248" EFFECT_SIZE="1.4637096774193548" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.3468097217766995" LOG_CI_START="-0.01589983335690695" LOG_EFFECT_SIZE="0.16545494420989623" ORDER="509" O_E="0.0" SE="0.2130573881267348" STUDY_ID="STD-Katz-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.04539345063538612" WEIGHT="12.629643489626783"/>
<DICH_DATA CI_END="2.0215879295543435" CI_START="1.2987281738680632" EFFECT_SIZE="1.620337372297458" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.3056926358451822" LOG_CI_START="0.11351826197173107" LOG_EFFECT_SIZE="0.2096054489084566" ORDER="510" O_E="0.0" SE="0.11288417849175787" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" VAR="0.01274283775375905" WEIGHT="24.297517845358954"/>
<DICH_DATA CI_END="1.9836458889032347" CI_START="1.2243543979684224" EFFECT_SIZE="1.5584240655516892" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.29746414653726916" LOG_CI_START="0.08790714559085233" LOG_EFFECT_SIZE="0.19268564606406074" ORDER="511" O_E="0.0" SE="0.12309481967980966" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" VAR="0.015152334632004856" WEIGHT="22.746722422501865"/>
<DICH_DATA CI_END="8.007343704622013" CI_START="0.8750617775006169" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.903488470422633" LOG_CI_START="-0.057961285628493536" LOG_EFFECT_SIZE="0.42276359239706973" ORDER="512" O_E="0.0" SE="0.5647603459574805" STUDY_ID="STD-Zohar-2002" TOTAL_1="17" TOTAL_2="15" VAR="0.31895424836601305" WEIGHT="2.5141663766161257"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="18.342743730619436" CI_END="-3.3396673428853116" CI_START="-9.639896957175248" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.48978215003028" ESTIMABLE="YES" I2="34.579034760386094" I2_Q="0.0" ID="CMP-007.03" NO="3" P_CHI2="0.10567307317531927" P_Q="0.32736980995865095" P_Z="5.393980827487842E-5" Q="0.9592749510178349" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="10.424033957322997" TOTALS="YES" TOTAL_1="963" TOTAL_2="936" UNITS="" WEIGHT="100.00000000000001" Z="4.03786530342318">
<NAME>Industry versus non-industry funded trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="17.118894467097363" CI_END="-3.571415571284822" CI_START="-10.088417160445822" DF="11" EFFECT_SIZE="-6.829916365865322" ESTIMABLE="YES" I2="35.74351415541419" ID="CMP-007.03.01" NO="1" P_CHI2="0.10440763576475742" P_Z="3.9885161616773894E-5" STUDIES="12" TAU2="10.613941273458273" TOTAL_1="933" TOTAL_2="907" WEIGHT="94.17107625334805" Z="4.108143879167011">
<NAME>Industry funded trials</NAME>
<CONT_DATA CI_END="-0.2675583461650568" CI_START="-16.732441653834943" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="43.4" MEAN_2="51.9" ORDER="513" SD_1="28.1" SD_2="28.7" SE="4.200302515133641" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="9.203799751654573"/>
<CONT_DATA CI_END="-0.2782851153780168" CI_START="-13.321714884621985" EFFECT_SIZE="-6.800000000000001" ESTIMABLE="YES" MEAN_1="-33.0" MEAN_2="-26.2" ORDER="514" SD_1="23.8" SD_2="23.46" SE="3.3274666963599526" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="12.017041011968017"/>
<CONT_DATA CI_END="10.057709663791236" CI_START="-21.25770966379124" EFFECT_SIZE="-5.600000000000001" ESTIMABLE="YES" MEAN_1="-19.1" MEAN_2="-13.5" ORDER="515" SD_1="24.0" SD_2="25.0" SE="7.988774175085488" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="3.4793011587407263"/>
<CONT_DATA CI_END="2.325765142167416" CI_START="-23.925765142167425" EFFECT_SIZE="-10.800000000000004" ESTIMABLE="YES" MEAN_1="46.3" MEAN_2="57.1" ORDER="516" SD_1="29.7" SD_2="23.7" SE="6.696942007966361" STUDY_ID="STD-Katz-1994" TOTAL_1="33" TOTAL_2="31" WEIGHT="4.6735083707440594"/>
<CONT_DATA CI_END="-7.989096645353667" CI_START="-18.810903354646335" EFFECT_SIZE="-13.400000000000002" ESTIMABLE="YES" MEAN_1="-38.7" MEAN_2="-25.3" ORDER="517" SD_1="27.2" SD_2="25.8" SE="2.760715705659313" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="14.314810812465563"/>
<CONT_DATA CI_END="13.00529270362274" CI_START="-27.40529270362273" EFFECT_SIZE="-7.199999999999996" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="62.8" ORDER="518" SD_1="33.4" SD_2="40.8" SE="10.309012238489842" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="2.2135360132375066"/>
<CONT_DATA CI_END="8.441343414053849" CI_START="-7.441343414053849" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-27.4" MEAN_2="-27.9" ORDER="519" SD_1="27.12" SD_2="28.42" SE="4.0517802759102475" STUDY_ID="STD-Pfizer588" TOTAL_1="94" TOTAL_2="94" WEIGHT="9.624065719953677"/>
<CONT_DATA CI_END="10.754204583788948" CI_START="-6.154204583788946" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="-13.1" MEAN_2="-15.4" ORDER="520" SD_1="27.12" SD_2="28.42" SE="4.313448946243214" STUDY_ID="STD-Pfizer589" TOTAL_1="84" TOTAL_2="82" WEIGHT="8.898389358890894"/>
<CONT_DATA CI_END="8.550333731474097" CI_START="-30.550333731474097" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-29.6" MEAN_2="-18.6" ORDER="521" SD_1="31.5" SD_2="12.3" SE="9.974843357166067" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="2.3500321396042065"/>
<CONT_DATA CI_END="1.22911303151119" CI_START="-12.629113031511189" EFFECT_SIZE="-5.699999999999999" ESTIMABLE="YES" MEAN_1="-36.5" MEAN_2="-30.8" ORDER="522" SD_1="26.1" SD_2="25.37" SE="3.5353267132289923" STUDY_ID="STD-SKB627" TOTAL_1="109" TOTAL_2="103" WEIGHT="11.269205404574723"/>
<CONT_DATA CI_END="-5.253722783701645" CI_START="-16.346277216298358" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-35.5" MEAN_2="-24.7" ORDER="523" SD_1="24.6" SD_2="24.98" SE="2.8297852715900307" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="14.0149240920413"/>
<CONT_DATA CI_END="25.509284608808002" CI_START="-15.949284608808" EFFECT_SIZE="4.780000000000001" ESTIMABLE="YES" MEAN_1="60.28" MEAN_2="55.5" ORDER="524" SD_1="26.15" SD_2="29.07" SE="10.576359959834953" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="2.112462419472796"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.510415961147347" CI_START="-12.310415961147344" DF="0" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-007.03.02" NO="2" P_CHI2="1.0" P_Z="0.8771423857167263" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="5.828923746651969" Z="0.15459275035129175">
<NAME>Non-industry funded trials</NAME>
<CONT_DATA CI_END="10.510415961147347" CI_START="-12.310415961147344" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="42.7" MEAN_2="43.6" ORDER="525" SD_1="22.1" SD_2="22.6" SE="5.821747772485234" STUDY_ID="STD-van-der-Kolk-2004" TOTAL_1="30" TOTAL_2="29" WEIGHT="5.828923746651969"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.54305632742518" CI_END="1.834181748761566" CI_START="1.4124068887258021" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6095374916807543" ESTIMABLE="YES" EVENTS_1="350" EVENTS_2="209" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.26344236763357065" LOG_CI_START="0.14995982707875946" LOG_EFFECT_SIZE="0.20670109735616504" METHOD="MH" NO="4" P_CHI2="0.753556675439012" P_Q="0.8679656688477377" P_Z="9.34023060088972E-13" Q="0.027636768282511784" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="588" TOTAL_2="570" WEIGHT="200.0" Z="7.139894901935471">
<NAME>Industry versus non-industry funded trials</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.344046173012303" CI_END="1.8438437778342625" CI_START="1.411623568768471" DF="8" EFFECT_SIZE="1.6133236916124245" ESTIMABLE="YES" EVENTS_1="315" EVENTS_2="188" I2="0.0" ID="CMP-007.04.01" LOG_CI_END="0.2657241220871117" LOG_CI_START="0.14971890082185219" LOG_EFFECT_SIZE="0.20772151145448195" NO="1" P_CHI2="0.8248255108352199" P_Z="2.2328658129003336E-12" STUDIES="9" TAU2="0.0" TOTAL_1="533" TOTAL_2="520" WEIGHT="100.0" Z="7.019109602559459">
<NAME>Industry funded trials</NAME>
<DICH_DATA CI_END="2.3347996176444" CI_START="1.1451586885446934" EFFECT_SIZE="1.6351501668520578" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3682496135164242" LOG_CI_START="0.05886567251347047" LOG_EFFECT_SIZE="0.21355764301494734" ORDER="526" O_E="0.0" SE="0.18173365842034228" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" VAR="0.033027122602841644" WEIGHT="14.059165358123822"/>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="527" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.2" WEIGHT="2.321668889881898"/>
<DICH_DATA CI_END="10.385741110674171" CI_START="0.8163474914378822" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.0164374925699402" LOG_CI_START="-0.08812493745935067" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="528" O_E="0.0" SE="0.6488254390714155" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" VAR="0.4209744503862151" WEIGHT="1.1029975276418442"/>
<DICH_DATA CI_END="12.184256768115382" CI_START="0.328292490557773" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.0857990426425488" LOG_CI_START="-0.4837390513145864" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="529" O_E="0.0" SE="0.9219544457292886" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="10" TOTAL_2="4" VAR="0.8499999999999999" WEIGHT="0.5462750329133879"/>
<DICH_DATA CI_END="2.2223360012474958" CI_START="0.9640513489267248" EFFECT_SIZE="1.4637096774193548" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.3468097217766995" LOG_CI_START="-0.01589983335690695" LOG_EFFECT_SIZE="0.16545494420989623" ORDER="530" O_E="0.0" SE="0.2130573881267348" STUDY_ID="STD-Katz-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.04539345063538612" WEIGHT="10.22909189490899"/>
<DICH_DATA CI_END="2.0215879295543435" CI_START="1.2987281738680632" EFFECT_SIZE="1.620337372297458" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.3056926358451822" LOG_CI_START="0.11351826197173107" LOG_EFFECT_SIZE="0.2096054489084566" ORDER="531" O_E="0.0" SE="0.11288417849175787" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" VAR="0.01274283775375905" WEIGHT="36.43880483681151"/>
<DICH_DATA CI_END="5.156229672423908" CI_START="1.1588523051895705" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7123322537637644" LOG_CI_START="0.06402808900199841" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="532" O_E="0.0" SE="0.3808170755384335" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="22" VAR="0.145021645021645" WEIGHT="3.201823961568468"/>
<DICH_DATA CI_END="1.9836458889032347" CI_START="1.2243543979684224" EFFECT_SIZE="1.5584240655516892" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.29746414653726916" LOG_CI_START="0.08790714559085233" LOG_EFFECT_SIZE="0.19268564606406074" ORDER="533" O_E="0.0" SE="0.12309481967980966" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" VAR="0.015152334632004856" WEIGHT="30.64437192375694"/>
<DICH_DATA CI_END="8.007343704622013" CI_START="0.8750617775006169" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.903488470422633" LOG_CI_START="-0.057961285628493536" LOG_EFFECT_SIZE="0.42276359239706973" ORDER="534" O_E="0.0" SE="0.5647603459574805" STUDY_ID="STD-Zohar-2002" TOTAL_1="17" TOTAL_2="15" VAR="0.31895424836601305" WEIGHT="1.4558005743931572"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8632500345540586" CI_END="2.8679397753496407" CI_START="0.8136423386073217" DF="2" EFFECT_SIZE="1.5275723307917168" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="21" I2="30.149306701693863" ID="CMP-007.04.02" LOG_CI_END="0.4575700272231181" LOG_CI_START="-0.08956646059524302" LOG_EFFECT_SIZE="0.18400178331393754" NO="2" P_CHI2="0.2389207083102758" P_Z="0.1874132071082883" STUDIES="3" TAU2="0.11994938597939209" TOTAL_1="55" TOTAL_2="50" WEIGHT="100.0" Z="1.3182702174532555">
<NAME>Non-industry funded trials</NAME>
<DICH_DATA CI_END="1.9490540424429341" CI_START="0.983130100611921" EFFECT_SIZE="1.3842592592592593" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.2898238811952842" LOG_CI_START="-0.007389006848286702" LOG_EFFECT_SIZE="0.14121743717349877" ORDER="535" O_E="0.0" SE="0.17458432166431703" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="26" VAR="0.030479685370989718" WEIGHT="68.66489908374113"/>
<DICH_DATA CI_END="9.142381322469094" CI_START="0.9844262323516123" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9610593314567514" LOG_CI_START="-0.006816822017426501" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="536" O_E="0.0" SE="0.5685352436149611" STUDY_ID="STD-Davidson-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.3232323232323232" WEIGHT="23.30691178999093"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="537" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="8.028189126267934"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Subgroup analyses - Clinical criteria</NAME>
<CONT_OUTCOME CHI2="15.828086225947322" CI_END="-0.1607594480615189" CI_START="-0.4509397796292415" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3058496138453802" ESTIMABLE="YES" I2="36.82116803478879" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="0.10466060464244209" P_Q="0.7998363897720497" P_Z="3.602501613465309E-5" Q="0.06429209339349007" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.019578559430936497" TOTALS="YES" TOTAL_1="737" TOTAL_2="718" UNITS="" WEIGHT="100.0" Z="4.131597924530781">
<NAME>Inclusion of major depression vs. non-inclusion: CAPS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.217524240424176" CI_END="-0.23400809106482146" CI_START="-0.45947538884313943" DF="8" EFFECT_SIZE="-0.34674173995398044" ESTIMABLE="YES" I2="2.6470775632655448" ID="CMP-008.01.01" NO="1" P_CHI2="0.41251555849556987" P_Z="1.6561085795098865E-9" STUDIES="9" TAU2="8.447907701829469E-4" TOTAL_1="662" TOTAL_2="642" WEIGHT="86.19015001034654" Z="6.02838042539319">
<NAME>Trials including patients with major depressive disorder</NAME>
<CONT_DATA CI_END="-0.00664127874628706" CI_START="-0.5895376112948504" EFFECT_SIZE="-0.2980894450205687" ESTIMABLE="YES" MEAN_1="43.4" MEAN_2="51.9" ORDER="538" SD_1="28.1" SD_2="28.7" SE="0.14870077642915258" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="13.144463745991475"/>
<CONT_DATA CI_END="0.3986098546125714" CI_START="-0.4107445930281101" EFFECT_SIZE="-0.00606736920776936" ESTIMABLE="YES" MEAN_1="32.56" MEAN_2="32.7" ORDER="539" SD_1="15.69" SD_2="28.75" SE="0.20647176530404796" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="8.808977675798626"/>
<CONT_DATA CI_END="-0.009375730054707987" CI_START="-0.5641118072857365" EFFECT_SIZE="-0.2867437686702222" ESTIMABLE="YES" MEAN_1="-33.0" MEAN_2="-26.2" ORDER="540" SD_1="23.8" SD_2="23.46" SE="0.1415169058224324" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="13.83640418346951"/>
<CONT_DATA CI_END="0.41215545035722767" CI_START="-0.8629583681030543" EFFECT_SIZE="-0.2254014588729133" ESTIMABLE="YES" MEAN_1="-19.1" MEAN_2="-13.5" ORDER="541" SD_1="24.0" SD_2="25.0" SE="0.325290114644508" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="4.370279237696734"/>
<CONT_DATA CI_END="-0.29723332229000743" CI_START="-0.7118851370269652" EFFECT_SIZE="-0.5045592296584863" ESTIMABLE="YES" MEAN_1="-38.7" MEAN_2="-25.3" ORDER="542" SD_1="27.2" SD_2="25.8" SE="0.10578046790851219" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="17.810641486680158"/>
<CONT_DATA CI_END="0.3558615707587884" CI_START="-0.7347695685391478" EFFECT_SIZE="-0.18945399889017972" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="62.8" ORDER="543" SD_1="33.4" SD_2="40.8" SE="0.2782273419054369" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="5.650114267990754"/>
<CONT_DATA CI_END="0.45754916886105906" CI_START="-1.2935921151388816" EFFECT_SIZE="-0.4180214731389113" ESTIMABLE="YES" MEAN_1="-29.6" MEAN_2="-18.6" ORDER="544" SD_1="31.5" SD_2="12.3" SE="0.44672792403654343" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="2.5006297835670623"/>
<CONT_DATA CI_END="-0.20811002565264114" CI_START="-0.6609300035613686" EFFECT_SIZE="-0.43452001460700485" ESTIMABLE="YES" MEAN_1="-35.5" MEAN_2="-24.7" ORDER="545" SD_1="24.6" SD_2="24.98" SE="0.11551742314667861" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="16.644952235584974"/>
<CONT_DATA CI_END="0.9077395643008296" CI_START="-0.5614884124012499" EFFECT_SIZE="0.17312557594978983" ESTIMABLE="YES" MEAN_1="60.28" MEAN_2="55.5" ORDER="546" SD_1="26.15" SD_2="29.07" SE="0.3748099425017914" STUDY_ID="STD-Tucker-2003" TOTAL_1="25" TOTAL_2="10" WEIGHT="3.423687393567249"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.1001089041225205" CI_END="0.5595885566449048" CI_START="-1.524226859796619" DF="1" EFFECT_SIZE="-0.4823191515758572" ESTIMABLE="YES" I2="85.91570899117657" ID="CMP-008.01.02" NO="2" P_CHI2="0.007707945937040717" P_Z="0.36424549394228467" STUDIES="2" TAU2="0.488644296440668" TOTAL_1="75" TOTAL_2="76" WEIGHT="13.809849989653452" Z="0.9073050891973026">
<NAME>Trials excluding patients with major depressive disorder</NAME>
<CONT_DATA CI_END="0.37594389230206804" CI_START="-0.3584425561572733" EFFECT_SIZE="0.0087506680723974" ESTIMABLE="YES" MEAN_1="54.9" MEAN_2="54.6" ORDER="547" SD_1="33.9" SD_2="34.2" SE="0.18734692429352984" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" WEIGHT="10.022398870662123"/>
<CONT_DATA CI_END="-0.3645289665281869" CI_START="-1.751039764056276" EFFECT_SIZE="-1.0577843652922314" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="31.3" ORDER="548" SD_1="11.3" SD_2="15.0" SE="0.3537082335350826" STUDY_ID="STD-Kosten-1991" TOTAL_1="19" TOTAL_2="18" WEIGHT="3.78745111899133"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.6579913829726785" CI_END="1.8911074960106404" CI_START="1.3907474466778462" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.621743790328834" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="144" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.27671621609906916" LOG_CI_START="0.14324827127708287" LOG_EFFECT_SIZE="0.209982243688076" METHOD="MH" NO="2" P_CHI2="0.4625706754476545" P_Q="1.0" P_Z="6.953695023868499E-10" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="410" TOTAL_2="402" WEIGHT="100.00000000000001" Z="6.167138267850903">
<NAME>Inclusion of major depression vs. non-inclusion: Clinical Global Impressions scale improvement item (CGI-I)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.6579913829726785" CI_END="1.8911074960106404" CI_START="1.3907474466778462" DF="6" EFFECT_SIZE="1.621743790328834" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="144" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.27671621609906916" LOG_CI_START="0.14324827127708287" LOG_EFFECT_SIZE="0.209982243688076" NO="1" P_CHI2="0.4625706754476545" P_Z="6.953695023868499E-10" STUDIES="7" TAU2="0.0" TOTAL_1="410" TOTAL_2="402" WEIGHT="100.00000000000001" Z="6.167138267850903">
<NAME>Trials including patients with major depressive disorder</NAME>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="549" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.2" WEIGHT="3.0732589469247378"/>
<DICH_DATA CI_END="9.142381322469094" CI_START="0.9844262323516123" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9610593314567514" LOG_CI_START="-0.006816822017426501" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="550" O_E="0.0" SE="0.5685352436149611" STUDY_ID="STD-Davidson-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.3232323232323232" WEIGHT="1.9015789734096817"/>
<DICH_DATA CI_END="10.385741110674171" CI_START="0.8163474914378822" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.0164374925699402" LOG_CI_START="-0.08812493745935067" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="551" O_E="0.0" SE="0.6488254390714155" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" VAR="0.4209744503862151" WEIGHT="1.4600691059066573"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="552" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="0.5268443909013837"/>
<DICH_DATA CI_END="2.0215879295543435" CI_START="1.2987281738680632" EFFECT_SIZE="1.620337372297458" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.3056926358451822" LOG_CI_START="0.11351826197173107" LOG_EFFECT_SIZE="0.2096054489084566" ORDER="553" O_E="0.0" SE="0.11288417849175787" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" VAR="0.01274283775375905" WEIGHT="48.235079286293946"/>
<DICH_DATA CI_END="5.156229672423908" CI_START="1.1588523051895705" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7123322537637644" LOG_CI_START="0.06402808900199841" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="554" O_E="0.0" SE="0.3808170755384335" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="22" VAR="0.145021645021645" WEIGHT="4.238345174564863"/>
<DICH_DATA CI_END="1.9836458889032347" CI_START="1.2243543979684224" EFFECT_SIZE="1.5584240655516892" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.29746414653726916" LOG_CI_START="0.08790714559085233" LOG_EFFECT_SIZE="0.19268564606406074" ORDER="555" O_E="0.0" SE="0.12309481967980966" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" VAR="0.015152334632004856" WEIGHT="40.56482412199875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trials excluding patients with major depressive disorder</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="19.213889508226394" CI_END="-2.663396918715752" CI_START="-9.687536581142243" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.175466749928998" ESTIMABLE="YES" I2="42.74974884554026" I2_Q="62.714452477323846" ID="CMP-008.03" NO="3" P_CHI2="0.057360589728655986" P_Q="0.1014879824685937" P_Z="5.682914238610484E-4" Q="2.6820043326219754" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="14.714215161156094" TOTALS="YES" TOTAL_1="904" TOTAL_2="897" UNITS="" WEIGHT="100.0" Z="3.4463131427555447">
<NAME>Inclusion of war veterans versus non-inclusion: CAPS</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.042995635945819" CI_END="4.0714164226946306" CI_START="-7.535246282883513" DF="3" EFFECT_SIZE="-1.7319149300944416" ESTIMABLE="YES" I2="1.4129378116066595" ID="CMP-008.03.01" NO="1" P_CHI2="0.38504371027342665" P_Z="0.5586007814404463" STUDIES="4" TAU2="0.5383286384938004" TOTAL_1="199" TOTAL_2="186" WEIGHT="24.911614900182798" Z="0.5849210877198877">
<NAME>Trials including war veterans</NAME>
<CONT_DATA CI_END="12.802022321866549" CI_START="-12.202022321866554" EFFECT_SIZE="0.29999999999999716" ESTIMABLE="YES" MEAN_1="54.9" MEAN_2="54.6" ORDER="556" SD_1="33.9" SD_2="34.2" SE="6.378700027388721" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" WEIGHT="5.795680434505399"/>
<CONT_DATA CI_END="10.057709663791236" CI_START="-21.25770966379124" EFFECT_SIZE="-5.600000000000001" ESTIMABLE="YES" MEAN_1="-19.1" MEAN_2="-13.5" ORDER="557" SD_1="24.0" SD_2="25.0" SE="7.988774175085488" STUDY_ID="STD-Davis-2001" TOTAL_1="26" TOTAL_2="15" WEIGHT="4.088541017733689"/>
<CONT_DATA CI_END="2.325765142167416" CI_START="-23.925765142167425" EFFECT_SIZE="-10.800000000000004" ESTIMABLE="YES" MEAN_1="46.3" MEAN_2="57.1" ORDER="558" SD_1="29.7" SD_2="23.7" SE="6.696942007966361" STUDY_ID="STD-Katz-1994" TOTAL_1="33" TOTAL_2="31" WEIGHT="5.390781573907217"/>
<CONT_DATA CI_END="10.754204583788948" CI_START="-6.154204583788946" EFFECT_SIZE="2.3000000000000007" ESTIMABLE="YES" MEAN_1="-13.1" MEAN_2="-15.4" ORDER="559" SD_1="27.12" SD_2="28.42" SE="4.313448946243214" STUDY_ID="STD-Pfizer589" TOTAL_1="84" TOTAL_2="82" WEIGHT="9.636611874036491"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="12.046690709257053" CI_END="-3.7124154980755306" CI_START="-11.370202542284291" DF="7" EFFECT_SIZE="-7.541309020179911" ESTIMABLE="YES" I2="41.89275570409572" ID="CMP-008.03.02" NO="2" P_CHI2="0.09903389017384656" P_Z="1.132459141427575E-4" STUDIES="8" TAU2="11.699380950895497" TOTAL_1="705" TOTAL_2="711" WEIGHT="75.0883850998172" Z="3.860304286475985">
<NAME>Trials without war veterans</NAME>
<CONT_DATA CI_END="-0.2675583461650568" CI_START="-16.732441653834943" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="43.4" MEAN_2="51.9" ORDER="560" SD_1="28.1" SD_2="28.7" SE="4.200302515133641" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" WEIGHT="9.923505709309122"/>
<CONT_DATA CI_END="9.339431733377683" CI_START="-9.619431733377684" EFFECT_SIZE="-0.14000000000000057" ESTIMABLE="YES" MEAN_1="32.56" MEAN_2="32.7" ORDER="561" SD_1="15.69" SD_2="28.75" SE="4.836533634367892" STUDY_ID="STD-Brady-2004" TOTAL_1="49" TOTAL_2="45" WEIGHT="8.426236244954673"/>
<CONT_DATA CI_END="-0.2782851153780168" CI_START="-13.321714884621985" EFFECT_SIZE="-6.800000000000001" ESTIMABLE="YES" MEAN_1="-33.0" MEAN_2="-26.2" ORDER="562" SD_1="23.8" SD_2="23.46" SE="3.3274666963599526" STUDY_ID="STD-Davidson-2001a" TOTAL_1="98" TOTAL_2="104" WEIGHT="12.452080447996282"/>
<CONT_DATA CI_END="-7.989096645353667" CI_START="-18.810903354646335" EFFECT_SIZE="-13.400000000000002" ESTIMABLE="YES" MEAN_1="-38.7" MEAN_2="-25.3" ORDER="563" SD_1="27.2" SD_2="25.8" SE="2.760715705659313" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" WEIGHT="14.375708062588606"/>
<CONT_DATA CI_END="13.00529270362274" CI_START="-27.40529270362273" EFFECT_SIZE="-7.199999999999996" ESTIMABLE="YES" MEAN_1="55.6" MEAN_2="62.8" ORDER="564" SD_1="33.4" SD_2="40.8" SE="10.309012238489842" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="27" WEIGHT="2.6538771250426265"/>
<CONT_DATA CI_END="8.441343414053849" CI_START="-7.441343414053849" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-27.4" MEAN_2="-27.9" ORDER="565" SD_1="27.12" SD_2="28.42" SE="4.0517802759102475" STUDY_ID="STD-Pfizer588" TOTAL_1="94" TOTAL_2="94" WEIGHT="10.314189312252275"/>
<CONT_DATA CI_END="8.550333731474097" CI_START="-30.550333731474097" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-29.6" MEAN_2="-18.6" ORDER="566" SD_1="31.5" SD_2="12.3" SE="9.974843357166067" STUDY_ID="STD-Reich-2004" TOTAL_1="12" TOTAL_2="9" WEIGHT="2.8113793424478404"/>
<CONT_DATA CI_END="-5.253722783701645" CI_START="-16.346277216298358" EFFECT_SIZE="-10.8" ESTIMABLE="YES" MEAN_1="-35.5" MEAN_2="-24.7" ORDER="567" SD_1="24.6" SD_2="24.98" SE="2.8297852715900307" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" WEIGHT="14.131408855225773"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="16.302796945174094" CI_END="1.7702225947891" CI_START="1.3781348359748997" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5619236297939594" ESTIMABLE="YES" EVENTS_1="383" EVENTS_2="244" I2="26.392998450782983" I2_Q="0.0" ID="CMP-008.04" LOG_CI_END="0.2480278797010222" LOG_CI_START="0.1392917107901124" LOG_EFFECT_SIZE="0.19365979524556728" METHOD="MH" NO="4" P_CHI2="0.17775783194870265" P_Q="0.5307029855638837" P_Z="2.922192565230596E-12" Q="0.3930460412520548" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.017658698179318907" TOTALS="SUB" TOTAL_1="644" TOTAL_2="628" WEIGHT="200.0" Z="6.9814161697328325">
<NAME>Inclusion of war veterans versus non-inclusion: CGI-I</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.899548624798058" CI_END="2.0016292499955157" CI_START="0.9861779514534363" DF="7" EFFECT_SIZE="1.40497780528016" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="65" I2="35.77715700929136" ID="CMP-008.04.01" LOG_CI_END="0.30138363878161484" LOG_CI_START="-0.006044711467372408" LOG_EFFECT_SIZE="0.14766946365712114" NO="1" P_CHI2="0.14306123763232914" P_Z="0.0597153232839261" STUDIES="8" TAU2="0.07676639996929782" TOTAL_1="169" TOTAL_2="148" WEIGHT="100.00000000000001" Z="1.8828896564021909">
<NAME>Trials including war veterans</NAME>
<DICH_DATA CI_END="1.3211022699534605" CI_START="0.7218305942998562" EFFECT_SIZE="0.976530612244898" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.12093643877823436" LOG_CI_START="-0.14156471460953687" LOG_EFFECT_SIZE="-0.010314137915651268" ORDER="568" O_E="0.0" SE="0.1541944769016426" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" VAR="0.023775936706971187" WEIGHT="32.435011687513686"/>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="569" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.2" WEIGHT="11.782831534270342"/>
<DICH_DATA CI_END="9.142381322469094" CI_START="0.9844262323516123" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9610593314567514" LOG_CI_START="-0.006816822017426501" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="570" O_E="0.0" SE="0.5685352436149611" STUDY_ID="STD-Davidson-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.3232323232323232" WEIGHT="8.152755686524916"/>
<DICH_DATA CI_END="10.385741110674171" CI_START="0.8163474914378822" EFFECT_SIZE="2.911764705882353" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.0164374925699402" LOG_CI_START="-0.08812493745935067" LOG_EFFECT_SIZE="0.46415627755529476" ORDER="571" O_E="0.0" SE="0.6488254390714155" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" VAR="0.4209744503862151" WEIGHT="6.551786663392157"/>
<DICH_DATA CI_END="12.184256768115382" CI_START="0.328292490557773" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.0857990426425488" LOG_CI_START="-0.4837390513145864" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="572" O_E="0.0" SE="0.9219544457292886" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="10" TOTAL_2="4" VAR="0.8499999999999999" WEIGHT="3.5187851709910456"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="573" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="2.622651715389406"/>
<DICH_DATA CI_END="2.2223360012474958" CI_START="0.9640513489267248" EFFECT_SIZE="1.4637096774193548" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.3468097217766995" LOG_CI_START="-0.01589983335690695" LOG_EFFECT_SIZE="0.16545494420989623" ORDER="574" O_E="0.0" SE="0.2130573881267348" STUDY_ID="STD-Katz-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.04539345063538612" WEIGHT="26.695283671701556"/>
<DICH_DATA CI_END="8.007343704622013" CI_START="0.8750617775006169" EFFECT_SIZE="2.6470588235294117" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.903488470422633" LOG_CI_START="-0.057961285628493536" LOG_EFFECT_SIZE="0.42276359239706973" ORDER="575" O_E="0.0" SE="0.5647603459574805" STUDY_ID="STD-Zohar-2002" TOTAL_1="17" TOTAL_2="15" VAR="0.31895424836601305" WEIGHT="8.240893870216901"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.024320616267536" CI_END="1.8128471043096799" CI_START="1.3871091103955764" DF="4" EFFECT_SIZE="1.5857543107752212" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="179" I2="0.0" ID="CMP-008.04.02" LOG_CI_END="0.2583611772037827" LOG_CI_START="0.14211062414391823" LOG_EFFECT_SIZE="0.2002359006738505" NO="2" P_CHI2="0.7312855889366031" P_Z="1.4593703505908112E-11" STUDIES="5" TAU2="0.0" TOTAL_1="475" TOTAL_2="480" WEIGHT="100.0" Z="6.751884501239099">
<NAME>Trials without war veterans</NAME>
<DICH_DATA CI_END="2.3347996176444" CI_START="1.1451586885446934" EFFECT_SIZE="1.6351501668520578" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3682496135164242" LOG_CI_START="0.05886567251347047" LOG_EFFECT_SIZE="0.21355764301494734" ORDER="576" O_E="0.0" SE="0.18173365842034228" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" VAR="0.033027122602841644" WEIGHT="14.118693841947684"/>
<DICH_DATA CI_END="1.9490540424429341" CI_START="0.983130100611921" EFFECT_SIZE="1.3842592592592593" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.2898238811952842" LOG_CI_START="-0.007389006848286702" LOG_EFFECT_SIZE="0.14121743717349877" ORDER="577" O_E="0.0" SE="0.17458432166431703" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="26" VAR="0.030479685370989718" WEIGHT="15.29870885589296"/>
<DICH_DATA CI_END="2.0215879295543435" CI_START="1.2987281738680632" EFFECT_SIZE="1.620337372297458" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.3056926358451822" LOG_CI_START="0.11351826197173107" LOG_EFFECT_SIZE="0.2096054489084566" ORDER="578" O_E="0.0" SE="0.11288417849175787" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" VAR="0.01274283775375905" WEIGHT="36.593091862323696"/>
<DICH_DATA CI_END="5.156229672423908" CI_START="1.1588523051895705" EFFECT_SIZE="2.4444444444444446" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7123322537637644" LOG_CI_START="0.06402808900199841" LOG_EFFECT_SIZE="0.3881801713828814" ORDER="579" O_E="0.0" SE="0.3808170755384335" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="22" VAR="0.145021645021645" WEIGHT="3.2153809346211357"/>
<DICH_DATA CI_END="1.9836458889032347" CI_START="1.2243543979684224" EFFECT_SIZE="1.5584240655516892" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.29746414653726916" LOG_CI_START="0.08790714559085233" LOG_EFFECT_SIZE="0.19268564606406074" ORDER="580" O_E="0.0" SE="0.12309481967980966" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" VAR="0.015152334632004856" WEIGHT="30.77412450521453"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Sensitivity analyses</NAME>
<DICH_OUTCOME CHI2="11.47534753861872" CI_END="0.7392456652318969" CI_START="0.5952999808095243" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6633799290949887" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="389" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.13121121339824238" LOG_CI_START="-0.2252641314484446" LOG_EFFECT_SIZE="-0.17823767242334354" METHOD="MH" NO="1" P_CHI2="0.48867935572821064" P_Q="0.8634417762256038" P_Z="1.0977664257547511E-13" Q="0.7413323381540688" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="644" TOTAL_2="628" WEIGHT="99.99999999999997" Z="7.428571614365776">
<NAME>Clinical Global Impressions scale improvement item (CGI-I) : non-response</NAME>
<GROUP_LABEL_1>Medication</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.806069928443706" CI_END="0.7382000637809764" CI_START="0.5806216981375395" DF="6" EFFECT_SIZE="0.6546869286901568" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="322" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-0.131825921617028" LOG_CI_START="-0.2361067383883953" LOG_EFFECT_SIZE="-0.18396633000271168" NO="1" P_CHI2="0.44526140200068065" P_Z="4.668228090180587E-12" STUDIES="7" TAU2="0.0" TOTAL_1="498" TOTAL_2="501" WEIGHT="81.34590600042982" Z="6.915315632094804">
<NAME>SSRIs</NAME>
<DICH_DATA CI_END="0.9030275252270714" CI_START="0.5395899055506961" EFFECT_SIZE="0.6980433632998414" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="61" LOG_CI_END="-0.04429901173295895" LOG_CI_START="-0.26793618354542076" LOG_EFFECT_SIZE="-0.1561175976391898" ORDER="581" O_E="0.0" SE="0.13136558174449434" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="90" VAR="0.017256916067069424" WEIGHT="17.6870973389082"/>
<DICH_DATA CI_END="1.0755698217334955" CI_START="0.13794327796127764" EFFECT_SIZE="0.3851851851851852" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.031638608316528205" LOG_CI_START="-0.8602994580369421" LOG_EFFECT_SIZE="-0.41433042486020694" ORDER="582" O_E="0.0" SE="0.5239288353406638" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="26" VAR="0.27450142450142445" WEIGHT="1.1119241177054142"/>
<DICH_DATA CI_END="2.4414660517054707" CI_START="0.639984323725708" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.3876506898491051" LOG_CI_START="-0.19383066383299224" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="583" O_E="0.0" SE="0.3415650255319866" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="0.11666666666666667" WEIGHT="2.6162121792653634"/>
<DICH_DATA CI_END="0.7818104907877275" CI_START="0.5143943763297923" EFFECT_SIZE="0.6341600112091915" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="117" LOG_CI_END="-0.10689850624880547" LOG_CI_START="-0.28870378802763236" LOG_EFFECT_SIZE="-0.19780114713821892" ORDER="584" O_E="0.0" SE="0.10679332246754196" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="186" VAR="0.011404813723656404" WEIGHT="26.762800484370395"/>
<DICH_DATA CI_END="0.8334001135413909" CI_START="0.36132665263999036" EFFECT_SIZE="0.5487528344671202" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="-0.07914644471099881" LOG_CI_START="-0.44210000226381563" LOG_EFFECT_SIZE="-0.26062322348740724" ORDER="585" O_E="0.0" SE="0.21320071635561044" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="22" VAR="0.045454545454545456" WEIGHT="6.7149445934477665"/>
<DICH_DATA CI_END="0.8285556180560135" CI_START="0.5262759770145772" EFFECT_SIZE="0.6603400013654673" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="97" LOG_CI_END="-0.08167833358852485" LOG_CI_START="-0.2787864538248728" LOG_EFFECT_SIZE="-0.18023239370669883" ORDER="586" O_E="0.0" SE="0.11578228552776187" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="156" VAR="0.013405537642032178" WEIGHT="22.768557472145964"/>
<DICH_DATA CI_END="1.0340654426866767" CI_START="0.3346217240822345" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.014548024733103637" LOG_CI_START="-0.4754458674896514" LOG_EFFECT_SIZE="-0.2304489213782739" ORDER="587" O_E="0.0" SE="0.2878248378005309" STUDY_ID="STD-Zohar-2002" TOTAL_1="17" TOTAL_2="15" VAR="0.08284313725490193" WEIGHT="3.6843698145867263"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3324524607824104" CI_END="1.4431250401004345" CI_START="0.4429835311634892" DF="1" EFFECT_SIZE="0.7995502649453269" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" I2="57.1266717408442" ID="CMP-009.01.02" LOG_CI_END="0.1593039623290885" LOG_CI_START="-0.3536124192797965" LOG_EFFECT_SIZE="-0.09715422847535399" NO="2" P_CHI2="0.12670226715832722" P_Z="0.457787806211039" STUDIES="2" TAU2="0.10608423216816909" TOTAL_1="87" TOTAL_2="91" WEIGHT="8.728423462316567" Z="0.7424944711657502">
<NAME>MAOIs</NAME>
<DICH_DATA CI_END="1.6183728143625604" CI_START="0.6628287821648601" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.20907857448871797" LOG_CI_START="-0.17859864137524423" LOG_EFFECT_SIZE="0.015239966556736905" ORDER="588" O_E="0.0" SE="0.22772351563165968" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="58" VAR="0.051857999571642756" WEIGHT="5.885779566679048"/>
<DICH_DATA CI_END="1.0711905404574895" CI_START="0.29650016500272364" EFFECT_SIZE="0.5635673624288425" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" LOG_CI_END="0.029866728823544433" LOG_CI_START="-0.527975060614213" LOG_EFFECT_SIZE="-0.24905416589533425" ORDER="589" O_E="0.0" SE="0.3276790284771311" STUDY_ID="STD-Katz-1994" TOTAL_1="31" TOTAL_2="33" VAR="0.10737354570371649" WEIGHT="2.842643895637518"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9563064224168384" CI_START="0.37644837633756034" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-009.01.03" LOG_CI_END="-0.019402927554505164" LOG_CI_START="-0.42429457167820767" LOG_EFFECT_SIZE="-0.2218487496163564" NO="3" P_CHI2="1.0" P_Z="0.03172869597998426" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="5.395937619734811" Z="2.14781196685036">
<NAME>TCAs</NAME>
<DICH_DATA CI_END="0.9563064224168384" CI_START="0.37644837633756034" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="-0.019402927554505164" LOG_CI_START="-0.42429457167820767" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="590" O_E="0.0" SE="0.23783535600422528" STUDY_ID="STD-Davidson-1990" TOTAL_1="22" TOTAL_2="18" VAR="0.05656565656565658" WEIGHT="5.395937619734811"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2001904564506072" CI_END="0.9785620692038118" CI_START="0.3537335014487569" DF="2" EFFECT_SIZE="0.5883452958292479" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="0.0" ID="CMP-009.01.04" LOG_CI_END="-0.009411622271909833" LOG_CI_START="-0.4513238070064776" LOG_EFFECT_SIZE="-0.2303677146391937" NO="4" P_CHI2="0.5487596213421717" P_Z="0.041008047824150844" STUDIES="3" TAU2="0.0" TOTAL_1="37" TOTAL_2="18" WEIGHT="4.529732917518783" Z="2.043448628441051">
<NAME>Other medication</NAME>
<DICH_DATA CI_END="3.723945821594102" CI_START="0.26853237074537567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.5710033539543428" LOG_CI_START="-0.5710033539543428" LOG_EFFECT_SIZE="0.0" ORDER="591" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.45" WEIGHT="0.6782772316613905"/>
<DICH_DATA CI_END="0.9437774644296312" CI_START="0.2181845497938071" EFFECT_SIZE="0.453781512605042" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="-0.025130396976863686" LOG_CI_START="-0.6611760061622609" LOG_EFFECT_SIZE="-0.34315320156956225" ORDER="592" O_E="0.0" SE="0.37361633931204574" STUDY_ID="STD-Davidson-2003" TOTAL_1="17" TOTAL_2="9" VAR="0.1395891690009337" WEIGHT="2.186593389961252"/>
<DICH_DATA CI_END="1.5430196879080178" CI_START="0.288035498138724" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.18837146740810207" LOG_CI_START="-0.5405539855194647" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="593" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="10" TOTAL_2="4" VAR="0.18333333333333335" WEIGHT="1.6648622958961403"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.411787439074825" CI_END="1.6887847997754348" CI_START="1.1181268211687132" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.374145399807076" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="232" I2="46.10957010583792" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="0.22757431136819264" LOG_CI_START="0.048491065276795246" LOG_EFFECT_SIZE="0.13803268832249396" METHOD="MH" NO="2" P_CHI2="0.0400030392594487" P_Q="0.431538127716097" P_Z="0.0025162694519031124" Q="2.7515489692741912" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04504375429521903" TOTALS="YES" TOTAL_1="666" TOTAL_2="609" WEIGHT="100.0" Z="3.0213780876325815">
<NAME>"Worst case" loss to follow up analysis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.54309416482686" CI_END="1.738716590116489" CI_START="1.3307670965289662" DF="6" EFFECT_SIZE="1.521126828478173" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="184" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="0.24022879800084873" LOG_CI_START="0.12410205431538801" LOG_EFFECT_SIZE="0.1821654261581184" NO="1" P_CHI2="0.8636139206791598" P_Z="7.792219296880965E-10" STUDIES="7" TAU2="0.0" TOTAL_1="526" TOTAL_2="501" WEIGHT="75.57050172651513" Z="6.1491033532356685">
<NAME>SSRIs</NAME>
<DICH_DATA CI_END="2.3113854055484135" CI_START="1.1322781044842944" EFFECT_SIZE="1.6177549523110786" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.36387236674591145" LOG_CI_START="0.05395310919245612" LOG_EFFECT_SIZE="0.2089127379691838" ORDER="594" O_E="0.0" SE="0.1820481060119666" STUDY_ID="STD-Brady-2000" TOTAL_1="94" TOTAL_2="90" VAR="0.03314151290254423" WEIGHT="14.153380912573377"/>
<DICH_DATA CI_END="1.9490540424429341" CI_START="0.983130100611921" EFFECT_SIZE="1.3842592592592593" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.2898238811952842" LOG_CI_START="-0.007389006848286702" LOG_EFFECT_SIZE="0.14121743717349877" ORDER="595" O_E="0.0" SE="0.17458432166431703" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="26" VAR="0.030479685370989718" WEIGHT="14.65221755380917"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="596" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="0.9132428419018106"/>
<DICH_DATA CI_END="1.9702995563921264" CI_START="1.2625980643511465" EFFECT_SIZE="1.5772432932469935" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.2945322595615962" LOG_CI_START="0.10126511918881614" LOG_EFFECT_SIZE="0.1978986893752062" ORDER="597" O_E="0.0" SE="0.1135260749427451" STUDY_ID="STD-Marshall-2001" TOTAL_1="188" TOTAL_2="186" VAR="0.012888169691905775" WEIGHT="19.10148657667933"/>
<DICH_DATA CI_END="4.415883274158453" CI_START="0.9547756396666225" EFFECT_SIZE="2.0533333333333332" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6450175850882468" LOG_CI_START="-0.020098670198720945" LOG_EFFECT_SIZE="0.312459457444763" ORDER="598" O_E="0.0" SE="0.3906925807341274" STUDY_ID="STD-Marshall-2004" TOTAL_1="25" TOTAL_2="22" VAR="0.15264069264069263" WEIGHT="5.597738646379304"/>
<DICH_DATA CI_END="1.8447003903145636" CI_START="1.1298587109011307" EFFECT_SIZE="1.4436934594988042" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.2659258396553734" LOG_CI_START="0.05302413825117136" LOG_EFFECT_SIZE="0.1594749889532724" ORDER="599" O_E="0.0" SE="0.125059513285247" STUDY_ID="STD-Tucker-2001" TOTAL_1="163" TOTAL_2="156" VAR="0.01563988186314287" WEIGHT="18.235325673522446"/>
<DICH_DATA CI_END="6.076280813914225" CI_START="0.6299869003625049" EFFECT_SIZE="1.9565217391304348" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7836378364737084" LOG_CI_START="-0.20066848095820689" LOG_EFFECT_SIZE="0.29148467775775083" ORDER="600" O_E="0.0" SE="0.5781864032543593" STUDY_ID="STD-Zohar-2002" TOTAL_1="23" TOTAL_2="15" VAR="0.3342995169082126" WEIGHT="2.917109521649692"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.52750790567147" CI_END="5.417923905936342" CI_START="0.014562013051405524" DF="1" EFFECT_SIZE="0.2808841017746768" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="41" I2="77.9127939512302" ID="CMP-009.02.02" LOG_CI_END="0.7338329011283006" LOG_CI_START="-1.8367785840418134" LOG_EFFECT_SIZE="-0.5514728414567565" NO="2" P_CHI2="0.03335420606664263" P_Z="0.40038072988844164" STUDIES="2" TAU2="3.725252837058892" TOTAL_1="94" TOTAL_2="81" WEIGHT="15.72879227806862" Z="0.8409414755537685">
<NAME>MAOIs</NAME>
<DICH_DATA CI_END="1.1677066338326452" CI_START="0.6080294810837369" EFFECT_SIZE="0.8426150121065376" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.06733374747606874" LOG_CI_START="-0.21607536289570894" LOG_EFFECT_SIZE="-0.07437080770982009" ORDER="601" O_E="0.0" SE="0.16647591433010422" STUDY_ID="STD-Baker-1995-a" TOTAL_1="59" TOTAL_2="58" VAR="0.0277142300520442" WEIGHT="15.209133105168211"/>
<DICH_DATA CI_END="0.8687283112505872" CI_START="0.0030272396440137973" EFFECT_SIZE="0.05128205128205128" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.06111602490170879" LOG_CI_START="-2.5189531978233277" LOG_EFFECT_SIZE="-1.290034611362518" ORDER="602" O_E="0.0" SE="1.4437457218643834" STUDY_ID="STD-Katz-1994" TOTAL_1="35" TOTAL_2="23" VAR="2.0844017094017095" WEIGHT="0.5196591729004081"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.120974538210573" CI_START="0.8582221218902779" DF="0" EFFECT_SIZE="2.64" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-009.02.03" LOG_CI_END="0.9096081488435758" LOG_CI_START="-0.06640029510391378" LOG_EFFECT_SIZE="0.42160392686983106" NO="3" P_CHI2="1.0" P_Z="0.09040190113756025" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="18" WEIGHT="2.9609183736980222" Z="1.6932814824089475">
<NAME>TCAs</NAME>
<DICH_DATA CI_END="8.120974538210573" CI_START="0.8582221218902779" EFFECT_SIZE="2.64" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="0.9096081488435758" LOG_CI_START="-0.06640029510391378" LOG_EFFECT_SIZE="0.42160392686983106" ORDER="603" O_E="0.0" SE="0.5733121912944715" STUDY_ID="STD-Davidson-1990" TOTAL_1="25" TOTAL_2="18" VAR="0.3286868686868687" WEIGHT="2.9609183736980222"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.38258599095718576" CI_END="2.4653422148076887" CI_START="0.508373882931697" DF="1" EFFECT_SIZE="1.1195157857293547" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-009.02.04" LOG_CI_END="0.39187721233008355" LOG_CI_START="-0.2938167688772658" LOG_EFFECT_SIZE="0.049030221726408856" NO="4" P_CHI2="0.53622282796832" P_Z="0.7792530406863467" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="9" WEIGHT="5.739787621718223" Z="0.28029258348912195">
<NAME>Other medication</NAME>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="604" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.2" WEIGHT="4.5158705292610755"/>
<DICH_DATA CI_END="11.183862579446217" CI_START="0.2955852774910108" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.048591822085899" LOG_CI_START="-0.5293172010743867" LOG_EFFECT_SIZE="0.2596373105057561" ORDER="605" O_E="0.0" SE="0.9268715709799871" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="11" TOTAL_2="4" VAR="0.8590909090909091" WEIGHT="1.2239170924571476"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.743597515893008" CI_END="1.9007834154737802" CI_START="1.2235077078352936" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5249993966417381" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="232" I2="51.63474031619973" I2_Q="22.768229839720153" ID="CMP-009.03" LOG_CI_END="0.27893263405465396" LOG_CI_START="0.08760670965821359" LOG_EFFECT_SIZE="0.18326967185643378" METHOD="MH" NO="3" P_CHI2="0.019205549441742575" P_Q="0.2742191703506687" P_Z="1.7343169239242558E-4" Q="3.8844118084747645" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.056192391010002146" TOTALS="YES" TOTAL_1="619" TOTAL_2="643" WEIGHT="99.99999999999997" Z="3.754869680418145">
<NAME>"Best case" loss to follow up analysis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.804750540197127" CI_END="1.8748530360293298" CI_START="1.4351345825794894" DF="6" EFFECT_SIZE="1.6403250986496063" ESTIMABLE="YES" EVENTS_1="295" EVENTS_2="184" I2="0.0" ID="CMP-009.03.01" LOG_CI_END="0.2729672303874799" LOG_CI_START="0.1568926298024059" LOG_EFFECT_SIZE="0.21492993009494288" NO="1" P_CHI2="0.44541390871017794" P_Z="3.918463953980851E-13" STUDIES="7" TAU2="0.0" TOTAL_1="498" TOTAL_2="520" WEIGHT="74.71176169826789" Z="7.258347994521869">
<NAME>SSRIs</NAME>
<DICH_DATA CI_END="2.4172812072869996" CI_START="1.1810519161189688" EFFECT_SIZE="1.6896551724137931" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3833271757155156" LOG_CI_START="0.07226898854359956" LOG_EFFECT_SIZE="0.2277980821295576" ORDER="606" O_E="0.0" SE="0.18271711890764297" STUDY_ID="STD-Brady-2000" TOTAL_1="93" TOTAL_2="93" VAR="0.03338554554190974" WEIGHT="14.100086940479127"/>
<DICH_DATA CI_END="2.0400804150473077" CI_START="1.0129043123783343" EFFECT_SIZE="1.4375" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.3096472866038363" LOG_CI_START="0.005568420119499969" LOG_EFFECT_SIZE="0.1576078533616681" ORDER="607" O_E="0.0" SE="0.17861743138756403" STUDY_ID="STD-Conner-1999" TOTAL_1="27" TOTAL_2="27" VAR="0.031904186795491146" WEIGHT="14.337182269660447"/>
<DICH_DATA CI_END="4.15310347381768" CI_START="0.06019594781976166" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6183727516127009" LOG_CI_START="-1.2204327429406634" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="608" O_E="0.0" SE="1.0801234497346432" STUDY_ID="STD-Hertzberg-2000" TOTAL_1="6" TOTAL_2="6" VAR="1.1666666666666665" WEIGHT="1.0328718468425822"/>
<DICH_DATA CI_END="2.0443391190327147" CI_START="1.3120420945661306" EFFECT_SIZE="1.63776035479528" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="69" LOG_CI_END="0.31055293906962067" LOG_CI_START="0.11794776883881952" LOG_EFFECT_SIZE="0.2142503539542201" ORDER="609" O_E="0.0" SE="0.11313723040454164" STUDY_ID="STD-Marshall-2001" TOTAL_1="183" TOTAL_2="188" VAR="0.012800032903610342" WEIGHT="18.307179566733186"/>
<DICH_DATA CI_END="6.464695160048781" CI_START="1.3921770133291311" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.8105480507276219" LOG_CI_START="0.14369445871170303" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="610" O_E="0.0" SE="0.39171310092866873" STUDY_ID="STD-Marshall-2004" TOTAL_1="21" TOTAL_2="27" VAR="0.15343915343915343" WEIGHT="6.025127070687707"/>
<DICH_DATA CI_END="2.037099117261091" CI_START="1.2541512061147373" EFFECT_SIZE="1.5983836569760916" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="59" LOG_CI_END="0.3090121605820539" LOG_CI_START="0.09834990014899399" LOG_EFFECT_SIZE="0.20368103036552396" ORDER="611" O_E="0.0" SE="0.12374405457338654" STUDY_ID="STD-Tucker-2001" TOTAL_1="151" TOTAL_2="160" VAR="0.015312591042261266" WEIGHT="17.663897774388712"/>
<DICH_DATA CI_END="10.389956449934758" CI_START="1.0820271082986657" EFFECT_SIZE="3.3529411764705883" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0166137271921476" LOG_CI_START="0.03423814139628748" LOG_EFFECT_SIZE="0.5254259342942175" ORDER="612" O_E="0.0" SE="0.5770522819340647" STUDY_ID="STD-Zohar-2002" TOTAL_1="17" TOTAL_2="19" VAR="0.3329893360853113" WEIGHT="3.245416229476131"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5330797404539402" CI_END="3.858929046900121" CI_START="0.05886152475823573" DF="1" EFFECT_SIZE="0.4765946365984268" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="41" I2="60.52236398129357" ID="CMP-009.03.02" LOG_CI_END="0.5864667933879193" LOG_CI_START="-1.230168492057829" LOG_EFFECT_SIZE="-0.32185084933495484" NO="2" P_CHI2="0.11148275553851861" P_Z="0.4873759731666617" STUDIES="2" TAU2="1.617513091382611" TOTAL_1="79" TOTAL_2="93" WEIGHT="15.703652965321115" Z="0.6944884073804117">
<NAME>MAOIs</NAME>
<DICH_DATA CI_END="1.2701832381264295" CI_START="0.6639975702776644" EFFECT_SIZE="0.9183673469387755" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.10386637730777136" LOG_CI_START="-0.17783350981411136" LOG_EFFECT_SIZE="-0.036983566253169974" ORDER="613" O_E="0.0" SE="0.16547190813232435" STUDY_ID="STD-Baker-1995-a" TOTAL_1="56" TOTAL_2="60" VAR="0.027380952380952384" WEIGHT="15.113152616404554"/>
<DICH_DATA CI_END="1.844000919209079" CI_START="0.0064400244002947695" EFFECT_SIZE="0.10897435897435898" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.26576113320748646" LOG_CI_START="-2.1911124871598617" LOG_EFFECT_SIZE="-0.9626756769761876" ORDER="614" O_E="0.0" SE="1.4431797263243429" STUDY_ID="STD-Katz-1994" TOTAL_1="23" TOTAL_2="33" VAR="2.082767722473605" WEIGHT="0.5905003489165628"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.812130942818229" CI_START="1.1329866484956743" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-009.03.03" LOG_CI_END="1.0339112966825372" LOG_CI_START="0.05422479201801394" LOG_EFFECT_SIZE="0.5440680443502757" NO="3" P_CHI2="1.0" P_Z="0.02948589719084652" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="21" WEIGHT="3.2606689080187907" Z="2.1769285725352225">
<NAME>TCAs</NAME>
<DICH_DATA CI_END="10.812130942818229" CI_START="1.1329866484956743" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0339112966825372" LOG_CI_START="0.05422479201801394" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="615" O_E="0.0" SE="0.5754727023663513" STUDY_ID="STD-Davidson-1990" TOTAL_1="22" TOTAL_2="21" VAR="0.3311688311688311" WEIGHT="3.2606689080187907"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.521314742573343" CI_END="2.5109631447547276" CI_START="0.5186062606348736" DF="1" EFFECT_SIZE="1.141140309994013" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-009.03.04" LOG_CI_END="0.39984033830148613" LOG_CI_START="-0.2851622447152075" LOG_EFFECT_SIZE="0.05733904679313929" NO="4" P_CHI2="0.4702814567772513" P_Z="0.7428188517652516" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="9" WEIGHT="6.323916428392179" Z="0.32812275284419207">
<NAME>Other medication</NAME>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.4162278132637267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.38066890263622855" LOG_EFFECT_SIZE="0.0" ORDER="616" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Butterfield-2001" TOTAL_1="10" TOTAL_2="5" VAR="0.2" WEIGHT="4.930110095585817"/>
<DICH_DATA CI_END="12.184256768115382" CI_START="0.328292490557773" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.0857990426425488" LOG_CI_START="-0.4837390513145864" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="617" O_E="0.0" SE="0.9219544457292886" STUDY_ID="STD-Hertzberg-1999" TOTAL_1="10" TOTAL_2="4" VAR="0.8499999999999999" WEIGHT="1.3938063328063628"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Head-to-head comparisons</NAME>
<CONT_OUTCOME CHI2="0.8227195764089672" CI_END="0.14399155645417033" CI_START="-0.2337823809696768" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04489541225775324" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" NO="1" P_CHI2="0.6627487158509229" P_Q="0.47335393560976746" P_Z="0.6413213707406216" Q="0.514136002050035" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="216" TOTAL_2="216" UNITS="" WEIGHT="100.0" Z="0.4658521003133649">
<NAME>Clinician administered scales: Symptom severity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.30858357435893213" CI_END="0.25068853404077407" CI_START="-0.6325591226072226" DF="1" EFFECT_SIZE="-0.19093529428322423" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.01" NO="1" P_CHI2="0.5785507687621287" P_Z="0.396779445036916" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="43" WEIGHT="18.293592370917636" Z="0.8473870207431924">
<NAME>Nefazodone versus sertraline</NAME>
<CONT_DATA CI_END="0.7561846130158952" CI_START="-0.781355572949468" EFFECT_SIZE="-0.012585479966786352" ESTIMABLE="YES" MEAN_1="28.77" MEAN_2="29.08" ORDER="618" SD_1="22.2" SD_2="25.4" SE="0.3922368467209816" STUDY_ID="STD-McRae-2004" TOTAL_1="13" TOTAL_2="13" WEIGHT="6.0368590269279165"/>
<CONT_DATA CI_END="0.2607501368226043" CI_START="-0.8183074530496605" EFFECT_SIZE="-0.2787786581135281" ESTIMABLE="YES" MEAN_1="4.35" MEAN_2="5.23" ORDER="619" SD_1="2.94" SD_2="3.24" SE="0.2752748515747568" STUDY_ID="STD-Saygin-2002" TOTAL_1="24" TOTAL_2="30" WEIGHT="12.25673334398972"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.6473344792395107E-34" CI_END="0.19676725963861422" CI_START="-0.2211631133263995" DF="0" EFFECT_SIZE="-0.012197926843892646" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-010.01.02" NO="2" P_CHI2="0.0" P_Z="0.9089135826230813" STUDIES="1" TAU2="0.0" TOTAL_1="179" TOTAL_2="173" WEIGHT="81.70640762908236" Z="0.1144089965535254">
<NAME>Venlafaxine versus sertraline</NAME>
<CONT_DATA CI_END="0.19676725963861422" CI_START="-0.2211631133263995" EFFECT_SIZE="-0.012197926843892648" ESTIMABLE="YES" MEAN_1="42.2" MEAN_2="42.6" ORDER="620" SD_1="33.58" SD_2="31.81" SE="0.10661685017214478" STUDY_ID="STD-Davidson-2004" TOTAL_1="179" TOTAL_2="173" WEIGHT="81.70640762908236"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.19678933880696" CI_START="-7.87678933880696" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8399999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8150113421190696" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="99.99999999999999" Z="0.2339660415772481">
<NAME>Comorbid symptoms: Depression (MADRS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nefazodone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours setraline</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.19678933880696" CI_START="-7.87678933880696" EFFECT_SIZE="-0.8399999999999999" ESTIMABLE="YES" MEAN_1="9.85" MEAN_2="10.69" ORDER="621" SD_1="9.4" SD_2="8.9" SE="3.5902646142032486" STUDY_ID="STD-McRae-2004" TOTAL_1="13" TOTAL_2="13" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.443183423322195" CI_START="-10.903183423322194" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2299999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.40934885865129067" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.825040054538854">
<NAME>Comorbid symptoms: Anxiety (Hamilton Anxiety Scale)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.443183423322195" CI_START="-10.903183423322194" EFFECT_SIZE="-3.2299999999999986" ESTIMABLE="YES" MEAN_1="9.31" MEAN_2="12.54" ORDER="622" SD_1="7.1" SD_2="12.2" SE="3.9149614400301664" STUDY_ID="STD-McRae-2004" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Publication Bias 2.</P>
<P>Funnel plot of publication bias on Clinical Global Impression Scale - Improvement item (CGI-S)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Publication Bias 1.</P>
<P>Funnel Plot of publication bias on Clinician Administered PTSD Scale (CAPS)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-04-12 17:03:40 +0100" MODIFIED_BY="Sarah  R Davies">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2016-04-12 17:03:40 +0100" MODIFIED_BY="Sarah  R Davies" NO="1">
<TITLE MODIFIED="2016-04-12 16:44:48 +0100" MODIFIED_BY="Sarah  R Davies">Comments submitted by Danielle Stacey</TITLE>
<DATE_SUBMITTED>
<DATE DAY="8" MONTH="12" YEAR="2015"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2016-04-12 17:03:40 +0100" MODIFIED_BY="Sarah  R Davies">
<P>In 2009, Stein DJ et al. published a Cochrane review which provided us with a very thorough explanation of the literature surrounding pharmacotherapy for post-traumatic stress disorder (PTSD).<SUP>1</SUP> After a thorough review of the publication, we have a few enquiries regarding the patient population represented in the meta-analysis and the statistical analysis conducted. In addition, we have provided some potential recommendations for future updates.</P>
<SUBSECTION>
<HEADING LEVEL="4">Clinical heterogeneity</HEADING>
<P>Within a systematic review we test for statistical heterogeneity, as did Stein DJ et al, however we often over look clinical heterogeneity or diversity.<SUP>2</SUP> We agree with the authors&#8217; conclusions that &#8220;the existing evidence base of RCTs includes a heterogeneous sample of participants with a range of different traumas, trauma duration and severity, and comorbidity.&#8221; As an example we can look at analysis 1.1 which includes the following patient populations: Brady 2004, patients suffering from alcoholism; Brady 2000 and Davidson 2001, patients with anxiety and MDD; Pfizer 589, predominantly war veterans; and some trials that have a combination of these various characteristics. The significantly greater reduction in symptom severity in trials with less veteran participants highlights how important clinical diversity can be when interpreting results and when analyzing comparisons for treatment within a meta-analysis. Given this, one could argue whether meta-analysis of trials with high clinical variability is even appropriate. At the very least it warrants a section to inform clinicians which patient populations are encompassed in each analysis. We also suggest completing an additional subgroup analysis for trials including participants with concurrent anxiety disorders. After a random selection of three trials (Brady 2000, Davidson 2001, Marshall 2004) from analysis 1.1, we found that all three included participants with concurrent anxiety disorders at various rates. Together, these three trials comprise a weight of 16.2% of the random effects model. This additional subgroup analysis will aid in further defining the treatment populations within the review and the potential impact on the pooled efficacy results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Inclusion of studies in meta-analysis 1.3</HEADING>
<P>Focusing again on the statistical analysis, at first glance, analysis 1.3 for clinical global impression scale improvement item (CGI-I) seemed to include a low number of RCTs for SSRIs. After scanning the included trial characteristics tables, we noticed 12 trials that had CGI-I (or similar scale) as a primary or secondary outcome (Davidson, Davidson 2001, Brady 2000, Pfizer588, Pfizer589, Zohar 2002, Marshall 2004, Tucker 2001, Marshall 2001, Herzberg 2000, Eli Lilly, and Connor 1999). Analysis 1.3 included only 7 trials in the forest plot (Brady 2000, Connor 1999, Hertzberg 2000, Marshall 2001, Marshall 2004, Tucker 2001, and Zohar 2002). It was mentioned in the description of studies section that Davidson would not be used for statistical analysis, however this does not explain why the remainder of the trials were not included. In addition, a similar statement claimed that data from Tucker 2003 would be excluded from statistical analysis, however this trial was included in other forest plots (eg. Analysis 1.1). A brief explanation to help understand the reasoning for inclusion of trials into each analysis would help in interpreting the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">References</HEADING>
<P>As previously mentioned, we took the time to randomly pull some of the trials that were cited in the review. Our first choice was Davidson 2001. From the included studies citations, we chose the second of four trials under Davidson 2001 given the lead author and year of publication.<SUP>3</SUP> It was very apparent that this trial was in fact a maintenance trial, and answering a very different question than the review. This particular Davidson publication cited another Davidson publication, which was in fact the acute treatment trial. Upon further inspection, data from the original trial was included in the analysis, which is great. However, it is confusing for readers because wherever Davidson 2001 is cited in the review, may lead them to look at the maintenance trial and not the main trial of interest. We suggest, for trials that have the same lead author and publication year (eg. Davidson 2001), adding a distinguishing mark for each will help readers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Additional points</HEADING>
<P>The combination of clinical variability, unclear trial methodology and very thorough inclusion of information can lead to confusion and misinterpretation without a clear, concise and easy to analyze presentation. To make it easier for readers to gain a quick and accurate interpretation of the included data and results, we suggest the following changes:</P>
<P>1. Include a risk of bias graph or a risk of bias summary figure for the included trials.<SUP>2</SUP> It is apparent that a bias assessment was completed, however each risk of bias section did not include all pertinent design factors to make an accurate assessment. Furthermore, placing these factors in the characteristic tables does not help viewers get an overall idea of the included trial quality, nor is it efficient. In addition, although it seems Cochrane is not a full supporter of quality scales, this information could also be displayed with or immediately after the risk of bias tool(s).</P>
<P>2. Conduct a subgroup analysis for trials including patients with concurrent anxiety disorders as previously suggested in an effort to address clinical heterogeneity.</P>
<P>3. Include reasoning for including or excluding trials in each analysis where applicable, as previously suggested.</P>
<P>4. For different trials that have the same lead author and publication year (eg. Davidson 2001), add a distinguishing mark for each.</P>
<P>5. On page 14, the following statement contains an error, &#8220;the conclusion that a short-term course of treatment with SSRIs may be inadequate is supported by increased relapse rates in trials of both fluoxetine (Davidson 2001) and sertraline (Martenyi 2002).&#8221; Davidson 2001 and Martenyi 2002 should be switched.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">References:</HEADING>
<P>1. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD002795. DOI: 10.1002/14651858.CD002795.pub2</P>
<P>2. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from <A HREF="http://www.cochrane-handbook.org">www.cochrane-handbook.org</A>
</P>
<P>3. Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo- controlled study. American Journal of Psychiatry 2001;158(12): 1974&#8211;81.</P>
</SUBSECTION>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2016-04-12 16:55:06 +0100" MODIFIED_BY="Sarah  R Davies">
<P>We would like to thank the reviewers for their close reading of our Cochrane review &#8216;Pharmacotherapy for posttraumatic stress disorder&#8217;. We would note that there have been considerable advances in methodological and reporting standards since this review was published, a decade ago in 2006, and that adherence to these standards in the imminent update of the review should help to address many of the reviewer&#8217;s concerns. Specifically, new Cochrane standards require a more thorough description of important aspects of studies in the description of included studies section, under the following subheadings &#8211; design, participant characteristics, diagnosis, co-morbidities, setting, interventions, and outcomes. The updated review will incorporate these headings and this information will make it easier for the reader to assess important aspects of studies included in the review. Nevertheless, we have responded as best we can to the individual comments kindly provided by the reviewers below.</P>
<SUBSECTION>
<HEADING LEVEL="4">Clinical heterogeneity</HEADING>
<P>The reviewers are correct in highlighting the importance of taking clinical variability into account when interpreting the results of this meta-analysis. It was in recognition of this fact that we originally decided to investigate whether effect sizes differed in trials of civilian trauma versus war veterans. That said, trials of very homogenous clinical populations may have limited generalizability. We have opted, in response to the reviewer&#8217;s comments, to present a general descriptive overview of the patients included in the eligible studies in the Description of studies section of the review. This was done instead of providing the suggested breakdown of the clinical background of trial participants for each analysis, in the interests of readability. As evident in this paragraph, the majority (18/22 or 82%) of RCTs included in the meta-analysis that described comorbid diagnoses in their patients documented comorbid anxiety disorders in addition to PTSD. The exceptions in this regards were Katz 1995, Kosten 1991, Chung 2004, and Reist 1989, with only Katz 1995 providing data for inclusion in the analyses of the review&#8217;s primary outcomes. Accordingly, we feel that there is not not much utility in conducting additional subgroup analyses to assess the effects of comorbid anxiety disorders in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Inclusion of studies in meta-analysis 1.3</HEADING>
<P>With regards to the observation that the analysis of the effect of medication on the CGI-I outcome (Analysis 1.3) does not appear to contain all included studies, when considered across all medication classes, Analysis 1.3 contains a total of 13 trials, including the majority of the trials that the reviewers listed as including the CGI-I as a primary or secondary outcome. The discrepancy noted by the reviewers is due to the fact that only those trials for which it was possible to extract data on the particular outcomes of interest were included in the analyses (after requesting data from the authors, where these were not reported in the study publication). In order to pre-empt confusion on this point, we have altered the text describing the primary outcomes in the Effects of interventions section, to make this observation explicit.</P>
<P>As far as the inclusion of data from Tucker 2003 in analyses conducted within the review is concerned, it was noted in paragraph 5 (now paragraph 6) of the Description of included studies section that &#8220;Summary statistics for the sertraline arm of the Tucker 2003 trial were excluded from the analysis, in favour of including the data from the less well represented citalopram arm.&#8221; Nevertheless, we determined that data from the sertraline arm of Tucker 2003 had inadvertently been included in the review in place of data from the citalopram arm from this trial (Analysis 1.2 and 2.2). This error has now been corrected, and the results of relevant analyses updated accordingly. This correction has not changed the findings of the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">References</HEADING>
<P>Additional entries have been added under the Included Studies category in RevMan (version 5.2) to accommodate the maintenance phases of both the Davidson 2001 and Martenyi 2002 short-term trials. Study IDs have been distinguished by appending them with alphabetical characters.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Additional points</HEADING>
<P>1. We thank the reviewers for this suggestion. Cochrane methodologies have improved in the 10 years since this review was published. Inclusion of two risk of bias summary figures - one that presents judgements about each risk of bias item as percentages across all included studies; and another that presents judgements about each risk of bias item for each included study is now a standard requirement for Cochrane reviews, and accordingly both will be included in the update to this review. Additionally Cochrane now supports the assessment of quality of included studies using the GRADE approach and this methodology will also be applied and incorporated in the interpretation of results in the update of the review.</P>
<P>2. This is not a viable option, given the fact that the vast majority of included trials that provide information on comorbid diagnoses include patients diagnosed with other anxiety disorders (please refer to the response to the first comment above).</P>
<P>3. We trust that we have sufficiently addressed the reviewer&#8217;s concerns regarding the rational for including or excluding RCTs in the review in our response to this particular query above.</P>
<P>4. We have distinguished between the acute and maintenance components of trials included in the review by assigning different labels to these study components, as described above. We have also updated the Characteristics of included studies section of the review accordingly.</P>
<P>5. We have made the suggested switch, and linked the text to the appropriate references for the maintenance components of the sertraline (Davidson 2001b) and fluoxetine (Martenyi 2002b) trials.</P>
</SUBSECTION>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2016-04-12 17:03:17 +0100" MODIFIED_BY="Sarah  R Davies">
<P>Feedback submitted by Danielle Stacey, BSc(Pharm), PharmD Student Aaron Tejani, BSc(Pharm), PharmD</P>
<P>Response submitted by Jonathan Ipser</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>